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Abstract 
HIV-infection is characterized by depletion of CD4
+
 T-cells from the gut-associated lymphoid 
tissue (GALT) which causes irreparable gastrointestinal tract damage and subsequent microbial 
translocation of bacterial products such as lipopolysaccharide (LPS), a component of Gram-
negative bacteria, into systemic circulation. HIV infection also affects the functions and relative 
population sizes of various immune cells, such as monocytes. Monocytes are important innate 
immune cells as they are often the first cells recruited to sites of infection and inflammation. 
They then either promote inflammatory processes; elicit adaptive immune responses, through 
their antigen presenting ability; aid in pathogen and debris clearance or aid in damage repair.  
This cross-sectional study investigated functional changes to monocytes and monocyte subsets 
(CD14+CD16- and CD14+CD16+) in HIV+, treatment naïve individuals and healthy uninfected 
controls, using whole blood assays and isolated monocytes. A number of chemokine receptors 
associated with function and homing, and specific gut-homing receptors, were investigated. 
Monocyte activation, apoptotic potential and intracellular monocyte cytokine production were 
also investigated. All markers were evaluated using multi-parameter flow cytometry. Monocyte 
responsiveness to in vitro LPS stimulation and expression of the afore-mentioned chemokine 
receptors to viral load, CD4
+
 count and CD38/8 T-cell expression was also assessed. 
During HIV-infection monocytes appeared primed to exit systemic circulation and migrate 
towards the gut, as seen through elevated CD62-L (p < 0.005) and CCR7 (p < 0.005), whereas 
the CD14+CD16+ subset was increased (p = 0.0461) and exhibited a higher activation status 
through increased CD69 expression (p < 0.005) compared to the CD14+CD16- subset. An 
interesting observation was the significantly increased IL-10 production by the CD14+CD16+ 
subset (p < 0.005). An elevated CCR5 expression in total monocytes (p < 0.005) was also seen. 
After LPS stimulation, the HIV+ group displayed unique and significant percentage increases in 
the total monocyte population.  
The findings of the current study suggest that monocyte functionality may be retained during 
HIV-infection and that CD14+CD16+ monocytes play a vital role during HIV-infection 
evidenced by their preferential expansion and priming for GALT migration. The production of 
IL-10 by this subset further highlights their importance and emphasizes the need for future 
studies on the role of these cells in chronic stable HIV-1 infection and whilst disease progresses. 
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Opsomming 
MIV-infeksie word gekenmerk deur die uitputting van CD4
+
 T-selle, veral uit die derm-verwante 
limfweefsel (GALT). Dit veroorsaak onherstelbare skade aan die spysverteringskanaal en die 
daaropvolgende mikrobiese translokasie van bakteriële produkte soos LPS, „n komponent van 
Gram-negatiewe bakterieë, wat gaan binne sistemiese sirkulasie. MIV-infeksie beinvloed die 
funksies en relatiewe bevolkingsgrootte van verskeie immuun selle, insluitend monosiete. 
Monosiete is belangrike ingebore immuun selle en is dikwels die eerste selle wat gewerf word na 
areas van infeksie en inflammasie. Monosiete kan inflammatoriese prosesse bevorder of 
aanpabare immuunstelsel reaksies ontlok deur middel van hul antigeen aanbiedings vermoë of 
help met patogeen en puin klaring en skade herstel. 
In hierdie deursnee-studie het ons veranderinge aan monosiete (CD14+CD16+ en CD14+CD16-) 
ondersoek in MIV+ behandelde naïef individue en gesonde onbesmette kontroles, deur die 
gebruik van hele bloed toetse en geïsoleerde monosiete. 'n Aantal chemokine reseptore, wat 
verband hou met homing en funksie was ondersoek in toevoeging tot spesifieke derm-homing 
reseptore. Monosiet aktivering, apoptese potensiaal en intrasellulêre monosiet sitokien produksie 
was ook ondersoek. Alle merkers is ondersoek deur multi-parameter vloeisitometrie. Die 
beoordeel reaksies van monosiete na in vitro LPS stimulasie en die uitdrukking van die merkers 
met merkers van algemene immuun aktivering en MIV-siekte patogenese was ook ondersoek. 
CD14+CD16+ monosiete was gedurende MIV-infeksie verhoog (p-waarde = 0.0461). Daar was 
'n hoër algehele monosiet uitdrukking van verskeie chemokine merkers soos CD69 (p-waarde < 
0.005) uitdrukking; CD62-L (p-waarde < 0.005), en CCR7 (p-waarde < 0.005) uitdrukking in die 
CD14+CD16+ subgroep. Daar was ook „n toename in IL-10 produksie, veral in die 
CD14+CD16+ subgroep (p-waarde < 0.005). Hoewel baie funksionele merker reaksies dieselfde 
was, het die MIV+ groep „n unieke en beduidende persentasie verhooging in die totale monosiet 
bevolking getoon.  
Ons algehele bevindinge dui op 'n voorkeur uitbreiding van CD14+CD16+ monosiete tydens 
MIV-infeksie. Die CD14+CD16+ monosiet subgroep blyk ook bevoordeel word met betrekking 
tot voorbereiding vir migrasie na limfknope en die GALT. Die toename in geaktiveer de 
CD14+CD16+ monosiete op siekte webwerwe is waarskynlik 'n groot bydraende faktor tot 
aanhoudende immuun aktivering wat op sy beurt virale replikasie bevorder. Hierdie resultate 
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beklemtoon die behoefte om die rol van hierdie selle en in veral die CD14+CD16+ subgroep, in 
kroniese stabiele MIV-1 infeksie verder te studeer en terwyl siekte bevorder. 
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Chapter 1: Introduction 
Since its emergence in 1983, Human Immunodeficiency virus-1 (HIV-1) infection has become a 
serious worldwide problem. Much has been learned about the pathogenesis of the disease in the 
years since initial discovery, but with new knowledge has come the challenge of further 
questions. An area of particular importance has been in trying to discern the exact role the 
immune system plays in HIV-1 infection. In the absence of any individual ever being cured 
naturally, researchers have been unable to define any clear immune correlates of protection. 
Understanding is hampered by pleiotropic effects of various components of the immune system, 
leading to conflicting reports of protective vs. damaging roles. A particularly fertile area of 
research is the role of the innate immune system, its constituent cells and their mediators in the 
pathogenesis of HIV-1 infection. The innate immune system includes various cell types such as 
monocytes/macrophages, natural killer cells (NK), mast cells, granulocytes, and dendritic cells 
(DCs). Monocytes are one of the most important cells of the immune system as they are often the 
first cells that encounter invading pathogens as resident tissue macrophages, and they are often 
also the first cells to respond to danger signals provided by pathogens. Macrophages are 
tissue/organ associated cells and whilst monocytes are often precursors to macrophages, not all 
tissue macrophages originate from blood monocytes, with some macrophages now known to 
originate from embryotic somatic cells (Guilliams et al., 2013), see Figure 1-1.  
Monocytes usually circulate systemically, after being released from the bone marrow, until they 
are recruited to sites of infection and in inflammatory situations, where they act upon invading 
pathogens. Monocytes are also the precursors of macrophages involved in inflammation 
resolution and promotion of tissue repair. Once migration into various tissues has occurred, 
monocytes differentiate into macrophages including specialised organ- or tissue-associated 
populations. These include, Kupffer cells in the liver, microglial cells in the brain and also the 
M1 (pro-inflammatory) or M2 (tissue repair) macrophage populations representing infection site 
recruits, which are involved in initiation of immune responses, and later in their resolution (Le 
Douce et al., 2010; Cassol et al., 2010; Laforge et al., 2011; Wu 2011; Mir et al., 2012). As early 
recruits to sites of inflammation and infection, monocytes play an important role as antigen 
presenting cells (APCs), inflammatory mediators and as phagocytes. However, they are also vital 
in the resolution of inflammation and in tissue repair; linked to the latter is their implication as 
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important role players in fibrotic conditions. Fibrosis is the aberrant deposition of collagen, 
which in moderation represents a normal repair mechanism, but in pathological conditions is 
problematic. The role monocytes play during immune responses, as phagocytes and APCs, has 
been extensively studied and well-characterised. The impact of HIV-1 infection on these cells has 
also been investigated. Monocytes may be directly infected with HIV-1; however their major role 
in this disease would appear to be in the induction (and continuation) of inflammation, the 
promotion and stimulation of acquired immunity and its role players, and also in mediation in 
lymphoid tissue fibrosis. However, due to the variability across the field in study populations, 
diseases status, infecting virus and baseline immunity, much conflicting and confusing data have 
been generated. More research is needed to clarify the impact HIV-1 has on monocytes (both 
directly and indirectly) and the consequence for the host‟s immune system and its ability to deal 
with the infection. 
  
Significant changes have been reported in monocytes during HIV-1 infection, such as expansion 
of particular subsets, impaired functional ability and resistance to programmed cell death. 
Macrophages, together with the main target cells of HIV-1, CD4
+ 
T-cells are the first to 
encounter the virus and are also the two cells primarily responsible for viral replication and 
dissemination. A large number of CD4
+
 T-cells (particularly memory CD4
+
 T cells expressing 
CCR5) reside in the gut associated lymphoid tissue (GALT) and generally in infection these cells 
Figure 1- 1: Diagram showing monocyte and macrophage origins. Monocytes originate from the bone marrow 
and become released into circulation, whereas macrophages are either monocyte or somatic in origin (Sieweke 
& Allen 2013) 
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are targeted by the virus, resulting in massive depletion of these T-cells. In parallel to this 
depletion, damage to the gut barrier occurs as a result of the pro-inflammatory milieu. 
Subsequent microbial translocation of bacterial products, such as lipopolysaccharide (LPS), into 
the systemic circulation then occurs. Microbial translocation itself leads to immune activation, 
both localised and systemic. Recruitment of monocytes from the bloodstream into the GALT and 
other lymphoid tissues then occurs resulting in on-going promotion of inflammation and immune 
activation ultimately leading to immune exhaustion. Monocytes thus play an important role 
during both immune activation persistence and repair in the lymph nodes and gut (Laforge et al., 
2011; Wu, 2011; Mir et al., 2012). 
Aberrant immune activation poses a new challenge in the fight against HIV-1 infection. The 
inability of the immune system to clear HIV-1 infection despite the advancement of anti-
retroviral therapy highlights the importance of immune activation in disease progression to 
acquired immunodeficiency syndrome (AIDS). This phenomenon has opened a new area of 
research into selective modulation or dampening of inflammation and immune activation. Several 
potential immuno-regulatory molecules and drugs have been proposed as intervention agents. A 
particularly promising mediator is vasoactive intestinal peptide (VIP), a neuropeptide that 
functions as a neurotransmitter and neuromodulator that when engaging with its receptors, 
vasoactive intestinal peptide receptor 1 (VPAC-1) and vasoactive intestinal peptide receptor 2 
(VPAC-2), has been seen to promote anti-inflammatory effects (Delgado et al., 2004). Although 
only recently investigated in the HIV-1 field, this mediator has been well studied in other 
inflammatory disorders and represents a unique and potentially powerful selective mediator 
which may both increase resistance to HIV-1 infection in monocytes/macrophages and dampen 
aberrant pro-inflammatory activity in chronic infection. 
Given the important role monocytes play in the immune system and particularly in HIV-1 
pathogenesis it is vital their role be further investigated. Most especially the role they play in 
linked processes of immune activation and immune exhaustion. A number of studies have been 
performed in Africa have reported conflicting results regarding immune activation caused by LPS 
in HIV-1 infection. The conflicting nature of current literature regarding the characterisation, 
phenotype and functioning of monocytes in different disease settings further highlight the 
importance of conducting studies on this innate cell subset. Therefore the current study set out to 
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determine if HIV-infection affects the function of monocytes. If monocytes are affected, how are 
they affected? Lastly, could monocyte be used as a therapeutic intervention? 
The aim of this research project was to investigate the phenotype and function of monocytes in 
South African individuals with a stable CD4 count (> 300cells/µl) and who are asymptomatic. 
Furthermore, this study set out to elucidate the role of these cells in HIV-1 infection in relation to 
markers of homing (gut and lymph node), activation, inflammation and apoptosis. The novel 
aspects of this study were the simultaneous evaluation of putative gut and lymph node homing 
markers and assessment of their expression in relation to standard markers of HIV disease (CD4 
count and viral load) as well as a general marker of immune activation status (CD38 on CD8
+
 T 
cells). The expression of the VIP receptor VPAC-2 on monocytes was also assessed with the aim 
of defining whether this modulatory pathway could be exploited in the monocyte cell population 
in this disease.  
This thesis will discuss the research in the following manner: Chapter 2 will be a review of 
current monocyte literature in relation to HIV-1 infection and will also outline the motivation, 
hypothesis, aims and objectives of the study. Chapter 3 will describe the materials and methods 
used to perform the research. The results obtained will be presented in Chapter 4 and discussed 
in Chapter 5. Chapter 6 will provide a concise conclusion to the work. 
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Chapter 2: Literature review 
The primary focus of this literature review is monocytes and their relation to HIV-1 pathogenesis. 
A brief introduction to HIV-1 epidemiology and virology is given, followed by the processes 
involved in inflammation, and HIV-1 pathogenesis. The chapter will address monocytes in detail, 
their role in HIV-1 pathogenesis and an overview of selected key monocyte markers which have 
been studied in more detail in this research project.  
2.1. HIV-1 
2.1.1. History 
HIV was first reported as the cause of acquired immunodeficiency syndrome (AIDS) in 1983 
(Barré-Sinoussi et al., 1983). There are two major sub-species of HIV namely; HIV-1 and HIV-2. 
HIV-1 is responsible for the current global AIDS pandemic and has successfully spread 
worldwide (Sasse & Van Beckhoven, 2012). HIV-2 on the other hand is not commonly found 
outside of Africa and was first isolated in West Africa in 1986 (Clavel et al., 1986).  
2.1.2. Epidemiology 
At the end of 2013 the Joint United Nations Programme on HIV/AIDS (Joint United Nations 
Programme on HIV/AIDS (UNAIDS) 2013), released a report estimating that 35.3 million people 
were living with HIV in 2012, an increase from previous years due to more people receiving anti-
retroviral therapy (ART) (Figure 2-1). This is most likely as a result of successful roll-out of 
ARV therapies in many areas. Sub-Saharan Africa continues to be disproportionately affected 
with 70% of all new global infections occurring in this region in 2012. Surveys in several sub-
Saharan African countries have shown that there is a decrease in condom use and/or an increase 
in the number of sexual partners, which highlights the fact that societal attitudes impose a major 
restriction to successful programmes aimed at eradicating this disease. Despite this, the annual 
number of new HIV infections amongst adults in sub-Saharan Africa has reduced by 34% from 
2001 to 2012 (Figure 2-2). Globally there has been a 33% decline in the number of new 
infections from 3.4 million in 2001 to 2.3 million in 2012 (Figure 2-1). The number of AIDS 
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deaths has also been declining from 2.3 million AIDS deaths in 2005 to 1.6 million in 2012 
(Figure 2-1) (Joint United Nations Programme on HIV/AIDS (UNAIDS) 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notable reductions in HIV prevalence has been achieved amongst young people (15-24 years) 
across diverse countries of sub-Saharan Africa. HIV prevalence amongst young women and men 
has declined by 42% from 2001 to 2012. However, the prevalence is still more than double 
amongst young women than in young men throughout sub-Saharan Africa (Figure 2-3). 
  
Figure 2- 1: Graphs depicting HIV epidemiology globally and within Sub-Saharan Africa. The graph on the far left 
number shows the number of people living with HIV globally from 2001-2012. The graph in the middle shows the number 
of newly infected people, globally from 2001-2012 and the graph on the right shows the number of AIDS deaths in sub-
Saharan Africa from 2001-2012. The amount of people living with HIV globally has increased in 2012 with an estimated 
35.3 million people are living with HIV, whilst the number of .newly infected adults declined by 33% in 2012.There has 
also been a decline of AIDS deaths from 2005 to 2012(Joint United Nations Programme on HIV/AIDS (UNAIDS) 2013). 
Figure 2- 2: The number of new HIV infections amongst adults in Sub-Saharan Africa from 2001-2012. The annual number 
of newly infected adults has decreased by 34% since 2001 (Joint United Nations Programme on HIV/AIDS (UNAIDS) 2013). 
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Despite an improvement in both globally and particularly in sub-Saharan Africa, HIV-1 infection 
and AIDS remains a major health concern. ARTs are effective in most cases but universal access 
and compliance remain logistical problems. Attitudes to sex (e.g. use of condom, multiple 
partners) remains an area of concern. In the absence of an effective vaccine or cure, global efforts 
at optimising therapy remain a primary focus area. 
2.2. HIV-1 structure 
HIV belongs to the Lentivirus group of the family Retroviridae. It is an enveloped RNA virus of 
spherical shape and particle size of 100-120nm in diameter. The HIV-1 genome is made up of 
two identical 9.2 kb single stranded RNA molecules enclosed in a cone-shaped nucleocapsid, 
surrounded by a lipid bilayer membrane (Frankel & Young, 1998).  
Encoded in the genome are nine open reading frames (ORFs) (Figure 2-4). Three of the ORFs 
encode for a structural proteins; Gag, Env and Pol. The gag gene encodes four glycoproteins, viz. 
matrix (p17), capsid (p24), nucleocapsid (p9), and p6; Env is cleaved to produce gp120 and 
gp41. These are all structural proteins of which the virion core and outer membrane envelope 
consist. The Pol proteins, viz. viral protease (p10), RNA polymerase (p15), reverse transcriptase 
(p50) and integrase (p31) play a vital enzymatic role promoting the processes of transcription and 
integration. Tat and Rev are regulatory proteins that play critical roles in gene regulation. Tat is 
essential for HIV-1 replication by lengthening the phase if HIV-1 transcription, whilst Rev plays 
a role in the transition from early to late phase of HIV gene expression. The viral genome also 
Figure 2- 3: The prevalence of HIV infection amongst young people from different parts of Africa from 2001-
2012. The prevalence of HIV infection amongst young people from different parts of Africa from 2001-2012. 
There was a decrease in the prevalence of HIV amongst young men and women of Southern Africa from 2001-
2012. However, the prevalence amongst young women of Southern Africa remains higher than in young men 
of Southern Africa despite the decrease seen since 2001 (Joint United Nations Programme on HIV/AIDS 
(UNAIDS) 2013). 
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encodes four accessory proteins, Vif, Vpr, Vpu and Nef (the latter also sometimes included as a 
regulatory protein) that represent important virulence factors in vivo (Frankel & Young 1998). 
2.3. HIV-1 replication and transmission 
HIV infection is usually characterised by three disease stages (Figure 2-5); the Acute Phase 
where initial viral replication occurs unhindered by specific immune pressure. This phase 
includes the process of initiation of inflammatory responses and stimulation of innate immune 
cells. During this time the initiation and amplification of acquired immunity also occurs. Cell-
mediated and humoral immunity develops later in this stage creating selective pressure that 
results in a decrease in viral replication. This decline in viral replication results in the 
establishment of a relatively stable viral load, defined as the viral load set point. The 
establishment of the viral set point is accompanied by stabilisation of the CD4 count, and both 
these phenomena generally represent the Chronic Phase (i.e. a transition from acute to chronic 
infection).During the Chronic Phase infected individuals are usually asymptomatic, however, this 
phase is also characterised by continued unresolved inflammation and immune activation, which 
may be caused by antigenemia.  
Antigenemia may arise as a result of HIV itself, but also to other chronic viral infections (e.g. 
Cytomegalovirus (CMV)) and to increased gut content antigens entering the circulation due to 
translocation. This clinically latent phase may last many years and eventually leads to the 
destruction of the host‟s immune system as a result of chronic immune activation eventually 
leading to immune exhaustion. This culminates in the onset of AIDS, the appearance of 
opportunistic infections in the host and ultimately the death of many un-treated patients 
Figure 2- 4: Genomic structure of HIV-1. The figure shows the genes gag, pol and env and the accessory 
genes vif, vpu, vpr, tat, rev and nef. Kbp represents kilo-base pair (Frankel & Young 1998). 
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(Coleman & Wu, 2009; Kedzierska et al., 2003). The implementation of combination ART 
(cART) has however led to a decrease in the number of AIDS deaths, allowing HIV-infected 
individuals to live much longer. The use of ART drugs leads to a reduction in plasma viral load 
to undetectable levels. Infected individuals will subsequently be less infectious and this could 
most likely decrease the transmission of HIV via sexual contact. With the use of ART the chronic 
phase of HIV infection is prolonged and the onset of AIDS delayed (Centers for Disease Control 
and Prevention, 2009). 
 
There are three major routes of transmission, namely: 
 Horizontal (sexual contact, both hetero- and homosexual) 
 Vertical (mother-to-child) 
 Intravenous drug users 
Irrespective of the route of HIV infection and the first cells which are infected, viral replication 
converges on GALT in only a few days (Cohen, 2011). This is subsequent to detection of 
infection in localized draining lymph nodes (usually of the genital tract). Once the GALT is 
infected, a massive destruction of memory CD4
+ 
T cells occurs. This event marks a major turning 
point in the pathogenesis process, with the scales turning toward the virus‟s advantage. Normally, 
the immune system ensures that infection is contained and eradicated before irreversible damage 
to the host occurs. However, this does not occur during HIV infection. 
Figure 2- 5: Diagram illustrating the stages of HIV infection, including the length of each stage as well as the 
emergence of viral load and its effect on CD4
+
 T-cell count (William Chris Woodward 1999).  
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The pathogenesis of HIV-1 infection is an extremely complex process involving multiple role 
players. For the purposes of this thesis, the primary focus will be on inflammation, now an 
accepted driver of disease pathogenesis, and host immune response, particularly innate responses 
and the role of monocytes in HIV-1 disease progression.  
2.4. The host immune system 
2.4.1. An overview of the inflammatory response 
The acute inflammatory response is initiated by infection or tissue injury and consists of the 
coordinated delivery of blood components, such as plasma proteins and leukocytes to the site of 
infection or tissue injury. This response has been best characterised for microbial infections 
where the response is triggered by a family of Pattern-Recognition Receptors (PPRs), which 
recognise Pathogen-Associated Molecular Patterns (PAMPs). Toll-like Receptors (TLRs) and 
NOD (nucleotide-binding oligomerisation-domain protein)-like receptors (NLRs) are two 
families of PPRs that represent the major receptors of the innate immune system. TLRs recognize 
extracellular or endosomal antigens as they are membrane bound receptors. NLRs recognize 
intra-cytoplasmic antigens as they are located intra-cytoplasmically. TLRs and NLRs are two 
important groups of PRRs that serve to initiate inflammatory responses through the recognition 
of various PAMPs (Lehner, 2002).. There are also other PPRs including RIG-Like Receptors 
(RLRs) and C-type Lectin Receptors (CLRs). The initial recognition of infection is facilitated 
through tissue-resident macrophages, mast cells and dendritic cells. Following antigen 
recognition via PRRs, innate cells are induced to secrete various inflammatory mediators such as, 
chemokines, cytokines, vasoamines, eicosanoids and other products of proteolytic cascades. The 
central and most important role of these mediators is to initiate an inflammatory response that 
creates a local pro-inflammatory microenvironment. This involves the translocation of plasma 
proteins and leukocytes from the blood vessels to the extra-vascular tissues at the site of infection 
through post-capillary venules (Figure 2-6). The activated endothelium of blood vessels allows 
for selective extravasation of leukocytes whilst preventing the exit of erythrocytes from the blood 
stream. This selective ability is achieved through the inducible ligation of endothelial-cell 
selectins with intergrins and chemokine receptors present on leukocytes (Medzhitov, 2008; Qu et 
al., 2014).  
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Upon arrival at the infected tissue site, neutrophils become activated. This occurs through either 
direct contact with the pathogen or through the effects of secreted cytokines by resident tissue 
cells. Neutrophils then make an attempt to eradicate the invading agents either through 
phagocytosis or through the secretion of the contents of their granules. These granules contain 
reactive oxygen species (ROS) and reactive nitrogen species (NOS), proteinase 3, cathepsin G 
and elastase. These extremely powerful effectors are not able to discriminate between microbial 
and host targets which leads to inevitable damage to surrounding host tissues (Medzhitov, 2008; 
Qu et al., 2014).  
 
If an inflammatory response is successful, elimination of the infectious agent will be achieved 
followed by termination of the inflammatory process and then a repair phase that is mediated 
mostly by resident tissue macrophages and other recruited monocytes/macrophages. One very 
important step in the resolution of the inflammatory response is the switch from the expression of 
pro-inflammatory prostaglandins, to anti-inflammatory lipoxins. Lipoxins are involved in 
inhibiting the recruitment of neutrophils and instead encourage the recruitment of monocytes to 
sites of inflammation. Here the monocytes are responsible for clearing of dead cells and 
facilitating tissue remodelling. Other non-cellular mediators include lipid mediators (resolvins & 
protectins), and cytokines e.g. Transforming Growth Factor-β (TGF- β) secreted by macrophages. 
These lipid mediators and cytokines also play an essential role in the initiation of tissue repair 
Figure 2- 6: Graphical  representation of the inflammatory response showing activation of neutrophil via 
bacterial products, recognition of neutrophils through the tetrasaccharide carbohydrate Sialyl-LewisX and 
the involvement of integrins and selectins in the diapesdis of neutrophils through the blood vessel wall as well 
as the subsequent phagocytosis and destruction of bacteria (Medzhitov, 2008). 
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following an inflammatory response via the stimulation of cell replication and deposition of 
collagen by fibroblasts (Medzhitov, 2008; Qu et al., 2014).  
If, however, the initiated inflammatory response is unable to clear the infectious agent the 
inflammatory response persists and develops novel characteristics. Neutrophils initially present at 
the site of infection are replaced with T-cells and monocytes that differentiate into macrophages. 
If the activity of both macrophages and T-cells are inadequate to eradicate the antigen, the 
inflammation becomes chronic and a chronic inflammatory state is established. This occurs in the 
lymph nodes and other lymphoid tissues (especially the GALT) during HIV-1 infection. The 
features of this type of inflammatory response are highly dependent on the effector class of T-
cells that are present, and in HIV infection during most stages of disease it is a pro-inflammatory 
Th1-type milieu (Medzhitov, 2008; Qu et al., 2014).  
The mechanisms involved in infection-induced inflammation are understood far better than any 
other inflammatory process. However, it has been said that even though infection-induced 
inflammation is important in clearing an infection, it may be unique for particular conditions 
(infectious agent, infectious dose, host status etc.). Therefore, it is essential to fully understand 
the mechanisms involved in infection-induced inflammation and how these mechanisms can be 
applied to other inflammatory processes (Medzhitov, 2008).  
In HIV infection the initiation of inflammation is important in the early acute stage as an attempt 
to control the virus and eradicate it. The virally-induced inflammation is also important for the 
initiation of effective acquired immunity. Innate cell-derived cytokines prime a pro-inflammatory 
Th1 antiviral immunity. The initial inflammation becomes problematic when the pathogen 
remains un-cleared. There is no resolution of inflammation, rather continued promotion of 
damaging pro-inflammatory immune responses (including helper and CTL activity, production of 
cytokines such as IL-6, tumour necrosis factor-alpha (TNF-α) and IFN-γ and hyper-stimulation of 
B cells. Chronic inflammation, particularly in lymphoid tissues, leads to chronic immune 
activation, hyper-responsiveness and ultimately exhaustion. Coincidental with immune collapse 
is the development of fibrosis in lymphoid tissue due to initiation aberrant repair mechanisms. 
This accumulation of multiple drivers towards immune collapse culminates in death of the host. 
The initial trigger is the natural initiation of normal innate immunity by the incoming virus 
(Medzhitov, 2008). 
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2.4.2. Innate immune system 
The immune system comprises of innate and adaptive arms. Innate immune responses are said to 
be older and are evolutionarily more conserved. Innate immunity is a first line defence system 
intimately linked to inflammation that includes phagocytes, both mononuclear (monocytes and 
dendritic cells) and polymorphonuclear (granulocytes); cytolytic cells, primarily NK cells, other 
innate lymphocytes, and all cellular associated cytokines (Figure 2-7). The purpose of the innate 
immune system is to eradicate invading pathogens without causing extensive host damage. The 
type of response can vary depending on which immune cells initiate the response and which 
predominate, as well as which cytokines are produced. Monocytes play an essential role in the 
early response of the innate immune system (Sasse & Van Beckhoven, 2012).  
The innate immune system is active during the acute phase of infection and precedes the 
development of specific adaptive immunity. Innate immune cells first function as effector cells in 
the innate response but later may act to dampen or enhance adaptive immune responses (Lehner, 
2002). The pro-inflammatory mediators in the inflammatory response are mostly produced by the 
innate immune cells that are stimulated through PPRs that are specific to bacterial products 
(Brenchley & Douek, 2012).. 
 
Figure 2- 7: Immune cells that comprise the innate and adaptive immune system (Dranoff, 2004). 
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2.4.3. Role of the Gut-Associated Lymphoid Tissue (GALT) in HIV-1 
pathogenesis 
Microbial translocation, whether it is microorganisms or microorganism components, from the 
gut lumen of the gastrointestinal tract (GIT) into the systemic circulation may have dramatic 
consequences, including promoting immune activation. A possible cause for this phenomenon is 
the extremely high levels of pro-inflammatory cytokines, such as tumour necrosis factor (TNF), 
that are produced in the GALT in response to gut leakage. Despite the fact that the release of 
these cytokines initiates a favourable immune response, the over production of these cytokines 
leads to an enhanced systemic inflammatory response. In some cases this is more damaging than 
the infection itself. If microbial products such as Lipopolysaccharide (LPS), an outer-membrane 
component of Gram-negative bacteria, move across the mucosal and epithelial barriers a large 
amount of specialized resident macrophages prevent the bacterial products from translocating 
into the systemic circulation (Brenchley & Douek, 2012).  
HIV-1 infection that usually stems from mucosal exposure results in epithelial and resident innate 
immune cell stimulation and production of pro-inflammatory cytokines. Dendritic cells aid in 
translocation of viral particles to the draining lymph nodes. Once within the lymphoid tissue, the 
virus has optimal exposure to its primary target, CD4
+
 T-cells. Following initial viral expansion 
in the lymph nodes, the virus gains access to the GALT, a CD4
+
 T-cell store, this results in the 
characteristic rapid depletion of these cells. CD4
+
 T-cell depletion affects primarily the lamina 
propria of the gut and to a lesser degree the Peyer‟s patches. This phenomenon is also seen in 
rhesus macaques (RM) infected with simian immunodeficiency virus (SIV) and the natural hosts 
of SIV, African green monkeys (AGM) and Sootey Mangabeys (SMs) (Cohen, 2011). CD4
+
 T-
cells present in the gut are said to have a “memory‟ phenotype and express CCR5, the main co-
receptor for M-Tropic HIV strains. It has been suggested that half of the CD4
+
 T-cells found in 
the body are present in the GALT (Stellbrink et al., 2010). The environment of the GALT is 
optimal for viral replication. Within a few days most of the cells present in the GALT are 
infected and they die due to cytopathic effects of the virus infection or due to bystander cell 
death. Bystander death occurs as a result of cellular activation and activation of death receptor 
pathways (Cohen, 2011).  
Weakening of gut barrier integrity also occurs as tight junctions are breached during the CD4
+
 T-
cell depletion, this facilitates the entry of microbial products into the body, such as LPS, from the 
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gut lumen into the tissues of the host (Figure 2-8) (Cohen, 2011; Wasserman et al., 2011). This 
leads to the activation of both the innate and adaptive immune responses (Cohen, 2011). During 
HIV infection chronic systemic immune activation persists, various causes have been suggested. 
Many of these causes are multifactorial, including: the constant increased levels of type I and 
type II interferons, innate and adaptive immune responses to HIV-1 infection, bacterial products 
that translocate from the damaged or “leaky” gut, effects of the HIV-1 virions or viral proteins, 
co-infections with non-HIV pathogens (e.g. CMV), and the dysregulation of cytokine and 
chemokine production. This persistent immune activation is also evident in the later stages of 
infection as the host progresses towards AIDS (Kamat et al., 2012).  
 
Interestingly there is no increase in the levels of LPS translocation and low levels of immune 
activation are seen in AGMs and SMs infected with SIV, where non-pathogenic disease is 
observed. Furthermore, it has been shown that there is an absence of microbial translocation in 
SIV‟s natural hosts (Douek, 2007). It has therefore been suggested that the CD4+ T-cell depletion 
on its own cannot account for the translocation of LPS seen in chronic HIV-1 infection and that 
on-going immune activation is rather linked to GIT damage and microbial translocation 
(Brenchley et al., 2006; Hofer et al., 2010; Estes et al., 2010; Vassallo et al., 2012; Hunt, 2012). 
This further highlights the pivotal role of LPS translocation and the role immune activation plays 
in the pathogenesis of SIV infection and ultimately its application in understanding HIV-1 
infection.  
Figure 2- 8: “Leaky gut” observed during HIV infection. The height of the villi decrease leading to increased 
crypt depth, which has been associated with CD8
+
 T-cell infiltration. Abnormal enterocyte differentiation and 
apoptosis is seen as well as the loss of the tight junctions (Sandler & Douek, 2012). 
Stellenbosch University  http://scholar.sun.ac.za
16 
 
2.4.4. Role of Lipopolysaccharide in HIV pathogenesis 
LPS is an important bacterial component that can enter systemic circulation due to GIT damage 
and translocation. Due to the importance of LPS as a stimulus for monocytes, this will be 
discussed in more detail. 
The concept of microbial translocation is seen in many disease settings. These include graft 
versus host disease, inflammatory bowel disease and surgery of the gut. Microbial translocation 
has been correlated with systemic immune activation in several of these conditions. Since 2007 it 
has been acknowledged that those infected with HIV-1 may have a significant increase in gut 
permeability. Immunological and structural defects act together in HIV-1 infection in causing 
microbial translocation (Figure 2-9).  
 
 
 
 
 
 
 
 
 
 
LPS is a well-known immune stimulator. This immune stimulation is linked to the binding of 
LPS to the CD14/TLR-4 complex. CD14 is the primary LPS receptor and exists in both cell 
membrane (mCD14) bound and soluble (sCD14) forms. mCD14 is expressed on cells of the 
monocyte lineage and sCD14 is thought to represent mCD14 which has been cleaved in response 
to either monocyte activation or differentiation. SIV infection in SMs has been connected to low 
levels of immune activation, even in the presence of high viral loads. Microbial translocation that 
occurs early in HIV infection has been implicated as a cause for the systemic immune activation 
Plasmacytoid DC 
Figure 2- 9: HIV-1 infection leading to CD4
+
 T-cell depletion and consequent damage to gut barrier and 
“leaky gut” syndrome. Microbial translocation follows, resulting in stimulation of TLR4, present on 
monocytes, through elevated levels of LPS leading to release of pro-inflammatory cytokines that can cause 
immune activation. Additionally stimulation by HIV-1- encoded TLR7 ligands on plasmacytoid DC can also 
lead to immune activation through pro-inflammatory cytokines (Chang & Altfeld, 2009). 
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seen during chronic infection (Douek, 2007). It is suggested that the mucosal damage that occurs 
in the GIT of SIV-infected RMs and HIV-1 infected individuals may lead to high levels of LPS 
being released. This could hinder the ability of the host‟s defence mechanisms and therefore 
permits the generation of persistent immune activation (Vassallo et al., 2012). The degree of 
mucosal damage seen in pathogenic SIV infection has been linked to the extent of the microbial 
translocation, which in turn drives the production of inflammatory cytokines from resident 
macrophages and recruited monocytes (Vassallo et al., 2012) Innate immune cells and 
specifically monocytes, from HIV-1 infected individuals, have been shown to be refractory to 
LPS stimulation ex vivo; it was then suggested these monocytes had already been stimulated with 
LPS in vivo (Brenchley et al., 2006).  
This is evidence that LPS is a contributor to systemic activation and that this concept may be 
applied to diseases like HIV-1 infection, where the microbial translocation is seen. Therefore, the 
level of microbial translocation seen in HIV-1 infected individuals may be used to establish the 
rate of progression to AIDS (Douek, 2007). Due to its importance as a monocyte stimulus, LPS 
stimulation of whole blood or purified monocytes can be used to test monocyte function. This 
procedure has been applied in the current study to assess functional responsiveness of monocytes 
in HIV-infected and uninfected individuals. 
2.4.5. Immune activation and its role in HIV pathogenesis 
As mentioned previously, a key feature of both pathogenic SIV and HIV-1 infection is the 
persistent immune activation that leads to, pro-inflammatory cytokine production, uninhibited 
viral replication in activated T-cells and ultimately immune exhaustion. Continuous immune 
activation in HIV-1/SIV infection is characterized by polyclonal B-cell activation, an increased 
T-cell production as well as elevated levels of activated T-cells. Also seen is augmented 
production of pro-inflammatory cytokines (Estes et al., 2010; Hunt, 2012). Immune activation 
and inflammation observed during HIV-1 infection are mediated directly and indirectly by HIV-1 
itself. Direct immune activation is characterized by HIV-1 specific CD8
+
 T-cell cytolytic 
responses, a decrease in CD4
+
 T-cells responses to the HIV-1 infection as a result of CD4
+
 T-cell 
depletion as well as activation of HIV-1-specific and non-specific antibody producing B-cells, 
NK cells and monocytes. Indirect immune activation, on the other hand, can occur due 
reactivation of other latent viruses such as CMV or Herpes viruses (Douek, 2007; Lehner, 2002; 
Wasserman et al., 2011; Brenchley & Douek, 2012; Kamat et al., 2012; Mir et al., 2012). 
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Immune activation has both negative and positive effects during HIV-1 infection by promoting 
aspects of immunity to control the virus but also systematically causing damage. Immune 
activation has also been suggested as a better measure of disease progression than viral load or 
CD4
+
 T-cell count (Haynes, 2006; Douek, 2007; Cassol et al., 2010; Kwon et al., 2012). 
The excessive nature of the immune activation observed in HIV-1 infection causes it to be a 
major driver of HIV-1 replication and progression to AIDS. In a study performed by Brenchley & 
Douek (2012), elevated levels of circulating LPS were a contributing factor to the abnormal 
immune activation seen in those infected with HIV-1, as a result of microbial translocation. 
Consequently it can be stated that in developed countries, microbial translocation and immune 
activation may play a significant role in HIV-1 pathogenesis but it still remains, to some extent, 
unclear what role they play in HIV-1 infection in Africa. A study performed in Uganda, showed 
no association was found between circulating LPS and progression to AIDS (Redd et al., 2009). 
However, another 2009 study conducted in Kenya on female sex workers, identified a significant 
association between HIV-1 infection and plasma LPS (Lester et al., 2009). The authors further 
stated the inflammatory responses to LPS were extremely variable between the individuals. This 
would suggest differences in the host immunity and levels of background immune activation are 
able to modify the influence of microbial translocation on HIV-1 disease. These contrasting 
studies highlight the necessity to elucidate the relationship between the pathogenesis of HIV-1 
infection and immune activation through microbial translocation (Brenchley & Douek, 2012). It 
further highlights the need to understand the role the immune system plays in HIV-1 infection 
and its progression to AIDS, especially in the African setting.  
Various studies have recently linked surrogate markers of the persistent inflammatory state to 
clinical outcomes; this confirms persistent immune activation as a therapeutic target worth 
exploring. Widespread immune activation has been acknowledged as an important feature of 
AIDS pathogenesis. According to Hunt (2012), the polyclonal T-cell activation that is seen in 
untreated HIV-1 infection should be attributed to the generalized immune activation seen and not 
an outcome of the expansion of HIV-specific CD8
+
 T-cells. During HIV-1 infection in addition to 
immune activation, higher frequencies of immune cell proliferation, activation and apoptosis 
have been observed (Mir et al., 2012). 
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2.5. Monocytes 
2.5.1. Origin 
Cells of the myeloid lineage include monocytes, macrophages, myeloid or conventional dendritic 
cells (mDC/cDC), granulocytes and mast cells. These cells play an extremely important role in 
the innate immune system as they are the first line of defence against invading pathogens. These 
cells also play an important role in HIV-1 infection and transmission (Le Douce et al., 2010; 
Cassol et al., 2010; Laforge et al., 2011; Wu, 2011; Mir et al., 2012). Cells of this lineage, 
particularly monocytes/macrophages are important to study as they may be targeted by HIV-1 in 
vivo and are also the main responders to LPS thus serving as the link between GIT translocation 
and immune activation in HIV-1 infection. 
Monocytes are generated in the bone marrow from haematopoietic stem cells. They are released 
into the blood stream and circulate for up to three days before migrating to specific tissues, 
relocating to the spleen and entering the stored monocyte pool or being eliminated through 
natural homeostatic apoptosis. Whilst circulating in the blood stream, monocytes are able to 
detect a large number of pathogens via their broad range of PRRs. Monocytes make up 3-8% of 
blood leukocytes and serve as precursor cells to macrophages and in some cases mDCs. 
Macrophages and DCs are important APCs and play a central role in HIV pathogenesis. 
Monocytes are able to respond in the blood to circulating antigen, this characteristic may be 
important in HIV as increased levels of LPS (and other GIT products) in the blood is well 
described (Le Douce et al., 2010; Cassol et al., 2010; Laforge et al., 2011; Wu 2011; Mir et al., 
2012). 
In a recent study by Sassè et al. (2012), it was shown that the spleen is a reservoir for a large 
amount of monocytes. The authors provide clear evidence that there are un-differentiated 
monocytes inhabiting the spleen and that the monocytes outnumber those that are in circulation. 
This observation identified the spleen as a site of storage and deployment of splenic monocytes 
which performs as a reserve the body uses to control inflammatory responses. The current 
working hypothesis is that monocytes freely circulate in the blood stream and they patrol vessels 
and irreversibly differentiate into macrophages and mDCs.  
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2.5.2. Properties 
Monocytes are characterized by a large degree of plasticity, widespread tissue distribution and 
the ability to respond to a large variety of environmental stimuli, such as microbial products and 
host cytokines. Whilst in circulation monocytes are exposed to cytokines such as macrophage- 
colony stimulating factor (M-CSF) which alter their phenotype and functional properties. 
Therefore monocytes can be classified into subsets based on their cellular surface expression of 
functional receptors. It has not been clarified whether the monocyte subsets signify cells that are 
already predisposed to differentiate into polarized M1 or M2 macrophages or DCs. It has been 
suggested that during a non-disease state blood monocytes are most likely predisposed toward 
M2 phenotype, which is aligned with tissue repair, due to their stimulation by elevated levels of 
M-CSF that is present in plasma (Cassol et al., 2010; Laforge et al., 2011).  
Monocytes are phagocytic cells that are able to recognize and eradicate pathogens in a rapid 
fashion, with no need for antigen sensitization. This is achieved via a network of innate immune 
receptors that are expressed on their cellular surface which leads to either phagocytosis, killing of 
pathogens, the production of cytokines as well as the production of reactive oxygen and nitrogen 
species (Le Douce et al., 2010; Wu, 2011; Ackerman & Dugast et al., 2012; Gama et al., 2012; 
Mir et al., 2012). 
2.5.3. Function and activation 
Monocytes primarily function to initiate innate immune responses against a large range of 
pathogens. They make use of phagocytosis, intracellular killing (phagocytic burst response), and 
the secretion of cytokines, chemokines and other mediators to eradicate microbes (Le Douce et 
al., 2010; Mir et al., 2012). Monocytes have the ability to assimilate phagocytosed antigen and 
then present them in the lymphoid tissues. This then results in the prompt induction of adaptive 
immunity and the initiation of long-lived memory responses (Ackerman & Dugast et al., 2012; 
Gama et al., 2012). The differentiation that blood monocytes undergo in tissues is dependent on 
signals received from the local microenvironment (Le Douce et al., 2010; Mir et al., 2012).  
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2.6. Monocyte subsets  
Several schemes of monocyte classification exist but monocytes are usually divided into two 
major subsets. This division is based on surface protein marker expression, but extends to 
cytokine production and the gene expression profiles (Mir et al., 2012). Monocytes can be either 
termed “classical”, “intermediate” or “non-classical” depending on their varied expression levels 
of CD14 and CD16, however, there is much debate surrounding the delineation of monocyte 
subsets. For the purposes of the current study monocyte subsets have been defined using the 
expression of CD16 on monocytes as CD14+CD16- or CD14+CD16+.  
2.6.1. CD14+CD16- monocyte subset 
CD14+CD16- monocytes are the largest subset, accounting for >80% of blood monocytes in 
disease free individuals. They express high levels of CD14, almost no CD16 and are reported to 
have a pro-inflammatory phenotype. CD14+CD16- monocytes express elevated levels of 
chemokine receptor 2 (CCR2), the receptor for chemotactic ligand 2 (CCL2), also known as 
Monocyte Chemotactic Protein-1 (MCP-1). This receptor is involved in directing the migration 
of these monocytes towards sites of inflammation. CCL2 is expressed by cells in response to 
activation either by, pro-inflammatory cytokines, or stimulation of innate immune receptors by a 
range of microbial molecules (Shi & Pamer, 2011). At these sites of infection there is a high 
concentration of CCL2 present, which is the ligand for CCR2 (Sasse & Van Beckhoven, 2012). 
L-selectin (CD62-L), which is best described as being involved in homing of lymphocytes to 
lymph nodes, is also expressed at high levels in CD14+CD16- monocytes. MCP-1/CCR2 
facilitates the migration of CD14
+
CD16
-
CCR2
+
CD62-L
+
 monocytes into lymph nodes during 
inflammation (Ancuta et al., 2003; Hearps et al., 2012). However, CD14+CD16- monocytes may 
possess anti-inflammatory properties via their ability to produce high levels of IL-10. 
2.6.2. CD14+CD16+ monocyte subset 
CD14+CD16+ monocytes also have a pro-inflammatory phenotype; however, they preferentially 
express the fractalkine receptor (CX3CR1) instead of CCR2, and using CX3CR1, CD14+CD16+ 
monocytes migrate into tissues in response to CX3CL1 (Bocchino et al., 2001; Ancuta et al., 
2003; Bergamaschi & Pancino, 2010; Iijima et al., 2011; Zawada et al., 2011; Mir et al., 2012). 
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CD14+CD16+ monocytes account for 5-10% of the total circulating monocyte population. 
CD14+CD16+ monocytes display characteristics of tissue macrophages and therefore may 
represent a higher level of differentiation as compared to the CD14+CD16- subset (Bergamaschi 
& Pancino, 2010). This monocyte subset is more susceptible to HIV-1 infection due to the high 
expression levels of CD4 and CCR5 receptors. Unlike CD4
+
 T-cells, CD14+CD16+ monocytes 
are expanded up to 40% during HIV-1 infection and have the ability to migrate to tissues where 
they are able to form long-lived viral reservoirs. Various studies have shown that monocytic 
functions such as phagocytosis, chemotaxis and cytokine secretion both in vivo and in vitro are 
changed during HIV-1 infection (Locher et al., 1994; Kedzierska & Crowe, 2002; Vlad et al., 
2003; Bergamaschi & Pancino, 2010; Cassol et al., 2010; Le Douce et al., 2010; Ackerman & 
Dugast et al., 2012; Gama et al., 2012; Hunt, 2012; Hearps et al., 2012; Mir et al., 2012; Sasse & 
Van Beckhoven, 2012; Martin et al., 2013).Furthermore, it has been shown that in vivo and in 
vitro CD14+CD16+ monocytes are an important source of the pro-inflammatory cytokine TNF-α 
(Cassol et al., 2010; Hearps et al., 2012).  
CD14+CD16+ monocytes secrete elevated levels of TNF-α and lower levels of IL-10, a 
regulatory cytokine primarily involved in dampening immune responses, compared to 
CD14+CD16- monocytes. IL-10 was first identified and described as an important facilitator of 
T-cell exhaustion and a critical determining factor of viral persistence in the lymphocytic 
choriomeningitis virus mouse model (Sasse & Van Beckhoven, 2012). CD14+CD16+ monocytes 
also have been reported to possess diminished phagocytic capacity whilst possessing a higher 
antigen presenting capacity. However, others have reported conflicting findings, with increased 
phagocytic capacity as compared to CD14+CD16- monocytes. CD62-L is expressed in very low 
levels in CD14+CD16+ monocytes. This suggests that CD14+CD16+ monocytes are not 
preferentially recruited to the lymph nodes during inflammation (Ancuta et al., 2003; Hearps et 
al., 2012). 
A study done in mice by Gautier et al. (2009) showed the behaviour of the CD14+CD16+ 
monocyte subset is context dependent. The authors showed that infiltration of the CD14+CD16+ 
monocyte subset into sites of tissue injury occurred in the late stages of inflammation and 
CD14+CD16+ monocytes are thought to play a role in tissue repair. However, in bacterial 
infections their recruitment is earlier. In myocardial infarction and skeletal injury studies, 
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CD14+CD16- monocytes are critical for setting up the resolution of inflammation by cleaning 
cellular debris and CD14+CD16+ monocytes are seen to mediate tissue repair. 
2.7. HIV Infection and monocyte impairment 
2.7.1. Monocyte population changes and functional impairment as a 
consequence of HIV-1 infection 
Alterations in circulating monocyte subsets are seen in HIV-1 and pathogenic SIV infection, 
including the above-mentioned and well described expansion of the CD14+CD16+ monocyte 
subset. The expansion of the CD14+CD16+ subset is known to correlate with plasma HIV-1 viral 
load; this is also observed in SIV-infected RMs, where it has also been shown to correlate with 
SIV viral load; whilst peripheral blood CD4
+
 T-cell count correlates inversely with 
CD14+CD16+ monocytes. It has also been seen that HIV-1 and pathogenic SIV infection lead to 
changes in the trafficking and the turnover of myeloid cells. SIV-infected RMs have shown 
increased monocyte turnover and this is said to be a better indicator of disease progression than 
CD4 count or viral load. In addition, this turnover probably reflects the increased recruitment 
from the bone marrow in response to elevated macrophage turnover that occurs in both peripheral 
and lymphoid tissues (Cassol et al., 2010; Mir et al., 2012).  
A study performed which involved three groups of HIV-infected individuals, namely; (1) 
asymptomatic untreated patients with CD4
+
-cell counts above 500cells/μl, (2) asymptomatic and 
symptomatic non-AIDS patients with CD4
+
-cell counts below 500cells/μl, and (3) AIDS patients, 
found that the monocyte count in group 1 was elevated when compared to groups 2 and 3. An 
overall more activated status of monocytes in HIV-1 infected individuals was also seen (Elbim et 
al., 1999).  
Monocytes play a very important role in the innate immune system through their antigen 
presentation function. Defects in this antigen presentation are a major issue during HIV-1 
infection, and its systemic impairment happens at every stage of the plasma viremia. Moreover, 
defects in major histocompatibility complex (MHC) class II expression, formation of class II 
antigen complexes and antigen uptake have been observed in chronically infected monocytes 
during HIV-1 infection. The impaired antigen presentation could be related to severe immune 
dysfunction in HIV-1 infected individuals. The means by which this process occurs is not fully 
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clarified but it has been seen that there is reduced capacity of HIV-1 infected monocytes to 
stimulate or present antigen to CD4
+
 T-cells. These defects may contribute to the 
immunosuppression seen during AIDS. Another reason that can account for this impaired 
stimulation of T-cells is the production of TNF-α induced by gp-120, which has been linked to 
defective antigen presentation capacity of monocytes in AIDS individuals (Sasse & Van 
Beckhoven, 2012). 
Monocytes and macrophages are highly secretory cells and play a role in the altered chemokine 
and cytokine secretion patterns observed during HIV-1 infection. Production of several cytokines 
such as IL-10 and TNF-α, are affected during HIV-1 infection. TNF-α is known to up-regulate 
HIV-1 expression whilst other cytokines like Interferon-α have been shown to be potent 
inhibitors of HIV-1 replication. In addition to causing dysfunctional cytokine production, HIV-1 
infection is also known to disrupt the normal synthesis of cytokines. It is important to note that in 
addition to direct infection, HIV protein released from infected cells may also affect monocyte 
and macrophage functioning in a bystander effect process (Sasse & Van Beckhoven, 2012). 
Monocytes together with lung alveolar macrophages isolated from HIV-1 infected individuals 
showed reduced phagocytic activity, diminished phagosome-lysosome fusion and decreased 
intracellular killing of opportunistic pathogens. Monocytes that were isolated from patients 
suffering from AIDS also displayed impaired migratory responses; this phenotype has been 
linked to a down-regulation of receptors for chemotactic ligands (Cassol et al., 2010; Laforge et 
al., 2011). However, in in vitro studies conducted on circulating monocytes, it was noted that 
these cells lack any considerable impairment to important functions such as antigen presentation 
and differentiation into macrophages and myeloid DCs (Lederman, 2004).  
2.7.2. Deficient intracellular killing 
Monocytes infected with HIV-1 appear to display an impaired ability to eradicate opportunistic 
pathogens via intracellular killing. The fusion of phagosome and lysosome is pivotal for the 
killing of ingested pathogens. However, this fusion is considerably reduced in HIV-1 infection of 
peripheral blood monocytes and monocyte-derived macrophages (MDMs) which correlates with 
disease progression (Kedzierska & Crowe, 2002). 
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2.7.3. Impaired chemotaxis 
HIV-1 infection is responsible for the deficient chemotactic ability observed in monocytes. 
Monocytic cells from AIDS patients have been shown to display defective migratory responses to 
chemotactic stimuli. This impaired chemotaxis is associated with the down-regulation of CCR2 
surface expression (Kedzierska & Crowe, 2002). 
2.7.4. Impaired phagocytosis 
According to Kedzierska and Crowe (2002) there is no correlation between inhibition of 
phagocytosis, seen during HIV-1 infection, and viral load or CD4
+
 T-cell count. This suggests 
that the defective phagocytosis observed in HIV-1 infection is not as a result of either of those 
measures of disease progression. It has been suggested that restoration of this impaired 
phagocytosis can be achieved by therapy with immuno-modulators such as granulocyte-
macrophage colony stimulation factor (GM-CSF). GM-CSF is said to enhance the ability of 
monocytes and MDMs to phagocytose almost to the levels of un-infected cells.  
2.7.5. Altered cytokine and chemokine production profile 
A key feature of HIV-1 infection is immune activation and altered cytokine production various 
immune cell types. Monocytes play a major role in the altered cytokine and chemokine profile 
seen during HIV-1 infection. Cells of the monocyte lineage are associated with increased 
production of inflammatory cytokines. The elevated levels of inflammatory cytokine production 
are believed to activate HIV-1 replication and sustain active HIV-1 expression (Kedzierska & 
Crowe, 2002).  
In the following sections a selection of cytokines and chemokines and their receptors which have 
been studied in this current study will be discussed. 
TNF-α and IL-10 
Increased levels of the pro-inflammatory cytokines TNF-α and GM-CSF seen during HIV-1 
infection could result in the shift of virus-infected monocytes towards differentiation into 
macrophages or DCs (Bennasser et al., 2002; Iijima et al., 2011; Hou et al., 2012; Mir et al., 
2012). It was found that HIV-infected humanized-mice had an elevated level of plasma TNF-α, 
which resulted in disruption of tight junctions and apoptosis of intestinal epithelia (Hofer et al. 
Stellenbosch University  http://scholar.sun.ac.za
26 
 
2010). This is further supported by the observed apoptosis of intestinal epithelia which 
contributes to barrier dysfunction and therefore facilitates microbial translocation (Guillemard et 
al., 2004).  
In chronically HIV-1 infected individuals, monocytes have been shown to produce more TNF-α 
upon re-stimulation with LPS. Monocytes from HIV-1 infected individuals also display impaired 
phagocytosis of Mycobacterium and there is also a decrease in LPS-mediated enhancement of 
phagocytosis when compared to the enhancement of monocyte phagocytosis in un-infected 
individuals (Bocchino et al., 2001). Ex vivo, monocytes of HIV-1 infected patients have shown a 
diminished pro-inflammatory cytokine response when stimulated with LPS; this has been 
speculated to be due to in vivo pre-stimulation (Hofer et al., 2010). 
Monocytes from viremic patients that had been stimulated with LPS showed an over-production 
of TNF-α (Sauce et al., 2013).TNF-α production has been linked to at least two consquences. 
Firstly, the stimulation of HIV-1 replication in chronically infected cells and the second is linked 
to neurological disorders. The HIV-1 protein Tat has also been implicated in acting extra-
cellularly to cause the production of TNF-α by peripheral blood monocytes. The Tat-generated 
production of TNF-α seems to contribute towards disease progression as a pathogenic factor 
through its pro-inflammatory characteristics (Bennasser et al., 2002). According to Cassol et al. 
(2010), the levels of TNF-α is already maximally expressed by HIV-1 infected individuals during 
the late stages of HIV-1 infection. The high level of viral replication that is observed during the 
late stages of chronic HIV-1 infection is expected to drive continual LPS responses and persistent 
immune activation; together these factors drive the progression of HIV-1 infection to AIDS. In 
contrast it has been found that in whole blood assays no significant difference in TNF-α 
production between HIV-1 infected and un-infected individuals were seen. Whole blood from 
SIV-infected SMs which had been stimulated by LPS was shown to secrete lower levels of TNF-
α than uninfected SMs, suggesting that there is a down-regulation of TNF-α in SIV-infected SMs. 
Furthermore, when whole blood samples from SMs, RMs and human volunteers were stimulated 
with LPS it was found that in control SMs TNF-α expression was 20%, whereas SIV-infected 
SMs showed an expression of 7%. SIV-infected RMs and HIV-1 infected human volunteers did 
not display this reduced expression of TNF-α after LPS stimulation. Together this means that 
SIV-infected SMs experience a decrease in TNF-α production upon LPS stimulation but not SIV-
infected RMs or HIV-1 infected humans (Cassol et al., 2010; Mir et al., 2012).  
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The down-regulation of TNF-α production due to LPS stimulation that is seen in SIV-infected 
SMs could be an early step in preventing high levels of immune activation. Through maintaining 
low levels of aberrant immune activation the disease progression to AIDS is hindered in non-
pathogenic infection. Since there is rapid regulation of monocyte responses to LPS in SIV-
infected SMs, it suggests that there needs to be stringent regulation of monocyte responsiveness. 
In addition, other monocyte responses must then also be regulated to prevent shift of immune 
activation towards disease progression (Mir et al., 2012).  
The decrease of TNF-α secretion seen in SIV-infected SMs is not in any way related to a 
diminished capacity of monocytes to phagocytose infectious agents. Therefore, the innate effector 
mechanisms that play a role in clearing opportunistic infections are preserved. Simultaneously the 
ability to promote immune activation is dampened by SIV infection in SMs. The regulation of 
TNF-α is very important as it‟s one of the earliest and most concentrated pro-inflammatory 
cytokines produced in response to LPS. Furthermore, TNF-α is a major role player in cell 
survival and cell death depending on which receptor it binds (TNFR1 or TNFR2). The decline of 
monocyte responsiveness in SMs to LPS is not likely due to direct infection with SIV infection 
since monocytes are usually infected at very low levels during HIV infection in humans and SIV 
infection in RMs. TNF-α secretion in response to LPS can add to the increased CD8+ T cell 
activation in SMs and highlights the importance of regulating monocyte LPS responses during 
non-pathogenic SIV infection. Natural hosts also alleviate the development of immune activation 
by increasing IL-10 production coupled with lower levels of T-cell activation and apoptosis 
during the acute and chronic phases of the disease. Monocytes have been shown to preserve their 
response to LPS in HIV-1 infection which implies that monocyte-derived pro-inflammatory 
cytokines play a role in facilitating an immune activation environment. The importance of 
uninhibited monocyte TNF-α production as being detrimental to clearing the disease is 
highlighted during pathogenic HIV-1 infection (Iijima et al., 2011; Mir et al., 2012). 
Recent data has provided evidence that there are increased levels of IL-10 and CD14 in AIDS 
patients (Sasse & Van Beckhoven, 2012). Soluble CD14 is the cleaved version of the cellular 
marker and increased plasma levels of CD14 have been correlated with levels of inflammation. 
The level of IL-10 has also interestingly been shown to correlate with levels of CD14, suggesting 
that IL-10 may be a potential driving force for the elevated levels of CD14 seen during systemic 
infection. IL-10 plays many roles in HIV-1 pathogenesis. In chronic infection it is elevated and 
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these levels closely correlate with viral load. Studies involving the blocking of IL-10 signalling 
resulted in the restoration of both CD4
+
 and CD8
+ 
T-cell proliferation as well as cytokine 
production. This suggests that IL-10 could possibly play a role in HIV-1 mediated immune 
exhaustion in that the cytokine induces hypo-responsiveness. Studies have shown that IL-10‟s 
anti-inflammatory effects could be protective during HIV-1 driven chronic immune activation. 
HIV-1 infected individuals who have genetic polymorphisms in their IL-10 gene, that are 
associated with elevated levels of IL-10 production, have shown slowed progression to AIDS, 
decreased decline of CD4
+
 T-cell count and a longer lifespan. Collectively, this means IL-10 may 
have divergent roles in HIV-1 associated immune dysfunction and disease progression (Mir et 
al., 2012; Sasse & Van Beckhoven, 2012).  
Production of IL-10 has been described in numerous cell types such as B cells, T- cells, NK cells 
as well as monocytes. However, monocytes ex vivo have been shown to be the primary producers 
of IL-10 in HIV-1 infected, untreated individuals. Studies have reported that monocyte subsets 
are vital in the regulation of T-cell responses in progressive HIV-1 infection and that increased 
IL-10 levels are characteristic of chronic HIV-1 disease. IL-10 is considered to specifically affect 
T-cell function through its effects on monocytes. This proposes the idea that T-regulatory (Tregs) 
cells may be stimulated by monocyte-derived IL-10. This would lead to a decreased ability of 
monocyte function as APCs through down-regulation of major histocompatibility complex class 
II (HLA-DR) and CD80/86 as well as a diminished cytokine production capacity – both via Treg 
activity. This interplay of Tregs and monocytes and the resulting up-regulation of IL-10 may lead 
to disease progression through limitation of host immune responses, impairment of pathogen 
clearance and its role in controlling inflammation. This interplay may also have the beneficial 
effect of restricting immune-mediated damage to the host (Kwon et al., 2012). 
IL-10 is capable of acting in an autocrine or paracrine manner and its role is to prevent the 
production of TNF-α and other pro-inflammatory cytokines (Mir et al., 2012). IL-10 is able to 
up-regulate CCR1, CCR2 and CCR5 expression in human monocytes; its effect on CCR3, which 
is expressed in low levels, has been shown to be selective. IL-10 has also been shown to promote 
the active replication of HIV in monocytes; this has been linked with an increase in viral entry. 
An up-regulation of CCR5 contributes to IL-10 augmentation of HIV-1 replication. It has been 
suggested that the increase in CCR5 on the cellular surface of monocytes as well as other 
chemokine receptors by IL-10 may facilitate the accumulation of free circulating virions and their 
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eventual cellular entry. In spite of this, it should also be noted that IL-10 exercise various 
functions during the course of HIV-1 infection for instance hindering HIV-1 replication (Sozzani 
et al., 1998; Kwon et al., 2012). 
IL-10‟s role in immune regulation is complex and it seems that this pleiotropic cytokine is 
responsible for the balance between the immune responses that are vital for pathogen clearance as 
well as excessive inflammation that results in collateral damage 
CCR2 and CX3CR1 
In SIV-infected RMs monocytes belonging to the CD14+CD16- subset displayed limited CCR2 
expression. When compared to CCR2
+
 CD14+CD16- monocytes the CCR2
low 
monocyte subset 
showed impaired expression of various cytokine including TNF-α and IL-10. The CCR2low subset 
also exhibited diminished capacity for chemotaxis, and phagocytosis. A comparable subset was 
found in HIV-1 infected individuals with the same characteristics as the CCR2
low
 monocyte 
subset RMs. It has been proposed that these cells developed in response to the virus-mediated 
immune activation and that the characteristics that the CCR2
low
 monocytes exhibit may be 
accelerate disease progression by hindering the development of the antiviral cytotoxic response 
mediated by T-cells (Iijima et al., 2011; Mir et al., 2012).  
Changes in monocyte phenotype in HIV-1 infection may impact early immune responses which 
could in the long run affect virus pathogenesis. Loss of surface CCR2 receptor expression may 
have an impact on cell trafficking as well as efficient responses during infection and 
inflammation. Monocytes in the CD14+CD16- subset that display a CD4
+
CD16
-
CCR2
low/negative
 
phenotype showing diminished expression of CD14 as well as a low CCR5 surface expression 
may be more resistant to HIV-1 infection (Gama et al., 2012). It is also known that CCR2 is 
required for the migration of monocytes from the bone marrow and that it may also be used by 
monocytes to diffuse into inflamed tissues (Iijima et al., 2011). CD14+CD16+ monocytes do not 
use CCR2 to migrate into tissues but CX3CR1 as they represent an advanced stage of 
differentiation closer to resident tissue macrophages (Kedzierska & Crowe, 2002). 
CX3CR1, like all chemokine receptors, is a G-protein-coupled receptor. Its ligand is fractalkine 
that is a unique chemokine that has various functions including being a chemo attractant and an 
adhesion molecule. Fractalkine plays a central role in the recruitment of monocytes of the 
CD14+CD16+ subset. It has also been suggested that CD14+CD16+ monocytes are favoured for 
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recruitment to sites that express fractalkine and that they add to vascular and tissue injury seen 
during pathological conditions where their numbers are elevated (Ancuta et al., 2003). CX3CR1 
has been implicated as a contributor to disease progression in HIV-1 infection. It was shown that 
progression to AIDS is either delayed or rapid and that the progression is influenced by specific 
mutations in the fractalkine receptor gene. The two polymorphisms detected, V249I and T280M 
have been shown to cause a slow progression or a fast progression to AIDS respectively, 
confirming that CX3CR1 plays a role in disease progression. When compared to HIV negative 
individuals HIV-1 infected patients have a higher percentage of cells expressing fractalkine in the 
T cell zones of their lymph nodes. Furthermore, there is no expression of fractalkine in the gut‟s 
Peyer‟s patches in healthy individuals, it is however, expressed by neurons and endothelial cells 
of the blood vessels (Becker, 2007).  
Studies done on fractalkine expression in tissues of HIV-1 infected individuals show that there is 
an up-regulation of fractalkine in the lymph nodes and in the plasma cells of the GALT. The 
absence of fractalkine found in the GIT of healthy individuals suggests that it does not contribute 
to the homing of immune cells to an un-inflamed GIT. Fractalkine molecules on blood endothelia 
have been observed to interact with CX3CR1 on monocytes and this interaction initiated the 
capture, firm adhesion and activation of circulating monocytes. This has elucidated a novel 
mechanism by which leukocytes can be recruited to sites of infection. It has also been seen that 
pro-inflammatory cytokines released upon LPS secretion such as TNF-α also play a role in 
fractalkine synthesis (Becker, 2007).  
2.7.6. Susceptibility to HIV-1 infection 
In addition to resting CD4
+
 T-cells, blood monocytes in vivo are known to be a major long-lived 
compartment of HIV-1 despite the low frequency of HIV-1 infection of these cells (Le Douce et 
al., 2010; Wu, 2011; Mir et al., 2012). HIV-1 exhibits tropism for both monocytes and 
macrophages, even though HIV-1 infection of monocytes and/or macrophages occurs at a low 
frequency. Subsequent to infection numerous direct and indirect effects on the innate immune 
system are induced. These effects include changes in immune recognition of pathogens, cytokine 
signalling, phagocytosis and also life span of monocytes, all of which directly affect the 
regulation and implementation of effective innate immune responses (Collini et al., 2010). Ex 
vivo studies have shown that peripheral monocytes are fairly resistant to productive infection 
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before differentiation into tissue macrophages. However, about 0.001-1% of monocytes are 
known to harbour HIV-1 during the course of infection (Le Douce et al., 2010; Mir et al., 2012).  
Ancuta et al. (2008), suggested that monocytes may become susceptible to HIV-1 infection after 
being activated in the bone marrow or whilst circulating in the blood of HIV-1 infected 
individuals, as a result of the inflammatory environment and immune activation. HIV-1 infected 
monocytes are known to be recruited to the GIT where they later differentiate into macrophages 
and may serve as viral reservoirs (Elbim et al., 1999). However, it has been noted that blood 
monocytes are rarely infected with HIV-1, which may down-play their role as reservoir cells 
(Collini et al., 2010).  
It has been shown that there is a direct association between the levels of CCR5 and the rate of 
monocyte differentiation into macrophages. The level of CCR5 expression is also related to 
monocyte resistance to infection. In addition, it has also been observed that the levels of CCR5 
correlate with the ability of maturing monocytes to be in infected with HIV-1 (Sasse & Van 
Beckhoven, 2012). One of the interesting clinical consequences of immune activation is 
described by Munsaka et al. (2009), who showed LPS stimulation of monocytes in HIV-1 
negative individuals resulted in an enhanced surface expression of CCR5 from approximately 
21% to 99% of cells. This elevated expression may increase the risk of infection in non-infected 
monocytes. 
2.8. Monocytes and Apoptosis  
Monocytes are fairly resistant to apoptosis following HIV-1 infection and may thus be a 
participant in viral persistence in a similar way to latently infected resting memory CD4
+
 T-cells, 
despite the low infectivity rate of monocytes. MDMs that are infected with HIV-1 have an 
increase in anti-apoptotic proteins, Bcl-2 and Bcl-xl and a decrease in pro-apoptotic proteins Bax 
and Bad through a mechanism that is TNF-dependent (Collini et al., 2010). 
Bcl-2 expression is up-regulated by R5-tropic (CCR5 dependant HIV-1 viral entry) HIV-1 or 
exogenous Tat in MDMs. The gp120 activated M-CSF regulated pathway results in a down-
regulation of tumour necrosis factor-alpha-related apoptosis inducing ligand (TRAIL) receptor 
TRAIL-R1 (DR4) and in monocytes from seropositive HIV-1 individuals it has been observed to 
display an increased resistance to Fas ligand- (FasL, CD95L) induced death. Irrespective of these 
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anti-apoptotic measures monocytes and macrophages may still undergo apoptosis (Collini et al., 
2010).  
Increased rates of macrophage apoptosis in mesenteric lymph nodes is linked with progression to 
AIDS. It has still not been determined however, if this is a consequence or the driver of monocyte 
turnover, and whether there is a direct contribution of HIV-1 to the observed apoptosis. In HIV-1 
infected individuals it has been observed that there is an increase in spontaneous monocyte 
apoptosis when compared to HIV negative controls. As a result of the vital role that apoptosis 
plays in immunity, the regulation of monocyte life span is of particular relevance in both 
physiological and pathological processes in HIV disease (Busca et al., 2009). 
Although infection of monocytes appears to confer apoptotic resistance, monocytes may be made 
more susceptible due to bystander effects. The pro-inflammatory milieu may up-regulate death 
receptor expression which allows for activated T-cells expressing death ligands to target 
monocytes/macrophages for elimination. 
2.8.1. The extrinsic and intrinsic pathways of apoptosis 
Generally there are two pathways that eventually lead to apoptosis of cells and they are 
dependent on the origin of the signal (Figure 2-10). The extrinsic pathway begins with the 
binding of ligands to molecules of the death receptor family; the intrinsic pathway however, is 
instigated by damage to the mitochondrial membrane that results in the release of cytochrome c 
into the cytosol and the eventual caspase activation. Bcl-2 is an anti-apoptotic protein that is part 
of three classes of anti-apoptotic proteins that are able to intervene at different stages of the 
caspase activation. They counteract death receptor-induced signalling and therefore prevent 
apoptosis. Bcl-2 maintains the integrity of the mitochondrial membrane and prevents the release 
of cytochrome c.  
During the process of maturation monocytes increase their resistance to spontaneous and induced 
apoptosis. This is a beneficial mechanism during times of immune responses to pathogens. This 
enhanced survival is critical in pathological conditions such as infections with intracellular viral 
and bacterial pathogens, inflammatory conditions as well as monocytic malignancies. When their 
survival is increased during these conditions it then ceases to be beneficial but rather becomes a 
factor in disease pathogenesis. Apoptosis plays a very important role in host immunity against 
HIV-1 infection.  
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These various roles include: 
1) Elimination or reduction of viability of intracellular pathogens,  
2) Prevention of microbe dissemination,  
3) Presenting microbial antigens in apoptotic bodies to other APCs,  
4) Prevention of persistent infection and reservoir formation.  
There is evidence, however, that shows intracellular pathogens may escape apoptosis of infected 
monocytes through the up-regulation of a number of host anti-apoptotic genes that are able to 
disrupt both the extrinsic and intrinsic apoptotic pathways of these cells (Busca et al., 2009).  
 
2.8.2. The role of anti-apoptotic and pro-apoptotic proteins in monocyte 
survival 
Suppression of HIV-1 infection in monocytes plays a part in viral latency and persistence via 
numerous mechanisms. Monocytes, which  remains undifferentiated in vivo, are resistant to HIV-
1 infection post-entry, while MDMs and myeloid DCs are much more susceptible to productive 
HIV-1 infection. Resistance to post-entry infection in blood monocytes may be explained by 
differentiation-dependant cellular factors. The mechanisms used by HIV-1 infection, during 
monocyte differentiation into macrophages, however, still remains to be clarified. It has been 
suggested that HIV-1- infected monocytes are able to function as cellular reservoirs and that once 
they differentiate into macrophages they are able to encourage productive HIV-1 infection 
(Guillemard et al., 2004; Wu, 2011).  
Figure 2- 10: Overview of the extrinsic and intrinsic pathway involved in apoptosis (Pai et al., 2006). 
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Exogenous recombinant HIV-1 Tat protein is known to enhance monocyte survival rates through 
the up-regulation of Bcl-2, an anti-apoptotic protein, which could be a way to establish viral 
persistence. With the use of an in vitro model of monocyte mediated death by TRAIL, it was seen 
that the Tat protein promotes the survival of monocytes in circumstances where they would 
usually undergo apoptosis and be removed. Tat is also known to increase the expression levels of 
IL-10 of monocytes in vitro. These interactions between HIV-1 virus and monocytes may 
augment the establishment of chronic HIV-1 infection and assist in disease progression (Coleman 
& Wu, 2009). Monocytes seem to be more susceptible to apoptosis following death receptor 
ligation compared to macrophages. These receptors include Fas (CD95), TRAIL-Receptor and 
TNFR1/2. The interaction between the death-receptors and their ligand result in the induction of 
death signalling. In mice with defective Fas/FasL genes an increase in monocytic cell counts was 
observed. During viral infections monocytes are known to be susceptible to FasL-induced death. 
In chronically infected SIV RMs there appears to be extensive turnover of peripheral monocytes 
that undergo apoptosis (Zheng et al., 2007; Laforge et al., 2011). 
During the late stages of infection monocytes and macrophages have been shown to be a major 
source of virus in the lymphoid tissues of HIV-1 infected individuals. Studies have shown that 
infected monocytes/macrophages are able to induce apoptotic death in CD4
+ 
and CD8
+
 T 
lymphocytes. It can therefore be said that viral persistence in monocytes/macrophages may play a 
major role in the dissemination and disease progression of HIV-1 infection. Resistance to virus-
induced death is known to be a common feature of monocytes/macrophages in HIV-1 infection. 
A down-regulation of Bcl-2 was observed in blood monocytes of HIV-1 infected individuals 
during the asymptomatic phase, whilst there appeared to be a gradual increase in the expression 
of Bcl-2 during the late stages of infection. Levels of TNF-α are known to be highly elevated in 
HIV+ patients. It has been shown in vitro that HIV-1 infection induces the production of TNF-α 
which in turn induces Bcl-2 expression. The high activation status of monocytes that is observed 
in conditions such as stimulation with LPS is linked to a higher capacity for pro-inflammatory 
cytokine production, such as TNF-α. This high level of monocytic cellular activation in the 
inflammatory context of AIDS can contribute to establishment of a viral reservoir (Elbim et al., 
1999; Guillemard et al., 2004; Le Douce et al., 2010).  
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2.9 VIP as a putative modulator of monocyte activation in HIV 
Exploring novel therapeutic targets that are able to diminish monocyte/macrophage 
responsiveness would be a good step forward in trying to diminish immune activation in a 
selective manner. One proposed therapy would is of neuropeptide, VIP, which has been shown to 
exhibit immuno-modulatory effects. Upon release from sensory neurons and T-lymphocytes at 
sites of lymphoid tissue it binds to its receptors VPAC-1 and VPAC-2, which are present in 
immune cells such as lymphocytes and monocytes (Delgado et al., 2004). VPAC-1 has been 
shown to mediate productive HIV infection, whilst VPAC-2 could be involved with inhibition of 
viral replication. When bound to CD4
+
 T-cells via VPAC-1/2 VIP acts to limit apoptosis and cell 
activation, VIP may also decrease responsiveness of monocytes/macrophages via VPAC-1/2, 
which have been shown to be expressed on these cells (Lara-Marquez et al., 2001). In this way 
through its receptors, VPAC-1/2, VIP may be used as a therapeutic approach  to diminish the 
hyper-responsiveness of immune cells (including monocytes) during HIV infection and alleviate 
the burden placed upon the immune system due to persistent immune activation. 
Persistent immune activation that is present during chronic HIV-1 infection provides an 
environment that aids in viral replication and facilitates disease progression. Cells belonging to 
myeloid lineage such as monocytes, macrophages and DCs are the primary targets of LPS-
induced activation and are important regulators of both inflammatory and anti-inflammatory 
responses. Therefore it is important to understand the relationship between immune activation, 
monocyte function and HIV-1 disease (Cassol et al., 2010). 
2.10 Research question, motivation, aim and objectives of the study 
The prevalence of HIV-1 infections in Sub-Saharan Africa makes up the majority of global HIV 
infections (Joint United Nations Programme on HIV/AIDS (UNAIDS) 2013). Although several 
studies characterising the role of monocytes have been performed in the United States of 
America, Europe and some African countries that characterise the role of monocytes, very few 
have been performed in South Africa. Furthermore studies performed in Africa, mentioned 
earlier, have reported conflicting results regarding immune activation caused by LPS in HIV-1 
infection. Therefore it‟s very important that studies be undertaken in South Africa so that the 
function of monocytes in HIV-1 pathogenesis can be clarified and their role be contextualised in 
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the South African setting. Unique features of this setting include higher levels of background 
infections, pre-existing pro-inflammatory immune status, infection with subtype C, and 
heterosexual transmission (Joint United Nations Programme on HIV/AIDS (UNAIDS) 2013). 
The hypothesis of this study was that HIV-1 infection induces changes in the monocyte cell 
population that affects their phenotype and functional responsiveness to LPS stimulation. The 
current study set out to determine the following research questions: 
1. Does HIV-infection affect the function of monocytes? 
2. If monocytes are affected, how are they affected?  
3. Lastly, could monocytes be used as a therapeutic intervention?  
Therefore, the aim of this study was to characterise the phenotype and function of monocytes in 
stable, untreated chronic HIV-1 infection in South Africa. An additional aim was to determine 
how markers of migration, homing, activation and apoptosis relate to standard markers of disease 
progression (CD4 count and viral load) and to generalised immune activation (CD38/8 T-cell 
expression).  
To achieve this, the following objectives were set: 
 To assess changes in CD14+CD16- and CD14+CD16+ monocyte subsets 
 To assess monocyte phenotype in HIV+ and HIV- individuals, with particular focus on  
o Activation markers (HLA-DR & CD69)  
o Migration-associated (CCR1, CCR2, CX3CR, CD62-L) and gut-associated 
(CCR7, CCR9) chemokine receptors  
o Expression of HIV co-receptor, CCR5 
 To evaluate the apoptotic potential of monocytes during  HIV-infection 
 To evaluate responsiveness of monocytes to TLR4 stimulation with LPS, and assess 
changes to marker expression in monocyte subsets 
 To relate novel marker expression patterns to general immune activation status   
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Chapter 3: Materials & Methods 
3.1 Study design 
This was a cross-sectional observational study with functional experimental components. The 
main objective of the study was to determine the phenotypic expression of chemokine homing 
receptors (CCR1, CCR2, CX3CR1, CCR9, and CCR7), other homing and activation markers plus 
the anti-apoptotic protein Bcl-2 in relation to immune activation. Whole blood assays were used 
to assess the phenotypic marker expression, cytokine expression as well as functional integrity of 
monocytes (following LPS stimulation) in chronic HIV-1 infection. Three (3) Flow cytometry 
panels (Panel 1, 2 and 3) were used for this purpose. Another objective was to determine the 
apoptotic sensitivity/potential of monocytes during chronic HIV-1 infection. Isolated monocytes 
and Flow cytometry Panel 4 were used for this purpose.  
3.2 Study participants 
Study participants were recruited from Emavudleni clinic in Crossroads and from local clinics in 
the Durbanville and Kayamandi areas in Cape Town. Ethical approval was granted by the 
Stellenbosch University Ethics Committee (N07/09/197).  Study participants were recruited by a 
research nurse. All participants had a CD4 count above 300 cells/µl, either at the time of the 
blood draw or at a prior visit, of maximally three weeks before the blood draw. Donors had no 
history of TB and HIV+ donors were not on anti-retroviral therapy/treatment naïve (determined 
using information from patient folders). Participants were also above 18 years of age. All donors 
were briefed on the study and signed consent forms in their preferred language. Study 
participants were split into two groups: HIV negative (n=26) and HIV positive (n=40), see Table 
4-1 for summary of study participant demographics. HIV status was confirmed by standard 
serological testing. CD4 count and viral load  
3.3 Venipuncture 
Whole blood was collected by a research nurse using 10ml sodium-heparin Vacutainer tubes (BD 
Biosciences, San Jose, California). Approximately 20 ml was acquired from each donor. The 
research nurse transported the blood samples to the Division of Medical Virology within two 
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hours of collection. CD4 count and viral load tests (HIV+ only) were performed, for research 
purposes only, using blood collected in 5ml EDTA Vacutainer® tubes (BD Biosciences, San 
Jose, California).  
3.4 CD4 Count 
TruCOUNT tubes (BD Biosciences, San Jose, California) and the Becton Dickson (BD) 
MultiTEST
TM
 CD3 FITC/ CD8 PE/ CD45 PerCP/ CD4 APC Reagent (BD Biosciences, San Jose, 
California) were used to perform CD4 counts. A TruCOUNT tube for each patient was labelled 
with an identification number. 20µl of MultiTEST CD3-FITC/ CD8-PE/ CD45-PerCP/ CD4-
APC reagent was added to the TruCOUNT tube just above the steel retainer. Following this, 50µl 
of EDTA blood was added to the TruCOUNT tube and mixed gently. The blood and reagent was 
incubated in the tube for 15 minutes at room temperature, in the dark. Then, 450µl of 1X 
Fluorescent Activated Cell Sorter (FACS) lysing solution (BD Biosciences, San Jose, California) 
was added to the tube and vortexed to mix. The tube was incubated for a further 15 minutes at 
room temperature in the dark, after which the cells were analysed on a Becton Dickinson 
FACSCalibur four-colour flow cytometer with MultiSET
TM
 software (BD Biosciences, San Jose, 
California). In addition to CD4 count; CD8
+
 count, %CD4
+
 and %CD8
+
 as well as CD4
+
CD8
+
 
ratios were also determined. This method is the standard CD4 count standard operation procedure 
(SOP) used in the Division of Medical Virology, which is accredited by South African National 
Accreditation System (SANAS). 
3.5 Viral Load 
The viral load test is a HIV-1 RNA quantitative assay based on nucleic acid sequence-based 
(NASBA) technology in combination with the detection of real-time molecular beacons.  The test 
has a detection range from 350 to 10
6
 copies/ml.  
2ml of blood was removed from EDTA tubes and placed in appropriately labelled 5ml BD 
Falcon Polystyrene Round-Bottom tube (BD Biosciences, San Jose, California). The tube was 
then centrifuged at 375 X gravity (g) for 5 minutes at 20°C. Approximately 1ml of plasma was 
decanted into a 1.7ml micro-centrifuge tube (Axygen, Union City USA). Samples were sent for 
routine viral load testing in the Division of Medical Virology. The NucliSens EasyQ® HIV-1 
v1.2 Viral Load Test (BioMerieux Inc., Boxtel, Netherlands) was used to perform the viral load 
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assay. This protocol is the viral load SOP used in NHLS laboratories located in the Division of 
Medical Virology and is also SANAS approved. 
3.6 CD38 on CD8+ T-cell expression 
The expression of CD38 on CD8
+
 T-cells is a measure of immune activation (Liu et al. 1997). A 
routine and standardized CD38 and PD-1 staining protocol was used for this purpose. 100µl of 
blood was removed and placed in appropriately labelled 5ml BD Falcon Polystyrene Round-
Bottom tube (BD Biosciences, San Jose, California). An antibody cocktail containing 10µl CD3- 
Fluorescein isothiocyanate (FITC), 2.5µl CD38- Allophycocyanin (APC), 10µl CD8- Peridinin 
chlorophyll protein (PerCP) and 2.5µl PD-1- Phycoerythrin (PE) was added to the tube followed 
by a 30 minute incubation step. All antibody volumes were based on earlier titration procedures 
and currently in use in the standardized assay. Thereafter, 2ml of 10x BD Lysing
TM
 solution (BD 
Biosciences, San Jose, California) was added to each tube and the tubes incubated for a further 10 
minutes at room temperature. After the incubation period the tubes were centrifuged at 375g for 5 
minutes with the brake off at 18°C. The supernatant was decanted using 3ml sterile Pastuer 
pipettes (Lasec, Ndabeni, Cape Town, South Africa), the cell pellet was resuspended and 2ml of 
BD CellWash
TM
 (BD Biosciences, San Jose, California) was added to each tube. The tubes were 
centrifuged again at 375g for 5 minutes with the brake off at 18°C. The supernatant was 
decanted, the cell pellet was resuspended and 400 µL of 1x BD Fixative TM solution (BD 
Biosciences, San Jose, California) was added. The tubes were stored in a 4°C fridge until flow 
cytometry acquisition the following day. Flow cytometry was performed on a BD FACSCalibur 
4-colour instrument with BD CellQuest analysis software (BD Biosciences, San Jose, California). 
Please see Figure 3-1 for flow cytometry gating strategy for CD38 expression on CD8
+
 T-cells. 
Lymphocytes were gated based on scatter (P1 = FSC vs. SSC), and CD3 FITC (P2). The 
expression of CD38 and PD-1 was determined in a CD8 PerCP vs. CD38 APC or PD-1 PE plot 
with quadrant statistics. 
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Figure 3- 1: Flow cytometry gating strategy used to acquire CD38 on CD8
+
 T-cell expression, illustrated using 
a HIV+ sample (P195). Side Scatter Height (SSC-H) is plotted against Forward-Scatter (FSC-H), this is used 
to differentiate between lymphocytes (R2), monocytes and granulocytes. A dot plot showing SSC vs. CD3-
FITC is used to define the CD3
+
 T-cells (R3). Using R3, CD38-APC expression (right dot plot) and PD-1-PE 
expression (left dot plot) of CD3
+
CD8
+
 T-cells is determined. 
1.17% 
10.92% 
20.18% 67.73% 
16.07% 44.72% 
5.40% 33.80% 
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3.7 Optimisation and quality control of multiparameter flow cytometry  
Multiparameter/multicolour flow cytometry can generate a large amount of biological 
information from a single sample. It is often the only technique available to sufficiently identify 
or characterise complex cell populations. The field of flow cyomtery has rapidly evolved in 
recent years leading to increases in the number of parameters that can be analysed 
simultaneously. High performance instruments with additional laser and detector options and data 
computational power are now available. With the added complexity of parameter detection there 
is a need to ensure proper experiment setup for the generation of accurate and meaningful results 
(BD Biosciences, San Jose, California, 2009). Factors influencing proper experiment setup 
include: Compensation, Antibody Titrations and Fluorescence-Minus-One (FMO) procedures for 
the discrimination of positive vs. negative events. These are all discussed in the sections to 
follow. 
3.7.1 Antibody Titrations 
Antibody titrations are performed for mainly two reasons, to determine the optimal antibody 
volume that produces bright labelling of target cells and to save money by being able to use 
lower adjusted volumes per test. The optimal antibody volume used in each flow cytometry panel 
(see Table 3-2) was established by performing a titration of each antibody. A total of 21 
antibodies were used in the study, the antibodies were divided into four different panels, namely 
(see Table 3-1): 
 Chemokine (CCR5, CCR1, CCR7, CCR9, CCR2, CX3CR1) 
 Activation and Apoptosis (CD69, TRAIL-R1, TNFR1, HLA-DR, CD62-L, CD95) 
 Cytokines and Function 1 (CD116, Bcl-2, VPAC-2, IL-10, TNF-α) 
 Apoptotic potential (Annexin V, 7AAD) 
The highest volume of each antibody used during titration experiments was selected according to 
the manufacturer‟s instructions. However, it should be noted that choosing a higher volume than 
that recommended would have been ideal to observe a tapering off at the top of the curve. This 
                                                 
1
 In addition to fresh whole blood, isolated monocytes were also stained with antibodies from this panel as a quality 
control for the use of isolated monocytes in panel 4. 
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volume was then titrated down in 5 µl increments to 1.5 µl, e.g. the manufacturers recommended 
volume for CCR5-FITC is 20 µl; in the titration experiment the volumes tested were 20 µl, 15 µl, 
10 µl, 5 µl, 2.5 µl and 1.5 µl.  An unstained control was also used for each antibody. Blood from 
uninfected donors was used during the titration experiments. Tubes were processed and treated as 
a patient sample.   
3.7.1.1 Cellular surface marker staining titrations 
Titrations were carried out on both LPS-stimulated and unstimulated blood to determine if 
stimulation had an effect on the antibody volume needed and also to generate a positive 
expression profile for markers that are not expressed at any significant level. After completion of 
the titration experiments it was determined that stimulation did not required altered dilutions for 
optimal expression. The protocol presented below is for unstimulated blood. Refer to section 3.8 
for LPS-stimulation protocol. 
3.7.1.1.1 Whole blood antibody titrations - Panel 1, 2 & 3 
Each tube was appropriately labelled with the antibody and the amount of antibody to be added 
during the staining protocol. 100µl of whole blood and 200µl tissue culture media (TCM) was 
added to each 5ml BD Falcon
TM
 Polystyrene Round-Bottom tube in an antibody‟s titration series, 
with the exception of tubes which had intracellular antibodies added to them. Tubes which would 
have intracellular antibodies added, also had 0.8 µL GolgiPlug™ added (BD Biosciences, San 
Jose, California). The tubes were then incubated for 4 hours at 30°C at 5% CO2. Post-incubation, 
120µl of a 2% EDTA (Sigma Aldrich, St Louis, Missouri, USA) solution was added to the tubes. 
After 10 minutes incubation at room temperature, the cells were stained with the appropriate 
volume of antibody and incubated in the dark for 30 minutes at room temperature. Thereafter, 
2ml of 10x BD Lysing
TM 
solution (BD Biosciences, San Jose, California) was added to each tube 
and the tubes incubated for a further 10 minutes at room temperature. After the incubation period, 
the tubes were centrifuged at 375g for 5 minutes with the brake off at 18°C. The supernatant was 
decanted using 3ml sterile Pasteur pipettes (Lasec, Ndabeni, Cape Town, South Africa), the cell 
pellet resuspended and 2ml of BD CellWash
TM
 (BD Biosciences, San Jose, California) was added 
to each tube. The tubes were centrifuged again at 375g for 5 minutes with the brake off at 18°C. 
The supernatant was decanted, the pellet resuspended and 400 µL of 1x BD Fixative TM solution 
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(BD Biosciences, San Jose, California) was added. The tubes were stored in a 4°C fridge until 
flow cytometry acquisition the following day. 
3.7.1.1.2 Isolated monocytes titrations - Antibody panels 3 and 4 
Monocytes were isolated from whole blood in a two phase process, namely monocyte enrichment  
using the RosetteSep® Negative Selection kit with Human Monocyte Enrichment Cocktail 
(Catalogue #15028, STEMCELLTM Technologies, Vancouver, Canada) and EasySep® Human 
CD14 Selection Kit (Catalogue #18058, STEMCELLTM Technologies, Vancouver, Canada) for 
positive selection. All isolation experiments were performed in a tissue culture biosafety flow 
cabinet. For the RosetteSep® and EasySep® protocol detailed in the FMO section, see Figure 3-
3. and Figure 3-5, respectively. 
Antibody titrations were not performed for antibodies AnnexinV-FITC and 7AAD-PerCP from 
panel 4 as the recommended volume was 5 µl, which was applied directly in the current study. 
Antibody titrations were also not performed for the panel 3 antibodies used in the staining of 
isolated monocytes as the titrated values obtained during the whole blood antibody titrations were 
applied for staining isolated monocytes. 
3.7.1.2 Intracellular marker antibody staining titrations –Panel 3 only 
3.7.1.2.1 Whole blood 
The staining protocol for cellular surface staining was followed for tubes from antibody panel 3, 
which is the only antibody panel that included intracellular antibodies (Bcl-2, IL-10 and TNF-α). 
The standard protocol was adhered to until the second centrifugation and supernatant decanting 
step. In the place of BD Fixative
TM
 (BD Biosciences, San Jose, California) being added to the 
tubes, 100µL of BD Cytofix/Cytoperm
TM
 (BD Biosciences, San Jose, California) was added to 
the tubes and placed in a 4°C fridge to incubate for 20 minutes. After 20 minutes 300µl of 1x 
PermWash
TM
 (BD Biosciences, San Jose, California) was added, the tubes were mixed gently and 
then centrifuged at 375g for 5 minutes with the brake off at 18°C. The supernatant was removed, 
the cell pellet resuspended and the intracellular antibody mix was added. The tubes were then 
incubated at 4°C for 30 minutes in the dark. After 30 minutes, 300µl of PermWash
TM
 (BD 
Biosciences, San Jose, California) was added and the tubes centrifuged at 375g for 5 minutes 
with the brake off at 18°C. The supernatant was discarded, the pellet resuspended and 400µl of 
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BD Fixative
TM
 (BD Biosciences, San Jose, California) was added and the tubes stored in a 4°C 
fridge until flow acquisition the next day.  
3.7.1.2.2 Purified monocyte titrations 
The staining protocol for cellular surface marker detection previously detailed was adhered to for 
isolated monocytes. The protocol was adhered to until the second centrifugation and supernatant 
decanting step. In the place of BD Fixative
TM
 (BD Biosciences, San Jose, California) being added 
to the tubes, 100µL of BD Cytofix/Cytoperm
TM 
(BD Biosciences, San Jose, California) was 
added to the tubes and placed in a 4°C fridge to incubate for 20 minutes. After 20 minutes 300µl 
of 1x PermWash
TM 
(BD Biosciences, San Jose, California) was added, the tubes were mixed 
gently and then centrifuged at 375g for 5 minutes with the brake off at 18°C. The supernatant was 
removed, the cell pellet resuspended and the intracellular antibody mix was added. The tubes 
were then incubated at 4°C for 30 minutes in the dark. After 30 minutes, 300µl of PermWash
TM
 
(BD Biosciences, San Jose, California) was added and the tubes centrifuged at 375g for 5 
minutes with the brake off at 18°C. The supernatant was discarded, the cells resuspended and 
400µl of BD Fixative
TM
 (BD Biosciences, San Jose, California) was added and the tubes stored in 
a 4°C fridge until flow acquisition the next day.  
3.7.1.3 Flow cytometry acquisition 
Titration samples were acquired and analysed on a BD FACS Canto II flow cytometer with 
FACS Diva software (BD Biosciences, San Jose, California). Additional post-acquisition analysis 
was performed using the same FACS Diva software (BD Biosciences, San Jose, California). Five 
thousand (5000) gated events were collected per a tube, the cells were gated according to 
monocyte population (population 2, P2) was defined based on P1 and using Side Scatter (SSC) 
versus CD14-V500. P1 was based on single cell (singlet) population (population 1, P1) using 
Forward Scatter-Height (FSC-H) versus Forward Scatter-Area (FSC-A). Note: CD14 titration 
was performed with only singlet and FSC vs. SSC gating. To ensure all monocytes had been 
gated, a dot plot was created using SSC versus FSC-H for back-gate display. This population was 
designated population 3 (P3). Histograms for each antibody titration value were then created 
using P3. The negative population marker was set using the unstained control tube. The negative 
marker indicator was then copy- pasted onto every histogram. The titration tubes were then 
acquired using the flow cytometer and the fluorescent peaks of each antibody visualised on the 
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histograms. The histograms displayed P2 and P3 events. Peaks that were seen to the right of the 
negative marker were deemed as positive. Population statistics of the histograms were generated 
and these values exported into an excel spread sheet for each antibody.  
Using these values a standard curve was created. In order to do this the staining index value for 
each titration value was determined by using the following formula: 
 
 
Equation 1: Formula used to calculate the staining index, which is used to generate a titration curve. MFI = 
mean fluorescence intensity, SD = standard deviation. 
Using the standard curve see Figure 3-2, the antibody volume that produced a positive 
fluorescent peak closest to the fluorescent peak created by the manufacturer suggested volume 
was determined to be the optimal volume to use in the assay.  
 
3.7.2 Fluorescence-Minus-One (FMOs) 
FMOs were performed in order to accurately determine positive vs. negative event discrimination 
for antibody markers that are novel or where there is a level of difficulty in determining whether 
a true positive signal is seen or t accuracy is questionable due to the strength of the fluorescent 
signal. In the cases of certain antibody markers a positive signal is seen at a low level and if 
 (MFIpos – MFIneg) 
SDneg 
Figure 3- 2: Titration curve for CD116-FITC. Calculated stain index is plotted against the correlating 
antibody. The curve is then used to determine the lowest antibody volume required (in this case 10µl) to 
produce a positive signal similar to the signal produced by the manufacturer recommended volume (20µl). 
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FMOs are not performed this low level of positivity can be overlooked or not seen at all. FMOs 
are also performed when a new batch of antibody is introduced in a panel. FMOs were performed 
as discussed below. 
3.7.2.1 Whole blood- Antibody panels 1, 2 and 3 
5ml BD Falcon
TM
 Polystyrene Round-Bottom tubes (BD Biosciences, San Jose, California) were 
labelled with the name of each antibody. Control (uninfected donor) blood was during the FMO 
experiments. Following on from the antibody titrations, the optimal volume of each antibody was 
added to each tube except the antibody that the tube was labelled with. For example, for a tube 
labelled -CD95-APC, which is part of the activation and apoptosis panel, every antibody in that 
panel except CD95-APC was added to the tube. After the correct antibodies were added to the 
appropriate tubes, 200µl of fresh whole blood was added and the tubes were gently mixed and 
incubated for 30 minutes in the dark at room temperature. The staining protocol used during the 
antibody titration experiment, detailed earlier, was followed for cellular surface and intracellular 
markers, up until the step before the addition of cell fixative. At this step half of the supernatant 
was removed and 350µl of BD CellWash (BD Biosciences, San Jose, California) was added 
instead of cell fixative. A negative, unstained control was also included. The tubes were mixed 
well and then data were acquired on the BD FACS Canto II.  
During flow cytometry acquisition, FSC-H versus FSC-A was used to determine single cells 
(singlets) (population 1, P1). Following this, SSC versus CD14-V500 was plotted to determine 
the monocyte population (population 2, P2). The control tube was acquired first followed by the 
tubes containing the antibody mixes. Histograms were then generated for each antibody including 
the unstained tube. A marker was set over the negative signal. This marker was copy and pasted 
onto the histograms of all the antibodies. As the tubes were acquired the negative control marker 
on each histogram was adjusted according to the strength of the negative signal. The final 
negative marker was used to determine a true positive fluorescent signal seen during 
implementation of the assay on patient‟s samples. 
LPS stimulation was also performed to determine whether stimulation would have an effect on 
positive signal detection. The full staining protocol and flow cytometry acquisition was also 
followed. No difference was seen between LPS stimulation FMOs and unstimulated FMOs.  
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3.7.2.2 Isolated Monocytes – Antibody panels 3 & 4 
FMOs were not performed on isolated monocytes stained with antibodies from panel 3 as the 
FMOs generated from whole blood experiments were used throughout. FMOs were also not 
performed for the antibodies CD14-V500 and CD16-APC-H7 in all panels for as the FMOs 
generated from the whole blood FMO experiments were used. FMOs were performed on 
Annexin V-FITC and 7AAD-PerCP. The section below details the monocyte isolation protocol 
followed for all the isolated monocyte work. 
3.7.2.2.1 Monocyte isolation 
3.7.2.2.1.1 RosetteSep® Negative Selection (enrichment) 
Approximately 10ml of whole blood that had been stored overnight in a 4°C fridge was decanted 
into a labelled 15ml BD Falcon ® centrifugation tube (BD Biosciences, San Jose, California); 
RosetteSep® Human Monocyte Enrichment Cocktail was added to the tubes at 50µl/ml of whole 
blood. The tubes were mixed well and incubated for 20 minutes at room temperature. 
RosetteSep® media was made up as per manufacturer‟s instructions i.e. , Phosphate Buffered 
Saline (PBS) (InvitroGen, San Diego, USA), 2% Fetal Bovine Serum (FBS) (InvitroGen, San 
Diego, USA) and 1mM EDTA (Sigma Aldrich, St Louis, Missouri, USA). After the incubation 
period the sample was diluted with an equal volume of RosetteSep® Media, approximately 10ml. 
The tube contents were then thoroughly mixed. The mixture was then layered onto 15ml of 
Ficoll
TM-
Histopaque (BD Biosciences, San Jose, California) in a 50ml BD Falcon
TM
 tube (BD 
Biosciences, San Jose, California). The tubes were centrifuged for 20 minutes at 1200g at room 
temperature with the brake off. The enriched cells were removed from the Ficoll
TM
 density 
medium: plasma interface along with a small quantity of the Ficoll
TM
 to ensure all the enriched 
cells were removed. The cells were then placed into a 50ml BD Falcon
TM
 (BD Biosciences, San 
Jose, California) tube and RosetteSep® media was added to the 35ml mark. The contents were 
gently mixed and the tubes were centrifuged again at 1200g at room temperature with the brake 
off for 10 minutes. After centrifugation the supernatant was discarded, the cell pellet resuspended 
and another 5ml RosetteSep® media was added. Before the tubes were centrifuged again, 50µl of 
the cell suspension was removed and added to 50µl of Turks staining solution (Sigma Aldrich, St 
Louis, Missouri, USA) in a 96-well plate with the lid labelled appropriately for each cell culture 
well being used (Corning Incorporated, Corning, NY). The tubes were then centrifuged again at 
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1200g at room temperature with the brake off for 10 minutes to wash them. During the 
centrifugation step, 10µl of the cell/Turk solution suspension was removed from the 96-well plate 
for cell count use. A Neubauer Bürker haemocytometric counting chamber was used to perform 
the cell count (Celeromics, Valencia, Spain), the cell count for each cell culture well was 
recorded. The average (n = 21) monocyte cell count at the end of the RosetteSep® enrichment 
step was 2.02x10
6
 cells/ml out of the original input of 10ml. After the centrifugation step the 
supernatant was discarded and the pellet re-suspended in the residual volume approximately 
150µl. This volume was then transferred to a 5ml BD Falcon
TM
 Polystyrene Round-Bottom tube 
(BD Biosciences, San Jose, California) for use during the EasySep® procedure. 
 
 
 
 
 
 
 
 
 
 
3.7.2.2.1.2 EasySep® Human CD14 Selection Kit (Positive selection) 
EasySep® Positive Selection Cocktail was added at 100µl/ml; e.g. for 2ml of cells, 200µl of 
cocktail was added. The contents were mixed well and incubated at room temperature for 15 
minutes. During this period the EasySep® Magentic Nanoparticles were thoroughly mixed to 
ensure uniform suspension. After the incubation period, the particles were added at 50µl/ml cells. 
The contents were mixed well and incubated at room temperature for 10 minutes. During this 
time the monocytes were labelled by the magnetically CD14-linked nanoparticles, see Figure 3-
Figure 3- 3: RosetteSep® protocol diagram (www.stemcell.com) 
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4. The total volume was then brought to 2.5ml using RosetteSep® media and the cells mixed by 
gently pipetting up and down 2-3 times. The tube was then placed into the Purple EasySep® 
magnet (Catalogue # 18000) and set aside for five minutes. After the five minutes, the 
supernatant fraction of the tube was discarded by inverting the magnet and the tube. The 
magnetically labelled monocytes remained in the tube. The tube was then removed from the 
magnet and the volume brought up to 2.5ml using RosetteSep® media and mixed by gently 
pipetting. The magnetic separation and supernatant decanting repeated. The volume was brought 
up to 2.5ml again and the magnetic separation and supernatant decanting repeated a third time. 
This resulted in a total of 3 x 5 minute magnetic separations. After the third supernatant 
decanting, the volume was brought up to 1ml with TCM and 50µl was removed and added to 
50µl Turks solution (Sigma Aldrich, St Louis, Missouri, USA) in an appropriately labelled 96-
well culture plate. The 1ml cell suspension was set aside and another cell count was performed 
using the Turks/cell suspension mixture as previously detailed. A schematic of how the positive 
selection kit works is found in Figure 3-5 and illustration of protocol followed in Figure 3-6. 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 3- 5: EasySep® cell selection protocol diagram (www.stemcell.com) 
Figure 3- 4: Schematic of EasySep® Tetrameric Antibody Complexes (TAC) labelling of human cells 
(www.stemcell.com) 
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Once the final cell count was performed, the isolated monocytes were placed into 5ml BD 
FalconTM Polystyrene Round-Bottom tubes (BD Biosciences, San Jose, California) at an 
average (n=21) concentration of 4.62x10
5
 cells/ml. 250µl of this cell suspension was added to 
each four tubes, two for panel 3 and two for panel 4, during ex vivo LPS stimulation at an average 
(n=20) concentration of 1,53x10
5
cells/ml [range 2,00x10
4
-5,50x10
5
]. 
Apoptosis had to be induced before FMOs for panel 4 could be generated. This was done by 
treatment with Camptothecin (Sigma Aldrich, St Louis, Missouri, USA). Isolated monocytes 
were stimulated with 2.5µl/ml Camptothecin (Sigma Aldrich, St Louis, Missouri, USA) in 
appropriately labelled 5ml BD Falcon
TM
 Polystyrene Round-Bottom tubes (BD Biosciences, San 
Jose, California) for 4 hours at 37°C, 5% CO2. The cells were then stained as described below. 
The cells were washed twice with cold staining buffer (PBS + 2% FBS) at 200g at room 
temperature for 5 minutes with the brake off. The cells were then re-suspended in Annexin V 
Binding Buffer. Antibodies were added to the tubes, volumes can be found in Table 3-2. The 
cells were gently vortexed and allowed to incubate at room temperature for 15 minutes. 
Thereafter, 400µl of Annexin V Binding Buffer was added and flow cytometry performed. 
3.7.3 Flow cytometry colour compensation 
Compensation experiments are performed to decrease spill-over of fluorescent signal from one 
detector channel to another. Emission spectra of fluorochromes may overlap and compensation 
ensures this overlap does not lead to spurious data generation. The purpose of compensation is to 
reduce this spill-over of a fluorochrome into a detector that is reserved to identify another 
fluorochrome that is in the same antibody panel. Compensation also aligns populations that are 
affected by spill over. This alignment results in increased accuracy of interpretation and analysis 
of data (Technical Bulletin, BD Biosciences, San Jose, California). Compensation experiments 
were not performed for all 21 antibodies but for every flourochrome, namely FITC, PE etc. The 
exception being tandem dyes (e.g. Pe-Cy7) which needed to have individual compensation set for 
each antibody tandem dye combination, irrespective of whether in different panels. The reason 
for this is that tandem dyes spectral spill-over varies amongst tandem lots (Johanssen & Macey, 
2013). The compensation experiments were performed as described below. Compensation 
experiments were performed based on compensation beads and not cells. 
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5ml BD Falcon
TM
 Polystyrene Round-Bottom tubes (BD Biosciences, San Jose, California) were 
labelled for each antibody. 100µl of staining buffer was added to each tube. BD CompBead Plus 
(BD Biosciences, San Jose, California) bottles were vortexed thoroughly before use. One drop of 
BD CompBead Plus Negative Control (BD Biosciences, San Jose, California) and 1 drop of BD 
CompBead Plus Anti-Mouse IgG1, κ beads was then added to each tube. BD CompBead Plus 
Anti-Rat IgG2a, κ beads were used where appropriate. Following this, the optimum volume of 
antibody was added to the appropriately labelled tube. The contents of the tubes were gently 
mixed, then incubated for 30 minutes in the dark at room temperature. After incubation, 2ml of 
staining buffer was added to each of the tubes, which were then centrifuged for 10 minutes at 
200g. The supernatant was discarded and the pellet re-suspended in 500µl of staining buffer and 
the tube vortexed. The tubes were run on the BD FACS CANTO II flow cytometer (BD 
Biosciences, San Jose, California) with BD FACS Diva software (BD Biosciences, San Jose, 
California). The compensation values were calculated and set by the flow cytometer. 
Compensation settings were checked when experimental samples were acquired to ensure that 
bead-based compensation were suitably adjusted. This compensation procedure was repeated 
before every batch of study samples were acquired on the flow cytometer.  
3.8 In vitro LPS-stimulation2 
3.8.1 Whole blood 
24-well flat bottomed Cell Culture Cluster plates (Corning Incorporated, Corning, NY) were used 
during the stimulation assay. Whole blood from donors either remained un-stimulated or was 
stimulated with 1µg/ml LPS (Clone O111:B4: Invivogen, San Diego, California, USA). Two 
wells were used per donor, appropriately labelled with donor identification number and whether 
the cells in the well were to be stimulated or remain un-stimulated. The total volume in each well 
was 1.2ml. This was obtained by adding 600µl of whole blood to each well. In the well labelled 
“stimulated” 120 µg/ml LPS was added to 480µl tissue culture media (TCM), that consisted of 
RPMI 1640 + GlutaMAX™ (InvitroGen, San Diego, USA) and 5% FBS (InvitroGen, San Diego, 
USA) as well as 0.8µl GolgiPlug™ (BD Biosciences, San Jose, California). In the well labelled 
                                                 
2
 In addition to fresh whole blood, isolated monocytes were also stimulated with LPS and stained with antibodies 
from panel 3 as a quality control for the use of isolated monocytes in panel 4. 
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“unstimulated”, 600µl TCM and 0.8µl GolgiPlug™ (BD Biosciences, San Jose, California) was 
added to whole blood. The plate was then incubated at 37°C, 5% CO2 for four hours. After 
stimulation 120µl of EDTA (Sigma Aldrich, St Louis, Missouri, USA) was added to the wells 
and the contents gently mixed by pipetting up and down slowly. The cells were set aside for 10 
minutes after which they were stained with monoclonal antibodies, see section 3.9. for antibody 
staining protocol and Figure 3-6 for workflow.  
3.8.2 Isolated monocytes – Panel 3 & 4  
Purified monocytes were added to 5ml BD FalconTM Polystyrene Round-Bottom tubes (BD 
Biosciences, San Jose, California), at an average concentration (n=20) of 1.53x10
5
cells/ml 
[2,00x104-5,50x105]. Two tubes per panel were labelled “stimulated” and “unstimulated”. The 
protocol detailed above for whole blood was followed to induce LPS stimulation in isolated 
monocytes but adjustments to volumes were made. 50µl of 1µg/ml LPS (Clone O111:B4: 
Invivogen, San Diego, California, USA), 0.8µl of GolgiPlug™ (BD Biosciences, San Jose, 
California) were added to the tubes labelled “stimulated” and only 0.8µl of GolgiPlug™ (BD 
Biosciences, San Jose, California) were added to the tubes labelled “un-stimulated”. The tubes 
were then placed in an incubator as detailed above. After incubation, 50µl of EDTA (Sigma 
Aldrich, St Louis, Missouri, USA) was added to all four tubes. The tubes were then set aside for 
10 minutes and thereafter they were stained with antibodies, see section 3.9. for antibody 
preparation protocol and Figure 3-6 for workflow.  
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Antibody 
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Flow cytometry 
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+ 600µl Blood 
+ 120µl LPS (1µg/ml) 
+ 480µl TCM 
+ 0.8µl GolgiblockTM 
4 hour incubation at 
37°C, 5% CO2 
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staining protocol 
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+ 50µl 2% EDTA 
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of 1.53x105 cells/ml 
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+ 0.8µl GolgiblockTM 
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37°C, 5% CO2 
+ 50µl 2% EDTA 
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Figure 3- 6: Illustration of workflow followed. Protocol for whole blood assays found in red and isolated 
monocytes in blue. Protocols for monocyte isolation, antibody staining and flow cytometry acquisition can be 
found in sections 3.7.2.2, 3.9.1 and 3.10, respectively. 
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3.9 Preparation of Antibody Staining Mix  
Monoclonal antibodies were taken out of storage at 4°C and placed in tissue culture laminar flow 
hood prior to usage in panel assembly.  
Table 3- 1: The composition of the 4 flow cytometry panels used during this study as well as the placement of 
the 19 antibodies into the relevant panels. 
Panel name FITC PE PerCP Pe-Cy7 APC APC-H7 BV421 V500 
(1)Phenotypic CCR5 CCR1 CCR9 CX3CR1 CCR2 CD16 CCR7 CD14 
(2)Activation 
& Apoptosis 
CD69 TRAIL-R1 HLA-DR CD62L TNFR1 CD16 CD95 CD14 
(3)Functional 
& Response 
CD116 Bcl-2 VPAC-2  IL-10 CD16 TNF-α CD14 
(4)Apoptotic 
Potential 
AnnexinV  7AAD   CD16  CD14 
PerCP = Peridinin chlorophyll protein; APC = Allophycocyanin; PE = Phycoerythrin; FITC = Fluorescein 
isothiocyanate; APC-H7 = Allophycocyanin-Hilite®7; PE-Cy7 = Phycoerythrin-Cyanine7; TNF-α = Tumour 
necrosis factor-alpha; TNF-R1 = Tumour necrosis factor-receptor 1; TRAIL-R1 = TNF-related apoptosis-inducing 
ligand-receptor 1; 7AAD = 7-Aminoactinomycin; VPAC-2 = Vasoactive intestinal peptide receptor 2. 
Antibody panels consisted of both cellular surface and intracellular markers. The staining 
procedure outlined below was the protocol followed during the staining of cells after in vitro 
stimulation. The details of all the antibodies, the titrated volumes and manufacturer details are 
presented in Table 3-2. 
3.9.1 Surface marker antibody staining  
3.9.1.1 Whole blood - Panel 1, 2 & 3 
5ml BD Falcon
TM
 Polystyrene Round-Bottom tubes (BD Biosciences, San Jose, California) were 
appropriately labelled with the antibody panel number and whether cells were stimulated or 
unstimulated.  100µl of cell incubation mixture and the correct volume of appropriate antibodies 
were added to each tube. The tubes were incubated in the dark for 30 minutes at room 
temperature. Thereafter, 2ml of 10x BD Lysing
TM
 solution (BD Biosciences, San Jose, 
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California) was added to each tube and the tubes incubated for a further 10 minutes at room 
temperature. After the incubation period the tubes were centrifuged at 375g for 5 minutes with 
the brake off at 18°C. The supernatant was decanted using 3ml sterile Pasteur pipettes (Lasec, 
Ndabeni, Cape Town, South Africa), the cell pellet was resuspended and 2ml of BD 
CellWashTM (BD Biosciences, San Jose, California) was added to each tube. The tubes were 
centrifuged again at 375g for 5 minutes with the brake off at 18°C. The supernatant was 
decanted, the pellet resuspended and 400 µL of 1x BD Fixative
TM
 solution (BD Biosciences, San 
Jose, California) was added. The tubes were stored in a 4°C fridge until flow cytometry 
acquisition the following day. 
3.9.1.2 Isolated monocytes - Panel 4 
After the last incubation step (see section 3.8.1 and 3.8.2), cells were washed twice with cold 
BioLegend Cell Staining Buffer (BioLegend Inc., San Diego, CA), and then re-suspended in 
Annexin V Binding Buffer. 5µl of AnnexinV-FITC and 5µl of 7AAD-PerCP was added to the 
tubes. The tubes were gently mixed and incubated for 15 min at room temperature in the 
dark.  Afterwards, 400 µL of 1x BD Fixative TM solution (BD Biosciences, San Jose, California) 
was added. The tubes were stored in a 4°C fridge until flow cytometry acquisition the following 
day. 
3.9.2 Intracellular marker antibody staining – Panel 3  
3.9.2.1 Whole blood 
The staining protocol for cellular surface staining was followed for tubes from antibody panel 3, 
which is the only antibody panel that included intracellular staining (for TNF-α, IL-10 and Bcl-
2). The standard protocol was adhered to until the second centrifugation and supernatant 
decanting step. In the place of BD Fixative
TM 
(BD Biosciences, San Jose, California) being 
added, 100µL of BD Cytofix/Cytoperm
TM 
(BD Biosciences, San Jose, California) was added to 
the tubes and placed in a 4°C fridge to incubate for 20 minutes. After 20 minutes, 300µl of 1x 
PermWash
TM 
(BD Biosciences, San Jose, California) was added, the tubes were mixed gently and 
then centrifuged at 375g for 5 minutes with the brake off at 18°C. The supernatant was removed, 
cell pellet resuspended and the intracellular antibody mix was added. The tubes were then 
incubated at 4°C for 30 minutes in the dark. After 30 minutes, 300µl of PermWash
TM 
(BD 
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Biosciences, San Jose, California) was added and the tubes centrifuged at 375g for 5 minutes 
with the brake off at 18°C. The supernatant was discarded and 400µl of BD Fixative
TM 
(BD 
Biosciences, San Jose, California) was added and the tubes stored in a 4°C fridge until flow 
acquisition the next day.  
3.9.2.2 Isolated monocytes  
The staining protocol for cellular surface staining (3.10.1.2) was followed until the second 
centrifugation and supernatant decanting step. In the place of BD FixativeTM (BD Biosciences, 
San Jose, California) being added to the tubes, 100µL of BD Cytofix/Cytoperm
TM
 (BD 
Biosciences, San Jose, California) was added to the tubes and placed in a 4°C fridge to incubate 
for 20 minutes. After 20 minutes 300µl of 1x PermWash
TM
 (BD Biosciences, San Jose, 
California) was added, the tubes were mixed gently and then centrifuged at 375g for 5 minutes 
with the brake off at 18°C. The supernatant was removed, the pellet resuspended and the 
intracellular antibody mix was added. The tubes were then incubated at 4°C for 30 minutes in the 
dark. After 30 minutes, 300µl of PermWash
TM
 (BD Biosciences, San Jose, California) was added 
and the tubes centrifuged at 375g for 5 minutes with the brake off at 18°C. The supernatant was 
discarded, the pellet resuspended and 400µl of BD Fixative
TM
 (BD Biosciences, San Jose, 
California) was added and the tubes stored in a 4°C fridge until flow acquisition the next day.  
Table 3- 2: Titrated antibodies volumes, manufacturer information and Isotype used (refer to Table 3-1 for 
panel design) 
Antibodies Manufacturer Volume 
(µl) 
Isotype (Clone) 
CCR5-FITC BioLegend Inc. , San Diego, CA 2.5 Rat IgG2a, κ (HEK/1/85a) 
CCR1-PE R & D Systems, Minneapolis, MN 5 Ms IgG2b (53504) 
CCR9-PerCP R & D Systems, Minneapolis, MN 5 Ms IgG2b (112509) 
CX3CR1- Pe-Cy7 BioLegend Inc. , San Diego, CA 2.5 Rat IgG2b, κ (2A9-1) 
CCR2- APC R & D Systems, Minneapolis, MN 5 Ms IgG2b (48607) 
CD16- APC-H7 BD Biosciences, San Jose, CA 2.5 Ms IgG1, κ (3G8) 
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CCR7 BV421 BioLegend Inc. , San Diego, CA 2.5 Ms IgG2a, κ (G043H7) 
CD69-FITC BD Biosciences, San Jose, CA 10 Ms IgG1, κ (FN50) 
TRAIL- R1- PE BioLegend Inc. , San Diego, CA 10 Ms IgG1, κ (DJR1) 
HLA-DR- PerCP BioLegend Inc. , San Diego, CA 2.5 Ms IgG2a, κ (L243) 
CD62L- PeCy7 R & D Systems, Minneapolis, MN 2.5 Ms IgG1, κ (DREG-56) 
TNFR1- APC R & D Systems, Minneapolis, MN 5 Ms IgG1 (16803) 
CD95- BV421 BioLegend Inc. , San Diego, CA 5 Ms IgG1, κ (DX2) 
CD14- V500 BD Biosciences, San Jose, CA 2.5 Ms IgG2a, κ (M5E2) 
CD116-FITC BioLegend Inc. , San Diego, CA 10 Ms IgG1, κ (4H2) 
Bcl-2 PE BD Biosciences, San Jose, CA 10 Ms IgG1, κ (Bcl-2/100) 
VPAC-2- PerCP Constituted in Medical Virology 5 IgG (SP235) 
IL-10- APC BioLegend Inc. , San Diego, CA 10 Rat IgG2s, κ (JES3-19F1) 
TNF-α- BV421 BioLegend Inc. , San Diego, CA 5 Ms IgG1, κ (MAb11) 
AnnexinV-FITC BioLegend Inc. , San Diego, CA 5 N/A 
7AAD-PerCP BioLegend Inc. , San Diego, CA 5 N/A 
3.10 Study sample flow acquisition and gating strategy 
Study samples were acquired and analysed on a BD FACS Canto II flow cytometer with FACS 
Diva software (BD Biosciences, San Jose, California). Additional post-acquisition analysis was 
performed using the same FACS Diva software (BD Biosciences, San Jose, California). The 
acquisition limit was set at 10 000 events per a tube but the average cell events during the study 
recorded was approximately 4500 events. The gating strategy for study sample acquisition was 
similar to the one followed during antibody titration experiments. Acquired cellular events were 
gated according to FSC-H versus FSC-A to identify single cell (singlet) populations, this was set 
as population 1 (P1). The monocyte population (population 2, P2) was defined based on P1 and 
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using SSC versus CD14–V500. To assess the position of the monocyte population within the 
total cells a back-gate plot of SSC versus FSC-H was generated displaying population 3 (P3). A 
CD14-V500 versus CD16-APC-H7 dot plot was then created using P2 to visualise both the 
CD14-positive (+) and CD 16+ monocyte population. An example of the gating strategy used is 
presented in Figure 3-7. All other marker expression was based on this scheme, and individual 
marker display patterns are included in the Chapter 4 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
17.1% 
82.9% 
Figure 3- 7: Schematic of gating strategy used during flow cytometry acquisition. Singlet cells are first gated 
on using FSC-H vs. FSC-A. SSC-A vs. CD14-V500 is then used to distinguish the monocyte population. 
Finally CD14-V500 vs. CD16-APC-H7 is used to differentiate between the two monocyte subsets. APC-H7 
represents CD16-APC-H7 and V500 represents CD14-V500. 
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3.11 Statistical Analysis 
Percentage positive expression of each marker was generated using quadrant statistics from total 
gated events and was exported from FACS DIVA software into a Microsoft Excel spread sheet. 
Statistical analysis was performed using these exported percentage expression values with the use 
of GraphPad PRISM version 6.00 for Windows (GraphPad Software, La Jolla California USA, 
www.graphpad.com).  
Student t-tests were used for intergroup comparisons. 2-Way Anova analyses were performed on 
marker expression between the two study groups, and determined which variable/s (HIV-1 
infection, LPS stimulation, or an interaction between HIV-1 & LPS stimulation) were the cause 
of the significant marker alterations seen after LPS stimulation. A 2-Way Anova analysis 
compares the effect two independent variable (in this study, HIV-1 infection & LPS stimulation) 
has on a dependent variable (marker expression) (GraphPad Software, La Jolla California USA, 
www.graphpad.com). Therefore, performing a 2-Way Anova analysis in the context of the 
current will determine if the changes in marker expression in seen in the HIV+ group after LPS 
stimulation was dependant HIV-1 infection itself or LPS stimulation alone or whether it is these 
two variables intertwined (defined as an interaction).  
Statistically significant correlations or differences were defined as having a p-value < 0.05, p-
values between 0.05 and 0.005 were defined as highly significant and -values < 0.005 were 
defined as extremely significant. Post-analysis consultation with a statistician was used to ensure 
that all tests performed were appropriate and correctly applied for the data sets under 
investigation in this study.  
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Chapter 4: Results 
This chapter presents the in vitro phenotyping data of both study groups pertaining to total 
monocytes, as well as CD14+CD16- and CD14+CD16+ subsets, plus the assessment of 
monocyte responsiveness to in vitro LPS stimulation. Whole blood samples and isolated 
monocytes were stimulated with LPS (1mg/µl) to assess the impact of LPS stimulation on 
monocytes in terms of cellular marker expression and intracellular cytokine production. All the 
data presented in this chapter represent mean percentage marker expression and are based on the 
CD14 positive gated events (i.e. total monocytes) acquired from flow cytometric analysis of 
whole blood and isolated monocytes. Unless otherwise stated, all data presented are based on 
whole blood assays. All data are presented graphically using median plus inter-quartile range 
box-and-whisker plots to illustrate data spread. In these figures, the middle line indicates the 
median, the box represents the interquartile range (25-75 percentiles), the whiskers indicate the 
10-90 percentile and outliers are shown by dots. Mean data (± standard deviation) will be 
discussed in text, unless otherwise indicated. Any major discrepancies between mean and median 
data are discussed.  
Student t-test analyses were used for intergroup comparisons. 2-Way Anova analyses were 
performed on marker expression between the two study groups (HIV+ & HIV-), and determined 
which variable/s (HIV-1 infection, LPS stimulation, or an interaction between HIV-1 & LPS 
stimulation) were the cause of the significant marker alterations seen after LPS stimulation. A 2-
Way Anova analysis compares the effect two independent variable (in the current study, HIV-1 
infection & LPS stimulation) has on a dependent variable (marker expression) (GraphPad 
Software, Inc., San Diego, CA, USA). Therefore, performing a 2-Way Anova analysis in the 
context of this study will determine if the changes in marker expression seen in the HIV+ group 
after LPS stimulation was dependent on HIV-1 infection itself or LPS stimulation alone or on 
these two variables effects combined (defined as an interaction).  
All correlation tests of clinical markers with monocyte subsets and marker expression were 
performed within the HIV+ group only, summary tables of all correlations performed can be 
found in Appendix 1. Only significant correlations are stated in text, and a select few are 
represented graphically with XY data and linear regression, with relevant correlation coefficient r 
- and p-values.  
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Data was seen as significant if p-value < 0.05, highly significant if p-value < 0.01 and extremely 
significant if p-value < 0.005. Only for p-values > 0.005 will actual p-values be indicated, 
otherwise p-value < 0.005 will be used. 
4.1. Patient demographics 
A total of 66 individuals were recruited for this study, consisting of 40 HIV+ and 26 HIV- 
individuals. The mean age in years for the HIV- group was 31 (range 22-46) and for the HIV+ 
group it was also 31 (range 22-43). The HIV+ group had an excess of female donors (76.5%) 
compared to the HIV- (50%) but this difference was not statistically significant (p-value = 
0.1218). The demographics of the study groups are summarized in Table 4-1. 
4.2. CD4 count & viral load 
Study participants were selected based on CD4 counts (> 300 cells/µl) at the time of, or prior to, 
collection of study samples. In a few cases the time between initial recruitment and sample 
collection was 3-6 weeks, which could allow for a drop in CD4 count as evidenced by the CD4 
count range extending below the inclusion cut-off seen in Table 4-1. The mean CD4 count 
(cells/µl) for the HIV+ group was much lower than the HIV- group at 400.03 ±167.26, whilst 
CD4 count for the HIV- group was 931.32 ±438.73. Extremely significant differences were found 
between the CD4 counts of the two groups (p-value < 0.005), see Figure 4-1. 
 
 
 
 
 
 
 
p-value < 0.005 
Figure 4- 1: Comparison of CD4 count across the two study groups, HIV+ (median 380.00cells/µl, range 
[203.00-763.00]) and HIV- (830.00, [481.00-2351.00]). HIV-: Uninfected donors; HIV+: HIV-infected donors. 
Statistically significant differences are indicated by bars with p-values. 
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The mean viral load of the HIV+ group was 1.26x10
5
 copies/ml ±2.10x10
5
. Interestingly, viral 
load showed a statistically significant positive relationship with CD38/8 expression (r-value = 
0.3530; p-value = 0.0297) and a negative relationship between CD4 count (r-value = -0.6931; p-
value < 0.005), see Figure 4-2. Correlation tests between CD4 count and CD38/8 were not 
significant (r-value = -0.1528; p-value = 0.4119). A summary of correlations can be seen in 
Appendix 1 (Table 1). A summary of viral load mean and median data can also be seen in Table 
4-1. 
 
4.4. Immune activation status – CD38/8  
CD38 expression on CD8
+
 T lymphocytes is a well-defined marker of generalized immune 
activation (Liu et al., 1997). In this study this parameter was measured for comparative analysis 
of the immune activation and the monocyte markers assessed. 
The HIV+ group was seen to have a significantly elevated activation status despite being 
generally healthy with stable CD4 counts (> 300cells/µl). The mean percentage of CD8
+
 T-cells 
expressing CD38 was 31.75 ±17.58 for the HIV+ study group and 20.59 ±19.12 for the HIV- 
group (p-value = 0.0173), see Figure 4-3 and Table 4-1 for a summary of this data.
Figure 4- 2: Correlation and linear regression showing negative relationship between viral load and CD4 count 
(r-value = -0.6931; p-value < 0.005) (left) and positive relationship between viral load and CD38/8 expression (r-
value = 0.3530; p-value = 0.0297) (right). 
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Table 4- 1: Study population demographic. HIV-: Healthy donors; HIV+: HIV-infected donors; SD: 
standard deviation 
 HIV+ HIV- P-values 
Number of donors 40 26 N/A 
Mean age[range] 31[22-43] 31[22-46] 0.9755 
% Males 23.5 50 0.1218 
% Females 76.5 50 0.1218 
CD4 count median(cells/µl)[range] 356.00[203-263] 830.00[481-2351] <0.005 
CD4 count mean (cells/µl)[±SD] 385.53[±175.40] 931.32[±438.73] <0.005 
Viral load median 
(copies/ml)[range] 
3.50x10
5
[485-8.46x10
5
] N/A N/A 
Viral load mean(copies/ml)[±SD] 1.26x10
5
[±2.10x10
5
] N/A N/A 
% CD38
+
/CD8
+
 median[range] 33.4[0.04-78.24] 17.53[0.25-78.05] 0.0173 
% CD38
+
/CD8
+
mean[±SD] 33.70[±17.58] 20.59[±19.12] 0.0173 
4.5. Monocyte subsets 
Data on monocytes presented in this chapter are based on the total monocyte population 
(CD14+), the CD14+CD16- subset or the CD14+CD16+ subset. The total monocyte 
population refers to the percentage of the total leukocytes or total events analysed; see section 
3.10 in Chapter 3 for a description and illustration of gating strategy. A summary of all the 
monocyte subset data can be found in Table 4-2. 
Figure 4- 3: Box-and-whisker plot showing % of CD38
+
 CD8
+
 T-cells in the two study groups, HIV+ 
(median 33.40%, range [0.04-78.24]) and HIV- (17.53, [0.25-78.05]). HIV-: Uninfected donors; HIV+: 
HIV-infected donors. Statistically significant differences are indicated by bars with p-values. 
p-value = 0.0173 
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4.5.1. Total monocyte population 
The HIV+ group had a higher percentage of total gated monocytes compared to the HIV- 
group. The mean percentage of total monocytes gated in whole blood analyses was 2.87 
±1.43 for the HIV+ group and 2.14 ±1.27 for the HIV- study group (p-value = 0.0419), see 
Figure 1 in Appendix 1 . 
After LPS stimulation in whole blood; a mean 0.07% increase (delta percentage) was seen in 
the HIV+ group. In the HIV- group a 0.25% decrease was observed after stimulation (p-value 
< 0.005). These changes could be due to changes in other cell populations affecting the total 
events or due to increased adherence of monocytes to test tubes during stimulation. 
Correlations performed between the total gated monocyte population and clinical markers, 
CD4 count, viral load and CD38/8 expression showed no significant correlations, indicating 
that the overall increase in monocytes was likely due to a decrease in total leukocytes (and 
especially CD4
+
 T cells) in the HIV group. A summary of these data can be seen in Appendix 
1 (Table 2). 
4.5.2. CD14+CD16- monocyte subset  
A decrease in the percentage of the CD14+CD16- monocyte subset within the total monocyte 
fraction was seen in the HIV+ group. The mean percentage of monocytes within the 
CD14+CD16- monocyte subset was 83.43 ±8.94 for the HIV+ group and 86.82 ±7.19 for the 
HIV- group (p-value = 0.0448) see Figure 4- 4. 
Stimulation with LPS resulted in a statistically significant increase (p-value = 0.0233) in the 
mean percentage of CD14+CD16- monocyte subset in the HIV+ group. In the HIV- group no 
p-value = 0.0448 
Figure 4- 4: Box-and-whisker plot showing comparison of the CD14+CD16- subset of both study groups, 
HIV+ (median 85.15%, range [56.00-96.40]) and HIV- (87.75, [66.30-97.00]) at baseline. HIV-: Uninfected 
donors; HIV+: HIV-infected donors. Statistically significant differences are indicated by bars with p-
values. 
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statistically significant difference was found before and after stimulation (p-value = 0.8810). 
Correlations performed between the CD14+CD16- monocyte subset and clinical markers; 
yielded a significant negative correlation (r = -0.3884, p-value = 0.0308) between CD38/8 
expression and CD14+CD16- monocyte subset percentage, see Figure 4-5 below. A 
summary of these data can be seen in Appendix 1 (Table 3). A converse relationship was 
seen in the CD14+CD16+ monocyte subset, see section 4.5.3. (Figure 4-7). 
4.5.3. CD14+CD16+ monocyte subset 
In counterbalance to the decreased CD14+CD16- monocyte subset, a higher percentage of the 
CD14+CD16+ monocyte subset within the total monocyte fraction was seen in the HIV+ 
group at baseline. The mean percentage of CD14+CD16+ monocyte subset in the HIV+ 
group was 16.54 ±8.95, whilst in the HIV- group it was 13.15 ±7.12 (p-value = 0.0461) see 
Figure 4-6.  
 
 
 
 
 
 
 
Figure 4- 5: Correlation, including linear regress ion, showing negative relationship (r  = -0.3884, p-value 
= 0.0308) between the CD14+CD16- subset of HIV+ group with % CD38+/CD8+ T-cells at baseline. 
p-value = 0.0461 
Figure 4- 6: Box-and-whisker plot comparing CD14+CD16+ subsets percentages across both study 
groups, HIV+ (median 14.85%, range [5.60-42.00]) and HIV-(12.25, [3.00-33.00]) at baseline. HIV-: 
Uninfected donors; HIV+: HIV-infected donors. Statistically significant differences are indicated by bars 
with p-values. 
CD14+CD16- 
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LPS stimulation produced a statistically significant decrease (p-value = 0.0239) in the 
CD14+CD16+ monocytes in the HIV+ group. In the HIV- group stimulation did not result in 
any significant changes. Correlations performed between the CD14+CD16+ monocyte subset 
and clinical markers produced a significant positive correlation (r = 0.3862, p-value = 
0.0319) between the CD14+CD16+ monocyte subset and CD38/8 expression, see Figure 4-7 
below. A summary of these data can be seen in Appendix 1 (Table 4).  
Table 4- 2: Summary of mean percentage data of the total gated monocyte population as well as monocyte 
subsets, at baseline and after stimulation in both study groups, * p –value < 0.05, *** p-value < 0.005 
 Stimulus HIV+ (mean ±SD) HIV- (mean ±SD) 
Total monocyte population (% 
of total events) 
Unstimulated 2.43 (±1.43)* 2.14 (±1.27)* 
LPS 2.94 (±.52)*** 1.89 (±1.21)*** 
CD14+CD16- monocyte subset 
(% total monocytes) 
Unstimulated 83.43 (±8.94)* 86.32 (±7.19)* 
LPS 86.17 (±6.90)* 86.60 (±6.97)* 
CD14+CD16+ monocyte subset 
(% total monocytes) 
Unstimulated 16.54 (±8.95)* 13.15 (±7.12)* 
LPS 13.81 (±6.90)* 12.67 (±7.17)* 
4.6. Phenotypic Marker expression on monocytes  
4.6.1. CCR5 
CCR5 is a cell surface chemokine receptor (G-protein coupled receptor) that is a well-known 
as the HIV co-receptor needed for productive infection of immune cells also expressing CD4 
Figure 4- 7: Correlation, including linear regression, showing positive relationship (r  = 0.3862, p-value = 
0.0319) between CD14+CD16+subset of HIV+ group with % CD38
+
/CD8
+
 T-cells at baseline. 
CD14+CD16+ 
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80.3% 
5.6% 9% 
5.2% 
57.5% 
31.6% 5.4% 
5.4% 
(Bucci, 2013). To test the potential susceptibility to HIV-1 infection CCR5 expression was 
assessed. 
Total monocyte population 
The HIV+ group had a higher expression of CCR5 at baseline compared to the HIV- group. 
The baseline mean percentage of CCR5 in HIV+ donors was 58.53 ±12.54, whilst for HIV- 
donors it was much lower at 11.47 ±8.41 (p-value <0.005), see Figure 4-8 and Figure 4-9 for 
flow representative data. 
  p-value < 0.005 
Figure 4- 8: Box-and-whisker plot showing comparison of CCR5 expression in the total monocyte 
population of study groups, HIV+ (median 56.35%, range [11.20-87.80]) and HIV-(10.00, [2.10-56.40]) at 
baseline. HIV-: Uninfected donors; HIV+: HIV-infected donors. Statistically significant differences are 
indicated by bars with p-values. 
Figure 4- 9 Representative flow cytometry dot plots showing CCR5 (FITC) expression in the total 
monocyte population, (PE = CCR1). In the first box on the left (Panel 1 CCR5 US), the expression of 
CCR5 FITC vs. CCR1 PE is illustrated in a FMO sample excluding CCR5 marker (negative unstained 
control). In the middle and right boxes baseline expression of CCR5 in a HIV+ (RP32) vs. a HIV- (RP25) 
study sample is shown, respectively. Increased expression of CCR5 can be seen for RP32 vs. RP25, total 
CCR5 positivity for RP25 is 14.6%, and for RP32 it is 37%. 
.  
.   
.  
.5  
.6  .  
.  
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After stimulation, the expression in the HIV+ group decreased to 16.05 ±10.07 whereas the 
HIV- group‟s expression decreased only moderately to 9.33 ±6.36. 2-Way Anova analysis 
showed that this sharp decrease in the HIV+ group was due to a statistically extremely 
significant interaction between HIV infection and LPS stimulation (p-value <0.005) see 
Figure 4-10. A summary of correlations performed between the total monocyte population‟s 
CCR5 expression and clinical markers can be seen in Appendix 1 (Table 5). 
CD14+CD16- monocyte subset  
The mean percentage CCR5 expressing CD14+CD16- monocytes of the HIV+ donors were 
12.07 ±18.71, whilst for HIV- donors it was 6.97 ±4.57. Despite the CCR5 expression in the 
CD14+CD16- monocyte subset of the HIV+ group observed to be almost double that of the 
HIV-group at baseline, no statistically significant difference was seen (p-value = 0.1933). 
LPS stimulation resulted in an increased CCR5 expression in both groups (p-value = 0.0131). 
Correlation tests performed between CCR5 expression and clinical markers yielded no 
significant correlations. A summary of these data can be seen in Appendix 1 (Table 6). 
CD14+CD16+ monocyte subset 
CCR5 was expressed on a higher percentage of CD14+CD16+ monocytes than CD14+CD16- 
in both study groups. Statistically significant differences were seen between the 
CD14+CD16- subset and CD14+CD16+ subset for the HIV+ group (p-value < 0.005) and for 
the HIV- group (p-value < 0.005), see Figure 4-11. 
p-value < 0.005 
Figure 4- 10: The expression of CCR5 in the total monocyte population of both study groups before 
stimulation, HIV+ (median 56.35%, range [11.20-87.80]) vs. HIV-(10.00, [2.10-56.40]), and after LPS 
stimulation, HIV+ (14.90, [3.70-59.90]) vs. HIV-(6.80, [1.90-29.90]). HIV-: Uninfected donors; HIV+: 
HIV-infected donors. Statistically significant differences are indicated by bars with p-values.  
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In the HIV+ group 49.63% ±17.13 were CCR5+ and 44.02% ±9.14 were CCR5+ in the HIV- 
group. These differences were not significant (p-value = 0.1420). After LPS stimulation 
CCR5 expression in the HIV+ group slightly decreased to 48.86 ±12.24 and, decreased more 
than 10%, in the HIV- group to 33.36 ±9.58. 2-Way Anova analysis showed a statistically 
significant interaction (p-value < 0.005) between HIV infection and LPS stimulation in 
causing only a slight decrease in the HIV+ group after stimulation, see Figure 4-12. 
Correlations performed between the CD14+CD16+ monocyte subset‟s CCR5 expression and 
clinical markers showed no significant correlations. A summary of these data can be seen in 
Appendix 1 (Table 7).  
The dramatic difference in total percentage of monocytes expressing CCR5 not being 
reflected in the subsets appears strange, however it may reflect that this marker is up-
regulated in both subsets in HIV and the cumulative percentage is significantly different to 
individual subsets.  
  
p-value < 0.005 
p-value < 0.005 
Figure 4- 11: Comparison of CCR5 expression across study group’s monocyte subsets at baseline. HIV+ 
CD14+CD16- (median 4.4%, range [2.40-87.60]) vs. CD14+CD16+ (50.85, [14.50-88.90]) and HIV- 
CD14+CD16- (6.70, [1.80-26.30]) vs. CD14+CD16+ (42.20, [25.50-64.60]) HIV-: Uninfected donors; 
HIV+: HIV-infected donors. Statistically significant differences are indicated by bars with p-values. 
 
Figure 4- 12: Comparison of CCR5 expression in the CD14+CD16+ subset of both study groups before 
stimulation, HIV+ (median 50.85%, range [14.50-88.90]) vs. HIV-(42.20, [28.50-64.60]), and after 
stimulation, HIV+ (49.65, [13.70-85.20]) vs. HIV-(31.10, [16.20-54.90]). HIV-: Uninfected donors; HIV+: 
HIV-infected donors. Statistically significant differences are indicated by bars with p-values.  
p-value < 0.005 
CD14+CD16- CD14+CD16+ 
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4.6.2. CD116 
CD116 or GM-CSF- receptor is involved in the stimulation of production of granulocytes and 
macrophages from the bone marrow. CD116 is also known to be involved with monocyte 
differentiation, survival and may play a role in enhancing viral replication during HIV-1 
infection (Allavena et al., 1998; Kedzierska et al., 1998). 
Total monocyte population 
CD116 was found to be expressed in the majority of monocytes (>78%). Expression of 
CD116 in the total monocyte population of the HIV+ group was higher than in the HIV- 
group. At baseline the expression in the HIV+ group was 89.08 ±13.17 and 79.8 ±23.25 in 
the HIV- group (p-value = 0.0094), see Figure 4-13. After LPS stimulation, the expression 
for HIV+ group was seen to moderately increase and slightly decrease in the HIV- group. 2-
Way Anova analysis showed the expression seen after stimulation resulted from LPS 
stimulation (p-value = 0.0219). Correlations performed between the total monocyte 
population‟s CD116 expression and clinical markers showed no significant correlations. A 
summary of these data can be seen in Appendix 1 (Table 8). 
 
 
 
 
 
 
 
CD14+CD16- monocyte subset 
CD116 expression was minimally increased in the HIV+ group compared to the HIV- group 
at baseline, with expression at 88.28 ±17.13 and 83.26 ±23.70 in the HIV-group. This was 
however not statistically significant (p-value = 0.3502). Overall the expression was similar to 
the total monocyte population. Upon stimulation there was a statistically significant 
interaction (p-value < 0.005) between HIV infection and LPS stimulation which resulted in 
p-value = 0.0094 
Figure 4- 13: Baseline comparison of CD116 expression in the total monocyte population of both study 
groups, HIV+ (median 90.25%, range [43.90-99.90]) and HIV-(86.30, [19.10-100]). HIV-: Uninfected 
donors; HIV+: HIV-infected donors. Statistically significant differences are indicated by bars with p-
values.  
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the mean expression of CD116 increasing to 92.63 ±13.08 in the HIV+ group, whilst the 
HIV- group‟s mean expression decreased 10% after stimulation to 75.09 ±32.33. Although 
there was an increase in the mean percentage of the HIV+ group and a mean percentage 
decrease in expression in the HIV- group, this was not evident in the median data analysis, 
see Figure 4-14. Correlations performed between the CD14+CD16- monocyte subset‟s 
CD116 expression and clinical markers produced no significant correlations. A summary of 
these data can be seen in Appendix 1 (Table 9). 
 
 
 
 
 
 
 
CD14+CD16+ monocyte subset 
Baseline expression of CD116 was higher in HIV+ group, with expression seen to be 87.96 
±18.12 and 79.02 ±21.72 in the HIV- group, (p-value = 0.0941). No major differences in 
expression between the CD14+CD16- and CD14+CD16+ subsets in the HIV+ group were 
seen (p-value = 0.7698). But the difference were statistically significant in the HIV+ group 
(p-value = 0.0118) 
An increase in CD116 expression to 90.93 ±15.05 and a decrease in excess of 10% in the 
HIV- group to 71.03 ±28.48 was seen after LPS stimulation. 2-Way Anova analysis showed a 
statistically significant interaction (p-value < 0.005) between HIV infection and LPS 
stimulation; see Figure 4-15 and Figure 2 in Appendix 1 for representative flow dot plots. 
This suggests that the slight increase in CD116 expression seen in the HIV+ group was 
caused by both HIV-infection and LPS stimulation since such a sharp decrease was not 
observed in the HIV- group. 
 
p-value < 0.005 
Figure 4- 14: Box-and-whisker plot showing CD116 expression in the CD14+CD16- subset across study 
groups before stimulation, HIV+ (median 91.05%, range [14.6-99.9]) vs. HIV-(89.1, [18-100]), and after 
stimulation, HIV+ (95.95, [33.1-100]) vs. HIV-(93.3, [0.9-100]). HIV-: Uninfected donors; HIV+: HIV-
infected donors. Statistically significant differences are indicated by bars with p-values.  
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Correlations performed between the CD14+CD16+ monocyte subset‟s CD116 expression and 
clinical markers produced no significant relationships. A summary of these data can be seen 
in Appendix 1 (Table 10). 
4.6.3. VPAC-2 (Vasoactive Intestinal Peptide Receptor 2)  
Vaso-active intestinal peptide (VIP), the ligand of VPAC-2, is known to mediate anti-
inflammatory effects and has been shown to inhibit certain pro-inflammatory activities and 
LPS-induced inflammatory pathways. VPAC-2 has been noted for its immune-regulatory role 
and is known to inhibit viral replication (Smalley et al., 2009). See section 2.9. in Chapter 2 
for more information on VPAC-2. To investigate the potential of monocyte as therapeutic 
target expression of VPAC-2 was assessed. 
Total monocyte population 
Baseline expression in HIV+ donors was higher but not significantly different to expression 
in HIV- donors. Expression was 5.86 ±6.27 in the HIV+ donors and 3.32 ±2.97 in HIV- 
donors. Although the differences were not statistically significant, they were tending towards 
significance (p-value = 0.0774). After LPS stimulation an increase in expression levels was 
seen in both study groups. See Appendix 1 for representative flow dot plots (Figure 4) 
correlation tests performed between VPAC-2 expression and clinical markers (Table 11). 
CD14+CD16- monocyte subset 
The CD14+CD16- monocyte fraction of the total monocytes displayed a statistically higher 
baseline VPAC-2 expression. The mean percentage in the HIV+ group was 5.45 ±6.13 and 
1.94 ±1.75 in the HIV- groups (p-value = 0.0065), see Figure 4-16 below.  
p-value < 0.005 
Figure 4- 15: Comparison of CD116 expression in CD14+CD16+ subset of both study groups before 
stimulation, HIV+ (median 94.25%, range [27.80-100]) vs. HIV-(81.60, [23.40-100]) and after stimulation, 
HIV+ (96.90, [35.40-100) vs. HIV-(69.4, [10-100]). HIV-: Uninfected donors; HIV+: HIV-infected donors. 
Statistically significant differences are indicated by bars with p-values.  
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Upon stimulation, there was a moderate increase in expression in the HIV+ group and a 
decrease in the HIV- group. 2-Way Anova analysis revealed the increase seen in the HIV+ 
group was due to HIV+ infection (p-value < 0.0011), see Figure 4-17. See Appendix 1 
(Table 12) for correlations performed between the CD14+CD16- monocyte subset‟s VPAC-2 
expression and clinical markers. 
 
 
 
 
 
 
 
 
CD14+CD16+ monocyte subset 
In HIV+ donors VPAC-2 expression was 12.06 ±10.16 and 10.14 ±8.09 in HIV- donors (p-
value = 0.4520). After LPS stimulation VPAC-2 expression increased in both groups. See 
Appendix 1 (Table 13) for correlation tests performed between the total monocyte 
population‟s VPAC-2 expression and clinical markers. 
p-value = 0.0065 
Figure 4- 16: Comparison of VPAC-2 expression in CD14+CD16- subset across both study groups, HIV+ 
(median 3.10%, range [0.30-31.20]) and HIV-(1.20, [0.10-6.20]), at baseline. HIV-: Uninfected donors; 
HIV+: HIV-infected donors. Statistically significant differences are indicated by bars with p-values.  
p-value < 0.0011 
Figure 4- 17: Comparison of VPAC-2 expression in CD14+CD16- subset of both study groups before, 
(n=36) HIV+ (median 3.00%, range [0.30-18.50]) vs. (n= 32) HIV-(3.40, [0.30-14.20]) and after 
stimulation, HIV+ (1.20, [0.1-6.2]) vs. HIV-(0.70, [0.10-5.50]). HIV-: Uninfected donors; HIV+: HIV-
infected donors. Statistically significant differences are indicated by bars with p-values. 
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4.6.4. IL-10 
IL-10 is a regulatory cytokine produced by several types of immune cells and has a primarily 
anti-inflammatory action. During the later stages of HIV-infection IL-10 production is known 
to be increased (Sozzani et al., 1997; Verani et al., 1997), see section 2.7.5. in Chapter 2 for 
more information on IL-10. Intra-cellular IL-10-production was assessed to determine if 
production is affected during HIV-1 infection. 
Total monocyte population 
Expression of intracellular monocyte-associated IL-10 was almost six times higher in the 
HIV+ group than in the HIV- group. Baseline expression in HIV+ donors was 3.71 ±2.66 and 
0.68 ±0.78 in HIV-donors (p-value < 0.005) see Figure 4-18 and Figure 6 in Appendix 1 for 
representative flow dot plot. Upon stimulation there was an increase in the IL-10 expression 
in the total monocyte population of both study groups. Using 2-way Anova analysis, it was 
seen that only LPS stimulation caused the responses seen (p-value-= 0.0202). Correlation 
tests performed between the total monocyte population‟s IL-10 expression and clinical 
markers produced no significant correlations. A summary of these data can be seen in 
Appendix 1 (Table 14). 
 
 
 
 
 
 
 
CD14+CD16- monocyte subset 
The percentage of IL-10 expression in the HIV+ group‟s CD14+CD16- subset was slightly 
higher than in the HIV-1 group, but overall expression in this subset was low 
(<0.70%)compared to the total monocyte population and the CD14+CD16+ subset. The 
p-value < 0.005 
Figure 4- 18: Baseline comparison of IL-10 expression in the total monocyte population of both study 
groups, HIV+ (median 3.15%, range [2.10-19.00]) and HIV-(0.50, [0.00-3.10]). HIV-: Uninfected donors; 
HIV+: HIV-infected donors. Statistically significant differences are indicated by bars with p-values.  
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baseline mean percentage in HIV+ donors was 0.63 ±0.35 and in HIV- donors it was 0.35 
±0.26 (p-value < 0.005) see Figure 4-19.  
 
 
 
 
 
 
 
After LPS stimulation, there was a slight decrease of expression in the HIV+ group and a 
small increase in HIV- group. 2-Way Anova analysis revealed the slight decrease in the 
HIV+ group was due HIV infection (p-value < 0.005), the analysis also showed that the 
responses in the HIV+ group was tending towards an interaction between HIV-infection and 
LPS stimulation (p-value = 0.0547). Correlations performed between the CD14+CD16- 
monocyte subset‟s IL-10 expression and clinical markers yielded no significant correlations. 
A summary of these data can be seen in Appendix 1 (Table 15). 
CD14+CD16+ monocyte subset 
Expression of IL-10 in this subset was more than 20 times higher than the CD14+CD16- 
subset; this difference was also statistically significant (p-value < 0.005). 
Expression of IL-10 in the CD14+CD16+ subset of the HIV+ group was almost three and a 
half times more than in the HIV- group. Baseline expression of IL-10 in the HIV+ group was 
12.66 ±2.91, and 3.99 ±2.38 in the HIV- group (p-value <0.005), see Figure 4-20 and Figure 
8 in Appendix 1 for representative flow plots, which shows the higher expression of IL-10 in 
the HIV+ groups compared to HIV- group. After LPS stimulation, there was a slight increase 
in expression in both study groups, these responses were attributed to LPS stimulation (p-
value < 0.005). 
  
p-value < 0.005 
Figure 4- 19: Comparison of IL-10 expression in CD14+CD16- subset of both study groups HIV+ (median 
0.60%, range [0.10-1.40]) and HIV-(0.04, [0.00-1.10]), at baseline. HIV-: Uninfected donors; HIV+: HIV-
infected donors. Statistically significant differences are indicated by bars with p-values 
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Correlations performed between the CD14+CD16+ monocyte subset‟s IL-10 expression and 
clinical markers showed no significant correlation. A summary of these data can be seen in 
Appendix 1 (Table 16). 
4.7. Homing Markers 
All the markers presented in this section are migration associated. This includes chemokine 
receptors (CCR1, CX3CR1, CCR2, CCR7 and CCR9) and L-selectin (CD62L). These 
markers are either involved in the recruitment of leukocytes to sites of infection and 
inflammation or to lymphoid organs or tissues such as the GALT or lymph nodes themselves; 
see section 2.7. in Chapter 2 for more information on these processes (Kedzierska & Crowe, 
2002). These markers were examined to determine if monocytes are primed in HIV-1 
infection to migrate to sites of infection, lymph nodes or sites of inflammation and thus also 
to exit the circulation. 
4.7.1. CCR1 
CCR1 is a chemokine receptor / migration marker involved with the recruitment and priming 
of monocytes to exit systemic circulation and travel to sites of infection (Shi & Pamer, 2011). 
Total monocyte population 
More than double the amount of monocytes expressed CCR1 in the HIV+ group vs. the HIV- 
group. At baseline expression in the HIV+ group was 6.48 ±3.20 and in the HIV- group was 
3.21 ±1.53 (p-value < 0.005), see Figure 4-21 and Figure 4-9 for representative flow dot 
plot. Upon stimulation the CCR1 expression decreased in both study groups, this was as a 
p-value < 0.005 
Figure 4- 20: Comparison of IL-10 expression in CD14+CD16+ subset of both study groups at baseline, 
HIV+ (median 12.05%, range [9.70-28.60]) and HIV-(3.4, [2.10-11.60]). HIV-: Uninfected donors; HIV+: 
HIV-infected donors. Statistically significant differences are indicated by bars with p-values 
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result of LPS stimulation (p-value = 0.0299). Correlations performed between the total 
monocyte population‟s CCR1 expression and clinical markers showed no significant 
correlations. A summary of these data can be seen in Appendix 1 (Table 17). 
 
CD14+CD16- monocyte subset 
Overall percentage CCR1 expression patterns were similar; if not slightly lower, than the 
total monocytes. Baseline expression in the HIV+ group was 3.92 ±8.23 and 1.66 ±0.67 in 
HIV- group. The expression of CCR1 in the HIV+ group was almost double the expression in 
the HIV- group; however, the differences were not statistically significant (p-value = 0.557) 
but were tending to statistical significance. Upon stimulation, expression in both groups 
decreased slightly. Correlation performed between the CD14+CD16- monocyte subset‟s 
CCR1 expression and clinical markers yielded no significant correlations. A summary of 
these data can be seen in Appendix 1 (Table 18). 
CD14+CD16+ monocyte subset 
Baseline expression in the CD14+CD16+ monocyte subset was more than double than the 
CD14+CD16- subset in both study groups. These differences were observed to be statistically 
significant in both study groups, with p-value < 0.005 for both study groups.  
The HIV+ group displayed slightly higher CCR1expression at 11.16 ±11.33 than the HIV- 
group at 9.52 ±4.24 in the CD14+CD16+ subset at baseline (p-value = 0.5002). After 
stimulation there was a slight decrease in both study groups. Correlation tests performed 
between the CD14+CD16+ monocyte subset‟s CCR1 expression and clinical markers showed 
no significant correlations. A summary of these data can be seen in Appendix 1 (Table 19). 
p-value < 0.005 
Figure 4- 21: Box-and-whisker plot showing baseline CCR1 expression in the total monocyte population 
of both study groups, HIV+ (median 7.35%, range [1.00-16.80]) and HIV-(3.00, [1.00-7.20]). HIV-: 
Uninfected donors; HIV+: HIV-infected donors. Statistically significant differences are indicated by bars 
with p-values.  
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4.7.2. CX3CR1 (Fractalkine receptor) 
CX3CR1 is a migration marker that primes leukocytes to exit circulation and migrate towards 
sites of infection; it is also known to be involved in monocyte survival. Expression of 
CX3CR1 is known to counterbalance the expression of chemokine receptor CCR2, which is 
also a migration marker. These receptors have the same function but their expression is 
usually inverse to each other, i.e. when CX3CR1 expression is increased CCR2 is normally 
decreased and vice versa ((Kedzierska & Crowe, 2002). The priming of monocytes to exit 
circulation by investigating the expression of both CXCR1 and CCR2 was assessed. In the 
current study this trend was observed; CX3CR1 expression was generally lower than CCR2 
expression in both study groups. However, CX3CR1 was still higher when comparing 
expression between study groups. The same trend was seen for CCR2 expression between the 
study groups, see section 4.7.3. 
Total monocyte population 
The baseline expression of CX3CR1 was almost three times lower in the HIV+ group 
compared to the HIV- group. Expression in the HIV+ group was 3.70 ±1.30, whereas in the 
HIV- group it was 9.01 ±3.21 (p-value < 0.005), see Figure 4-22 and Figure 5 in Appendix 1 
for representative dot plots.  
 
 
 
 
 
 
 
After LPS stimulation expression in the HIV+ group decreased minimally to 3.61 ±1.80, 
whilst in the HIV- group expression decreased moderately to 7.47 ±2.85, these responses 
were due to LPS stimulation alone (p-value = 0.0178). Correlations performed between the 
p-value < 0.005 
Figure 4- 22: Box-and-whisker plot showing comparison of CX3CR1 expression in the total monocyte 
population across both study groups at baseline, HIV+ (median 4.00, range [0.60-7.50]) and HIV-(9.00, 
[3.50-17.70]). HIV-: Uninfected donors; HIV+: HIV-infected donors. Statistically significant differences 
are indicated by bars with p-values.  
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total monocyte population‟s CX3CR1 expression and clinical markers showed no significant 
correlations. A summary of these data can be seen in Appendix 1 (Table 20). 
CD14+CD16- monocyte subset 
In the CD14+CD16- monocyte subset the baseline mean percentage expression of CX3CR1 
was the same as general expression in monocytes. In the HIV+ group expression was 3.70 
±1.88 and in the HIV- group it was almost twice as high at 6.65 ±2.04 (p-value <0.005), see 
Figure 4-23. After LPS stimulation expression was decreased in both groups, these decreases 
observed were caused by LPS stimulation only (p-value < 0.005). 
 
 
 
 
 
 
 
Correlations performed between CX3CR1 expression and clinical markers produced a 
significant negative relationship between CD38/8 expression and CX3CR1 after LPS 
stimulation (r -value = -0.4916, p-value = 0.0050), see Figure 4-24. A summary of these data 
can be seen in Appendix 1 (Table 21).  
p-value < 0.005 
Figure 4- 23: Box-and-whisker plot showing comparison of CX3CR1 expression in CD14+CD16- subset 
between both study groups at baseline, HIV+ (median 3.80%, range [0.30-8.20]) and HIV-(7.00, [2.60-
12.20]). HIV-: Uninfected donors; HIV+: HIV-infected donors. Statistically significant differences are 
indicated by bars with p-values.  
Figure 4- 24: Correlation, including linear regression, showing negative relationship of CX3CR1 
expression in CD14+CD16- subset with CD38/8 expression after LPS stimulation (r = -0.4961, p-value = 
0.0050). 
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CD14+CD16+ monocyte subset 
CX3CR1 expression was more than three times higher in the CD14+CD16+ subset than the 
CD14+CD16- subset. These differences were statistically significant in both study groups, 
with p-value < 0.005 in both study groups. The expression was twice as low in the HIV+ 
group as in the HIV group. Baseline expression of CX3CR1 in the HIV+ group was 11.13 
±2.97 and in the HIV- group it was 23.46 ±7.60 (p-value <0.005), see Figure 4-25. 
 
 
 
 
 
 
 
 
 
Stimulation resulted in an increased CX3CR1 expression in the HIV+ group to 14.91 ±5.43 
and to 23.96 ±7.33 in the HIV- group. Using 2-Way Anova analysis it was seen that the 
increase seen in the HIV+ group was due to an interaction between HIV infection and 
stimulation (p-value = 0.0187), see Figure 4-26. 
 
 
 
 
 
 
 
 
p-value < 0.005 
Figure 4- 25: Baseline comparison of CX3CR1 expression in CD14+CD16- subset across both study 
groups, HIV+ (median 10.95%, range [3.50-17.90]) and HIV-(21.80, [11.20-45.30]). HIV-: Uninfected 
donors; HIV+: HIV-infected donors. Statistically significant differences are indicated by bars with p-
values.  
p-value = 0.0187 
Figure 4- 26: Box-and-whisker plot showing comparison of CX3CR1 expression in CD14+CD16+  subset 
across both study groups before stimulation, HIV+ (median 10.95%, range [3.50-17.90]) and HIV-(21.80, 
[11.20-45.30]) and after stimulation, HIV+ (16.25, [2.40-24.80]) vs. HIV-(21.80, [12.00-45.00]). HIV-: 
Uninfected donors; HIV+: HIV-infected donors. Statistically significant differences are indicated by bars 
with p-values. 
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Correlations performed between the CD14+CD16+ monocyte subset‟s CX3CR1 expression 
and clinical markers showed no significant correlations, summary of these data can be seen in 
Appendix 1 (Table 22). 
4.7.3. CCR2  
CCR2 is a migration marker that primes leukocytes to exit systemic circulation and journey 
towards sites of infection or inflammation (Kedzierska & Crowe, 2002). As mentioned in 
section 4.7.2., there appears to be an inverse relationship with the expression patterns of 
CX3CR1 and CCR2. From the data below, CCR2 expression was observed to be higher in 
the total monocyte population and both the subsets of the HIV+ group compared to the HIV- 
group. However, it appears that CCR2 is expressed at higher levels than CX3CR1 in the 
HIV+ group. An important observation is that CCR2 expression appears to be higher in the 
CD14+CD16+ monocyte subset of the HIV+ group and the HIV- group irrespective of 
disease state. This is in contrast to reports by Mir et al. (2012) that state CX3CR1 is normally 
expressed in higher levels in the CD14+CD16+ monocyte subset. Despite the trend of inverse 
CX3CR1/CCR2 expression seen, correlation tests between these marker‟s expression in both 
monocyte subsets showed that only expression in the CD14+CD16+ subset exhibited a 
statistically negative correlation (r-value = -0.4401; p-value < 0.005), in the HIV+ group. See 
Table 23 and Table 24 in Appendix 1 for a summary of the correlation tests performed 
within the CD14+CD16- subset and CD14+CD16+ subset, respectively. 
Total monocyte population 
The mean baseline percentage for HIV+ donors was 51.97 ±21.25 and for HIV- donors, 33.37 
±16.21 (p-value < 0.005), see Figure 4-27 and Figure 3 in Appendix 1 for representative dot 
plots. Upon stimulation expression decreased in both study groups, this was due to LPS 
stimulation (p-value < 0.005). Correlations performed between the total monocyte 
population‟s CCR2 expression and clinical markers showed no significant correlations. A 
summary of these data can be seen in Appendix 1 (Table 25).  
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CD14+CD16- monocyte subset 
Expression of CCR2 in the HIV+ group was elevated compared to the HIV- group, with 
overall similar range of values as in the total monocytes. In the HIV+ group expression was 
53.95 ±21.85 and for the HIV-group it was 34.5 ±15.42. (p-value < 0.005), see Figure 4-28. 
After stimulation, expression in the HIV+ group decreased to 51.42 ±21.20 and in the HIV- 
group expression 31.76 ±15.75. 2-Way Anova analysis suggests that these differences are due 
to stimulation only (p-value < 0.005). Correlations performed between the CD14+CD16- 
monocyte subset‟s CCR2 expression and clinical markers showed a significant correlation 
between CCR2 expression and CD4 count (r -value = 0.3309, p-value = 0.0396). A summary 
of these data can be seen in Appendix 1 (Table 26).  
 
 
 
 
 
 
 
 
p-value < 0.005 
Figure 4- 27: Baseline comparison of CCR2 expression in the total monocyte population across both 
study groups at baseline, HIV+ (median 50.55%, range [12.40-99.90]) and HIV-(27.10, [19.20-82.60]). 
HIV-: Uninfected donors; HIV+: HIV-infected donors. Statistically significant differences are indicated 
by bars with p-values.  
p-value < 0.005 
Figure 4- 28: Box-and-whisker plot showing comparison of CCR2 expression in CD14+CD16- subset 
across both study groups at baseline, (median 56.80% [range 11.50-99.90]) and HIV-(28.40, [15.70-
72.80]). HIV-: Uninfected donors; HIV+: HIV-infected donors. Statistically significant differences are 
indicated by bars with p-values. 
Stellenbosch University  http://scholar.sun.ac.za
83 
 
CD14+CD16+ monocyte subset 
The CD14+CD16+ monocyte subset expressed slightly higher levels of CCR2 than the 
CD14+CD16- subset in HIV+ groups but these differences were not statistically significant 
(p-value = 0.3110). However, in the HIV- group the difference in CCR2 expression between 
the monocyte subsets was statistically significant (p-value < 0.005), see Figure 4-29. 
However, it is interesting to note that CCR2 expression in the HIV+ group was elevated (> 
50%) despite disease status. 
 
 
 
 
 
 
 
Baseline expression of CCR2 in the CD14+CD16+ subset of HIV+ donors was 57.96 ±17.99 
and 53.24 ±10.90 in HIV- donors (p-value = 0.2492). Upon LPS stimulation expression in 
HIV+ donors increased slightly to 58.31 ±17.08 and in HIV- donors the expression decreased 
to 52.08 ±13.06. Correlations performed between the CD14+CD16+ monocyte subset‟s 
CCR2 expression and clinical markers showed significant positive correlation between 
CD38/8 expression and CCR2 (r -value = 0.5946, p-value < 0.005), summary of these data 
can be seen in Appendix 1 (Table 27).  
4.7.4. CCR7 
CCR7 is a gut-homing marker that primes monocytes to migrate towards sites of infection, 
particularly in the gastrointestinal tract or GALT (Saleh et al., 2007). To assess whether 
monocytes are primed to migrate towards the GALT, CCR7 expression was investigated. 
p-value < 0.005 
Figure 4- 29: Comparison of CCR2 expression across study group subsets at baseline. HIV+ CD14+CD16- 
(median 56.3%, range [11.5-99.90]) vs. CD14+CD16+ (58.60, [25.20-100.00]) and HIV- CD14+CD16- 
(25.4, [15.70-72.80]) vs. CD14+CD16+ (55.10, [29.60-72.20]). Statistically significant differences are 
indicated by bars with p-values.  
CD14+CD16- CD14+CD16+ 
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Total monocyte population 
High levels of CCR7 expression were observed in both study groups (>75%). However, 
baseline CCR7 expression in the total monocyte population of the HIV+ group was 
significantly higher than in the HIV- group. Expression was 85.85% ±13.99 in the HIV+ 
group and 77.93% ±13.92 in the HIV- group (p-value < 0.005), see Figure 4-30 and Figure 3 
in Appendix 1 for representative dot plots. After LPS stimulation, the expression increased in 
both study groups. Correlations performed between the total monocyte population‟s CCR7 
expression and clinical markers showed no significant correlations. A summary of these data 
can be seen in Appendix 1 (Table 28). 
 
 
 
 
 
 
 
CD14+CD16- monocyte subset 
Expression of CCR7 was similar in both study groups as baseline. CCR7 expression in the 
HIV+ group was 77.13 ±13.64 and in the HIV- group it was 76.60 ±13.41 (p-value = 0.8815). 
Upon stimulation there was an increase in CCR7 expression in both study groups. 
Correlations performed between the CD14+CD16- monocyte subset‟s CCR7 expression and 
clinical markers yielded no significant correlations. A summary of these data can be seen in 
Appendix 1 (Table 29). 
CD14+CD16+ monocyte subset 
Overall, CCR7 expression was observed in a higher percentage of CD14+CD16+ monocytes 
than CD14+CD16- monocytes ones. This difference was statistically significant in both the 
HIV+ and HIV- study groups (p-value< 0.005 for both study groups).  
p-value < 0.005 
Figure 4- 30: Box-and-whisker plot showing CCR7 expression in the total monocyte population of both 
study groups at baseline, (median 89.6%, range [28.1-98.9]) and HIV-(77.1, [47.6-99]). HIV-: Uninfected 
donors; HIV+: HIV-infected donors. Statistically significant differences are indicated by bars with p-
values.  
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The mean percentages of CCR7 in both study groups were observed to be very similar at 
baseline. Expression in the HIV+ group was 90.40 ±9.64 and 90.45 ±8.98 in the HIV- group 
(p-value = 0.9827). After LPS stimulation expression increased in both study groups. 
Correlations performed between the CD14+CD16+ monocyte subset‟s CCR7 expression and 
clinical markers produced no significant correlation. A summary of these data can be seen in 
Appendix 1 (Table 30). 
4.7.5. CCR9 
CCR9 is a lymph-node homing marker that it also expressed on dendritic cells. Expression of 
this marker primes cells to migrate towards lymph nodes where they may be able to prime 
other immune cells into initiating an adaptive immune response cascade (Haas et al., 2011). 
An interesting trend was that CCR9 expression was increased in the total monocyte 
population and across monocyte subsets of the HIV+ group compared to the HIV- group but 
no statistical difference was found. Priming of monocytes, via CCR9, for migration to lymph 
nodes was assessed. 
Total monocyte population 
The mean percentage baseline expression in the HIV+ group was 6.56 ±7.93 and in the HIV- 
group it was 5.44 ±1.46 (p-value =0.1707). Upon stimulation the expression decreased in 
both groups. A summary of correlation data can be seen in Appendix 1 (Table 31) and 
Figure 5 for representative dot plots.  
CD14+CD16- monocyte subset 
At baseline the expression in the HIV+ group was approximately double than that observed 
in the HIV- group. Expression in the HIV+ group was 7.98 ±16.70 and 3.66 ±1.56 in the 
HIV- group (p-value = 0.2082). After stimulation the expression decreased in both the 
groups. Correlation performed between the CD14+CD16- monocyte subset‟s CCR9 
expression and clinical markers showed no significant correlations. A summary of these data 
can be seen in Appendix 1 (Table 32). 
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CD14+CD16+ monocyte subset 
The CD14+CD16+ subset again displayed significantly higher expression than the 
CD14+CD16- subset for both study groups, p-value = 0.0073 for HIV+ group and p-value < 
0.005 for HIV- group. 
The baseline mean percentage in the HIV+ group was slightly higher at 16.34 (±14.36) and in 
the HIV- group the expression it was lower at 13.86 (±4.07) (p-value = 0.4200). After LPS 
stimulation there was an increase in expression across both groups. Correlation performed 
between the CD14+CD16+ monocyte subset‟s CCR9 expression and clinical markers yielded 
no significant correlations. A summary of these data can be seen in Appendix 1 (Table 33). 
4.7.6. CD62-L (L-Selectin) 
CD62-L, also known as L-selection, is a homing marker that is involved in the migration of 
leukocytes from systemic circulation through blood vessels into sites of inflammation and 
infection (Ancuta et al., 2003). To determine if monocytes are primed to exit systemic 
circulation during HIV-infection CD62-L expression was investigated 
Total monocyte population 
At baseline CD62-L expression in the HIV+ group was almost double the expression seen in 
the HIV- group. Expression in the HIV+ group was 29.57 ±14.12 and 16.12 ±15.75 in the 
HIV- group (p-value < 0.005), see Figure 4-32 and Figure 4-31 for representative flow data. 
Mean data analysis, however, did not reflect the expression seen in the HIV- group. 
 
 
 
 
 
 
 
1.5 % 
86.1 % 9.0% 
3.3 % 1 % 
54.7 % 43.3 % 
0.9 % 
Figure 4- 31: Representative flow cytometry dot plots showing CD62-L (PE-Cy7) expression in the total 
monocyte population, (PerCP = HLA-DR). In the first box on the left (Panel 2 CD62-L US), the 
expression of CD62-L-PE-Cy7 vs. HLA-DR-PeCP is illustrated in a FMO sample excluding CD62-L- 
marker (negative unstained control). In the middle and right boxes, baseline expression of CD62-L- in a 
HIV- (RP25) vs. a HIV+ (P208) study sample is shown, respectively. Increased expression of CD62-L can 
be seen for P208 vs. RP25, total CD62-L positivity for RP25 is 12.30%, and for P208 it is 44.20%.  
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Upon LPS stimulation CD62-L expression decreased in both study groups, in the HIV+ 
group expression decreased to11.90 ±10.01 and in the HIV- group it expression decreased 
slightly to 13.90 ±11.9. The dramatic decrease in CD62-L expression in the HIV+ group was 
observed to be as a result of an interaction between HIV-1 infection and LPS stimulation (p-
value < 0.005). Despite the decrease in mean percentages seen in the HIV- group, the median 
data analysis did not reflect this decrease, see Figure 4-32. 
Correlations performed between the total monocyte population‟s CD62-L expression and 
clinical markers yielded no significant correlations. A summary of these data can be seen in 
Appendix 1 (Table 34). 
CD14+CD16- monocyte subset 
Expression of CD62-L was higher in the HIV+ group compared to the HIV- group. Baseline 
expression in the HIV+ group was 15.23 ±15.46 and 8.43 ±8.99 in the HIV- group (p-value = 
0.0820). Upon stimulation the percentage expression decreased in both groups, this was 
caused by LPS stimulation only (p-value = 0.0073). Correlations performed between the 
CD14+CD16- monocyte subset‟s expression and clinical markers yielded no significant 
correlations. A summary of these data can be seen in Appendix 1 (Table 35). 
CD14+CD16+ monocyte subset 
As with several other markers, CD62-L expression was higher in the CD14+CD16+ subset 
than the CD14+CD16- subset and this difference was statistically significant in both study 
groups (p-value< 0.005 for both study groups).  
p-value < 0.005 
Figure 4- 32: Box-and-whisker plot showing CD62-L expression in the total monocyte populations of both 
study groups before stimulation, HIV+ (median 25.00%, range [8.10-84.90]) vs. HIV-(10.70, [0.90-68.70]) 
and after stimulation, HIV+ (8.50, [2.40-47.00]) vs. HIV-(10.00, [0.30-39.60]). HIV-: Uninfected donors; 
HIV+: HIV-infected donors. Statistically significant differences are indicated by bars with p-values. 
Stellenbosch University  http://scholar.sun.ac.za
88 
 
Expression was slightly higher in the HIV+ group compared to the HIV- group. Baseline 
expression was 37.10 ±18.48 in the HIV+ group and 31.30 ±14.03 in the HIV- group, but not 
significantly (p-value = 0.2247). After LPS stimulation CD62-L expression decreased in both 
groups. Correlations performed between CD14+CD16+ monocyte subset‟s CD62-L 
expression and clinical markers showed no significant correlation. A summary of these data 
can be seen in Appendix 1 (Table 36). 
4.8. Activation Markers 
Monocyte activation status was assessed by investigating the expression of activation 
markers, CD69 and HLA-DR. 
4.8.1. CD69 
CD69 is a marker of cellular activation and expression usually increases as a cell is exposed 
to stimuli. CD69 expression has also well-described in T- cell activation (Funderburg & Sieg, 
2012). To measure the level of monocyte activation, CD69 expression was assessed. 
Statistical differences were only found between the CD14+CD16+ monocyte subsets of the 
two study groups despite CD69 expression always being higher in the HIV+ group compared 
to the HIV- group.  
Total monocyte population 
Baseline expression of CD69 was double in the HIV+ group when compared to the HIV- 
group. Expression was 10.47 ± 14.20 in the HIV+ group and 5.25 ±2.26 in the HIV- group. 
However, the differences were not statistically significant (p-value = 0.1059). After LPS 
stimulation, expression was increased minimally in HIV+ donors but slightly decreased in 
HIV- donors. Correlations performed between the total monocyte population‟s CD69 
expression and clinical markers yielded no significant correlations. A summary of these data 
can be seen in Appendix 1 (Table 37). 
CD14+CD16- monocyte subset 
CD69 expression in the CD14+CD16- monocyte subset was observed to be very similar to 
general expression in monocytes. Expression was again more than double in the HIV+ group 
than in the HIV- group. Baseline expression of CD69 in the HIV+ group was 9.11 ±13.94 and 
4.17 ±2.35 in the HIV- group (p-value =0.1189). Upon stimulation expression increased 
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slightly in the HIV+ group to 10.37 ±16.19 but decreased in the HIV- group to 3.11 ±1.15. 
This increase in the HIV+ group was as a result of HIV infection (p-value = 0.0090). 
Correlations performed between the CD14+CD16- monocyte subset‟s CD69 expression and 
clinical markers showed no significant correlations. A summary of these data can be seen in 
Appendix 1 (Table 38). 
CD14+CD16+ monocyte subset 
Significantly higher CD69 expression was observed in the CD14+CD16+ subset across both 
study groups when compared to the CD14+CD16- counterparts (p-value < 0.005 for both 
study groups). Expression of CD69 was more than double in the HIV+ group than in the 
HIV- group. Expression in the HIV+ group was 34.04 ±15.74 and 16.32 ±8.90 in the HIV- 
group (p-value < 0.005), see Figure 4-33 and Figure 4-34for flow representation of baseline 
CD69 expression between the two study groups. 
 
After LPS stimulation, expression decreased in both study groups, this was due to stimulation 
only (p-value = 0.0164). A summary of correlation data can be seen in Appendix 1 (Table 
39). 
  
p-value < 0.005 
Figure 4- 33: Box-and-whisker plot showing CD69 expression in the CD14+CD16+ subset of both study 
groups at baseline, HIV+ (median 35.60, range [5.10-77.40]) and HIV-(13.40[1.80-37.00]). HIV-: 
Uninfected donors; HIV+: HIV-infected donors. Statistically significant differences are indicated by bars 
with p-values. 
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4.8.2. HLA-DR (MHC class II) 
HLA-DR, a component of the MHC class II, is also a marker of activation that is 
constitutively expressed (usually >80% of cells) on all antigen-presenting cells, including 
monocytes (Cheadle et al., 1991). Monocyte activation defined by HLA-DR expression was 
assessed. 
Total monocyte population 
HLA-DR appeared to be constitutively expressed by both groups as expression was high. 
Baseline expression in the HIV+ group was 86.41 ±16.00 and 87.83 ±14.68 in the HIV- 
group (p-value = 0.7823), see Figure 4-31 for representative flow dot plots. Upon 
stimulation, there was an increase of expression across both groups, these responses were due 
to stimulation (p-value = 0.0330). Correlation tests performed show a negative relationship 
between HLA-DR expression and CD4 count after LPS stimulation (r-value = -0.3506; p-
value = 0.0168). A summary of correlation data can be seen in Appendix 1 (Table 40). 
CD14+CD16- monocyte subset 
In the CD14+CD16- monocyte subset HLA-DR was also constitutively expressed by both 
study groups. Expression at baseline was 87.89 ±16.62 for the HIV+ group and 87.08 ±12.27 
for HIV- group (p-value = 0.8480). After stimulation, expression increased in both groups.  A 
negative relationship between HLA-DR expression and CD4 count at baseline (r-value = -
2.2% 
%80.
0.1% 43.3%  
54.4% 8.6% 
0.1%%31
.6 % 
4.2% 
%5.4 % 
87.1%5.4 % 
Figure 4- 34: Representative flow cytometry dot plots showing CD69 (FITC) expression in the 
CD14+CD16+ subset, (PE = TRAIL-R1). In the first box on the left (Panel 1 CD69 US), the expression of 
CD69 FITC vs. TRAIL-R1 PE is illustrated in a FMO sample excluding CD69 marker (negative 
unstained control). In the middle and right boxes baseline expression of CD69 in a HIV+ (RP44) vs. a 
HIV-(RP38) study sample is shown, respectively. Increased expression of CD69 can be seen for RP44 vs. 
RP38, total CD69 positivity for RP44 is 43.40%, and for RP38 it is 4.30%. 
Stellenbosch University  http://scholar.sun.ac.za
91 
 
0.3629; p-value = 0.0232). After stimulation this relationship switched to a positive 
relationship (r-value = 0.3325; p-value = 0.0452). A summary of correlation data can be seen 
in Appendix 1 (Table 41). 
CD14+CD16+ monocyte subset 
HLA-DR was also constitutively expressed in the CD14+CD16+ monocyte subset by both 
study groups. Interestingly, HLA-DR expression was lower on the CD14+CD16+ subset than 
the CD14+CD16- in the HIV+ group, but this difference was not statistically significant (p-
value = 0.1103). The differences in HLA-DR expression between monocyte subsets in the 
HIV- group was also not statistically significant (p-value = 0.4595). 
Expression of HLA-DR in the CD14+CD16+ monocyte subset of the HIV+ group was 82.02 
±15.79 and 84.20 ±14.48 in HIV- group (p-value = 0.6117). After LPS stimulation, 
expression increased in both groups. Correlations performed between the CD14+CD16+ 
monocyte subset‟s HLA-DR expression and clinical markers yielded no significant 
correlations. A summary of these data can be seen in Appendix 1 (Table 42). 
4.9. Apoptotic Potential 
The apoptotic potential of monocytes was assessed by investigating the expression of 
apoptosis-related markers, TRAIL-R1, TNR1, CD95, Bcl-2 and 7AAD/AnnexinV dual 
expression. 
4.9.1. TRAIL-R1 (TNF-Related Apoptosis Inducing Ligand Receptor 1) 
TRAIL-R1 is one of 4 different cellular receptors that binds the apoptosis-inducing ligand 
TRAIL and results in cells becoming sensitive to apoptosis through this pathway (Yang et al., 
2003; Cerutti, 2009) .TRAIL-R1 expression was high in the total monocyte population and 
both monocyte subsets. The observed high levels of expression (higher than majority of 
published studies) may be due to brightness of flourochrome marker (PE), and inadequate 
compensation adjustment (all compensation was bead-based, not cell based). To determine 
monocytes sensitivity to apoptosis TRAIL-R1 expression was assessed. 
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Total monocyte population 
TRAIL-R1 expression was higher in the HIV+ group compared to the HIV- group. At 
baseline expression in the HIV+ group was 74.91 ±15.96 and 56.70 ±23.26 in the HIV- group 
(p-value < 0.005), see Figure 4-35 and Figure 4-34 for representative dot plots. After LPS 
stimulation, expression in the HIV+ group decreased slightly to 71.13 ±14.82 and in the HIV- 
group increased to 67.35 ±22.90, these responses were due to stimulation (p-value < 0.005). 
Correlations performed between the total monocyte population‟s TRAIL-R1 expression and 
clinical markers showed no significant correlations. A summary of these data can be seen in 
Appendix 1 (Table 43). 
 
 
 
 
 
 
 
 
CD14+CD16- monocyte subset 
Expression was slightly but insignificantly lower in the HIV+ group compared to the HIV- 
group. Baseline expression of TRAIL-R1 was 67.42 ±33.42 in the HIV+ group and 71.21 
±9.58 in the HIV- group (p-value = 0.6194). Upon stimulation there was an abrupt decrease 
in TRAIL-R1 expression in the HIV- donors was observed as compared to the HIV+ donors. 
The moderate decrease observed in the HIV+ group appears to be caused by an interaction 
between HIV-infection and LPS stimulation (p-value <0.005), see Figure 4-36.Correlations 
performed between the CD14+CD16- monocyte subset‟s TRAIL-R1 expression and clinical 
markers yielded no significant correlations. A summary of these data can be seen in 
Appendix 1 (Table 44). 
p-value < 0.005 
Figure 4- 35: Baseline comparison of TRAIL-R1 expression in total monocyte population in both study 
groups, HIV+ (median 74.70%, range [21.00-100.00]) and HIV-(58.30, [15.00-94.60]). HIV-: Uninfected 
donors; HIV+: HIV-infected donors. Statistically significant differences are indicated by bars with p-
values.  
Stellenbosch University  http://scholar.sun.ac.za
93 
 
CD14+CD16+ monocyte subset 
In the CD14+CD16+ monocyte subset the baseline expression of TRAIL-R1 in HIV+ donors 
was 71.79 ±19.51 and much lower in HIV- donors at 39.12(±34.31 (p-value <0.005), see 
Figure 4-37. Compared to CD14+CD16- monocytes the HIV+ group was increased (p-value 
= 4415), but the most dramatic difference was the low expression in the HIV- group (p-
value< 0.005).  
 
Upon LPS stimulation there was an increase in the TRAIL-R1 expression in HIV+ donors to 
77.95 ±11.59, compared to a decrease to 37.18 ±32.67 in HIV- donors. This increase in the 
HIV+ group was as a result of an interaction by HIV-infection and LPS stimulation (p-value 
= 0.0490). Correlations performed between the CD14+CD16+ monocyte subset‟s TRAIL-R1 
expression and clinical markers produced no significant correlations. A summary of these 
data can be seen in Appendix 1 (Table 45). 
p-value < 0.005 
Figure 4- 36: Box-and-whisker plot showingTRAIL-R1 expression in CD14+CD16- subsets of both study 
groups before stimulation, HIV+ (median 80.50%, range [1.70-100.00]) vs. HIV-(67.20, [61.40-94.70]) and 
after stimulation, HIV+ (66.30, [1.00-99.80]) vs. HIV-(5.00, [2.40-65.60]). HIV-: Uninfected donors; HIV+: 
HIV-infected donors. Statistically significant differences are indicated by bars with p-values. 
p-value < 0.005 
Figure 4- 37: Baseline comparison of TRAIL-R1 expression in the CD14+CD16+ subsets of both study 
groups, HIV+ (median 69.00%, range [6.4.00-100.00]) and HIV-(15.10, [4.90-95.80]). HIV-: Uninfected 
donors; HIV+: HIV-infected donors. Statistically significant differences are indicated by bars withpP-
values.  
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4.9.2. TNFR1 (TNF Receptor-1)  
TNFR1 (together with TNFR2) represents the cellular receptor for TNF-α. TNFR1 is 
primarily involved in cell survival whereas TNFR2 is associated with cell death. The signal 
transduction pathways of each receptor do however interlink, so this is not a hard-and-fast 
rule. When TNFR1 binds to its ligand, TNF-α, the cell usually becomes more resistant to the 
apoptosis-related functions of TNF-α (Herbein & Khan, 2008; Herbein & Varin, 2010). 
Resistance of monocytes to apoptosis during HIV-1 infection was investigated by assessing 
TNFR1 expression. 
Total monocyte population 
Baseline expression of TNFR1 in the HIV+ group was almost half the expression seen in the 
HIV- group. Expression was 2.44 ±1.43 in the HIV+ group and 4.14 ±3.14in the HIV- group 
(p-value = 0.0077), see Figure 4-38 and Figure 7 in Appendix 1 for representative dot plots. 
Upon stimulation there was a decrease in expression in both groups, this was due to 
stimulation only (p-value = 0.0139). Correlations performed between TNFR1 expression and 
clinical markers yielded no significant correlations. A summary of these data can be seen in 
Appendix 1 (Table 46). 
 
CD14+CD16- monocyte subset 
The baseline expression was very similar for both study groups. Expression of TNFR1 in the 
HIV+ group was 1.15 ±1.12 and 1.31 ±0.66 in the HIV- group (p-value = 0.5571). Upon 
stimulation there was a decrease in expression in both groups. Correlations performed 
between TNFR1 expression and clinical markers produced a significant positive correlation 
p-value = 0.0077 
Figure 4- 38: Box-and-whisker plot showing TNFR1 expression in total monocyte populations of both 
study groups at baseline, HIV+ (median 2.20%, range [0.60-9.10]) and HIV-(3.40, [1.20-13.80]). HIV-: 
Uninfected donors; HIV+: HIV-infected donors. Statistically significant differences are indicated by bars 
with p-values.  
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with CD4 count (r -value = 0.3789, p-value = 0.0174). A summary of these data can be seen 
in Appendix 1 (Table 47). 
CD14+CD16+ monocyte subset 
The CD14+CD16+ subset displayed significantly higher TNFR1 expression as compared to 
the CD14+CD16- subset, p-value< 0.005 for both study groups.  
The trend of HIV+ infection resulting in decreased expression also applied here. In the 
CD14+CD16+ monocyte subset the baseline expression of TNFR1 was slightly lower in the 
HIV+ group at 10.19 ±3.65 compared 13.53 ±6.93 in the HIV- group (p-value = 0.0216), see 
Figure 4-39. 
 
 
 
 
 
 
 
After stimulation expression increased in both groups, these increases in both groups were 
due to LPS stimulation (p-value = 0.0449). However, the increase in the HIV+ group was 
also seen to also be affected by HIV-infection (p-value = 0.0086), no interaction was seen as 
significant (p-value = 0.550). Correlations performed between the CD14+CD16+ monocyte 
subset‟s TNFR1 expression and clinical markers produce no significant correlations. A 
summary of these data can be seen in Appendix 1 (Table 48). 
4.9.3. CD95 (Fas) - Death marker and TNF-α (Tumor necrosis factor-
alpha) - Pro-inflammatory cytokine 
The expression percentages obtained for CD95 and TNF-α after flow cytometry acquisition 
were very high (> 90%) and were in conflict with current literature. Flow data analysis was 
performed when laboratory work had concluded. After reviewing the controls set for both 
markers during their respective FMO experiments, it was seen that whilst the negative 
p-value = 0.0216 
Figure 4- 39: Baseline comparison of TNFR1 expression in CD14+CD16+ subsets of both study groups, 
HIV+ (median 10.00%, range [10.70-20.40]) and HIV-(13.50, [3.00-32.50]). HIV-: Uninfected donors; 
HIV+: HIV-infected donors. Statistically significant differences are indicated by bars with p-values 
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controls were set correctly, expression of CD95 and TNF-α seen in tubes containing the 
antibodies from their FMO experiments were similar to the expression patterns seen in both 
HIV+ and HIV- samples after acquisition, see Figure 4-40 for CD95 and Figure 4-41 for 
TNF-α, respectively.  
Attempts were made to salvage the data. The titration experiments for both CD95 and TNF-α 
were reviewed with hopes that a more accurate expression would be seen compared to the 
patient samples; both markers were plotted against SSC-A to try to eliminate interference 
from other flourochrome markers; CD95 and TNF α were plotted against different markers 
from their respective panels (Panel 2 and 3, respectively), again attempting to eliminate 
interference from the marker they were plotted against during acquisition and analysis. 
Unfortunately, these attempts were unsuccessful. These errors could have occurred due to 
high expression of the flourochrome (BV421), it is interesting to note that both these markers 
make use of BV421; problematic adjusting of bead compensation to cells, especially for 
monocytes as a minority population; flow cytometer malfunctioning, the flow cytometer used 
during the early stages of this study broke and was replaced, however, the new flow 
cytometer also exhibited some problematic functioning; or human error. It was concluded 
that these results were unusable. Future studies should include detailed analysis of a few 
samples to check settings are correct. 
1 4 3 2 
Figure 4- 40: Representative flow cytometry dot plots showing CD95-BV421 (shown here as BD HV450*) 
expression in the total monocyte population, (APC = TNFR1). In the first dot plot on the left (Panel 2 C95 
US), the expression of CD95 BV421 vs. TNFR1-APC is illustrated in a FMO sample excluding C95 
marker (negative unstained control). The second dot plot (Panel 2 CD62-L US) shows CD95 expression in 
CD62-L’s FMO experiment. The second dot plot from the right (RP25 Panel 2 US) shows CD95 
expression in a HIV- study sample and the dot plot on the far right (RP32 Panel 2 US) shows CD95 
expression in HIV+ study sample (RP32). From the dot plots it can be seen that in plot 2 CD95 expression 
shifts completely to the right when CD95-BV421 is present in the tube. A similar pattern can be seen in 
both the HIV+ and HIV- study samples.*CD95-BV421 is shown as BD HV450 due to the settings of the 
FACS DIVA software that was used during analysis, see section 3.10. in Chapter 3 for study sample flow 
acquisition. 
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4.9.4. Bcl-2- Anti-apoptotic protein 
Bcl-2 is an anti-apoptotic protein that is involved in protecting cells from apoptosis, 
specifically associated with the intrinsic death pathway (Gautier et al., 2009). Bcl-2 
expression assessed to determine if monocytes are resistant to apoptosis during HIV-1 
infection. Although Bcl-2 expression was increased in the total monocyte population and in 
both monocyte subsets in the HIV+ group, no statistically significant differences were found 
between study groups. This could possibly be as a result of data spread, sample size, variation 
in study participants and outliers. 
Total monocyte population 
Highest expression was seen in the CD14+CD16+ subset. Baseline expression of Bcl-2 was 
more than twice as high in the HIV+ group compared to the HIV- group. Expression was 
7.44 ±13.31 in the HIV+ donors and 3.93 ±3.17 in the HIV- donors (p-value = 0.2071). Upon 
stimulation there was a moderate decrease in expression for HIV+ donors to but a slight 
increase in HIV- donors. Correlations performed between Bcl-2 expression after LPS 
stimulation and clinical markers produced a significant positive correlation with CD4 count (r 
-value = 0.3573, p-value = 0.0256). A summary of these data can be seen in Appendix 1 
(Table 49). 
1 4 3 2 
Figure 4- 41: Representative flow cytometry dot plots showing TNF-α- (BV421) expression in the total 
monocyte population, (APC = IL-10). In the first dot plot on the left (Panel 3 TNF-α S), the expression of 
TNF-α BV421 vs. IL-10-APC is illustrated in a FMO sample excluding C95 marker (negative unstained 
control). The second dot plot (Panel 3 CD116 S) shows TNF-α expression in CD116’s FMO experiment. 
The second dot plot from the right (RP25 Panel 3 US) shows TNF-α expression in a HIV- study sample 
and the dot plot on the far right (RP32 Panel 3 US) shows TNF-α expression in HIV+ study sample 
(RP32). From the dot plots it can be seen that in plot 2 TNF-α expression shifts completely to the right 
when TNF-α -BV421 is present in the tube. A similar pattern can be seen in both the HIV+ and HIV- 
study samples. 
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CD14+CD16- monocyte subset 
In the HIV+ group baseline expression was much higher than in the HIV- group. Expression 
was 9.22 ±16.85 in the HIV+ group and 3.13 ±2.81 in the HIV- group (p-value = 0.0989). 
After LPS stimulation the expression increased in both groups. Correlations performed 
between the CD14+CD16- monocyte subset‟s Bcl-2 expression and clinical markers yielded 
a significant positive correlation with CD4 count (r -value = 0.3551, p-value = 0.0265). A 
summary of these data can be seen in Appendix 1 (Table 50). 
CD14+CD16+ monocyte subset 
Bcl-2 expression was higher in the CD14+CD16+ subset compared to the CD14+CD16- 
subset, these difference were statistically significant for both study groups, p-value< 0.005 
for both study groups.  
The baseline expression in CD14+CD16+ monocyte subset of HIV+ donors was 12.52 
±17.63 and 7.48 ±5.86 in HIV- donors (p-value = 0.1712). LPS stimulation resulted in an 
increase of expression across both groups. Correlations performed between Bcl-2 expression 
and clinical markers produced a significantly positive correlation with CD4 count (r -value = 
0.4138, p-value < 0.005), summary of these data can be seen in Appendix 1 (Table 51). 
4.9.5. 7AAD/AnnexinV dual expression 
7AAD/AnnexinV dual expression is an indication of late apoptosis in cells (Lecoeur et al., 
1997; Dong et al., 2009). Expression patterns for dual expression were investigated on a 
small subset of study samples using isolated monocytes. The percentage of monocytes under-
going late apoptosis was assessed using 7AAD/AnnexinV dual expression. Overall, it was 
seen that a higher percentage of monocytes in the HIV+ group were in the late stages of 
apoptosis compared to the HIV- group, but the differences in expression between the two 
study groups were not statistically significant. Possible reasons for this could be loss of 
monocytes during the isolation process as well as adherence of cells to test tubes during 
stimulation. 
Total monocyte population 
Baseline mean percentage expression in HIV+ donors was 1.71 ±1.01 and in HIV- donors it 
was 1.23 ±0.18 (p-value = 0.3987). LPS stimulation resulted in an increased expression 
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across both groups (p-value < 0.005). Correlations performed between the total monocyte 
population‟s 7AAD/AnnexinV expression and clinical markers yielded no significant 
correlations. A summary of these data can be seen in Appendix 1 (Table 52). 
CD14+CD16- monocyte subset 
Baseline expression in the CD14+CD16- monocyte subset was higher in the total monocyte 
population com than in the CD14+CD16- monocyte subset. Expression in the HIV+ donors 
was 0.52 ±0.12 and 0.48 ±0.11 in the HIV- donors (p-value = 0.5548). Upon stimulation 
there was an increase in expression across both groups, these responses were due to LPS 
stimulation only (p-value < 0.005). A summary of correlation data can be seen in Appendix 1 
(Table 53) 
CD14+CD16+ monocyte subset 
7AAD/AnnexinV dual expression was, like other markers, increased in the CD14+CD16+ 
subset than in the CD14+CD16- subset. The differences seen between the CD14+CD16- 
subset and CD14+CD16+ subset for the HIV+ group were statistically significant (p-value < 
0.005), see Figure 4-42. Statistically significant differences between the two subsets were 
seen for the HIV- group as well, (p-value < 0.005). 7AAD/AnnexinV dual expression in the 
HIV+ group was 3.94 ±0.88 and 3.96 ±0.18 in the HIV- group (p-value = 0.5221). LPS 
stimulation caused an increase in the both the groups 7AAD/AnnexinV expression (p-value < 
0.005). Correlations performed between the CD14+CD16+ monocyte subset‟s 
7AAD/AnnexinV expression and clinical markers produced no significant correlations. A 
summary of these data can be seen in Appendix 1 (Table 54). 
  
Figure 4- 42: Comparison of 7AAD/AnnexinV dual expression across study group subsets at baseline. 
HIV+ CD14+CD16- (median 0.50%, range [0.40-0.80]) vs. CD14+CD16+ (4.10, [2.60-5.10]) and HIV- 
CD14+CD16- (0.50, [0.30-0.60]) vs. CD14+CD16+ (3.60, [3.40-3.90]). Statistically significant differences 
are indicated by bars with p-values 
p-value < 0.005 
p-value < 0.005 
CD14+CD16- CD14+CD16+ 
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4.10. Results Summary 
Overall during HIV-1 infection monocytes produced higher levels of IL-10 as well as appear 
to be primed to exit systemic circulation and migrate towards the GALT. Monocytes are also 
at a higher cellular activation status during HIV-infection compared to HIV- monocytes. 
These trends are especially true for the CD14+CD16+ subset, which generally displayed 
higher levels of expression and cytokine production that the CD14+CD16- subset. This 
higher expression trend in the CD14+ CD16+ subset was also observed between the HIV- 
group‟s subset, despite the difference in expression between study groups. This would 
suggest that monocyte function is generally still intact. LPS-induced responses were similar 
across both study groups. Overall, monocyte phenotype was altered in vitro during HIV-1 
infection, and in vitro LPS stimulation, lead to an enhancement of pre-existing differences. 
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Chapter 5: Discussion 
The hypothesis of this study was that HIV-1 infection induces changes in the monocyte cell 
population that affects their phenotype and functional responsiveness to LPS stimulation. 
Phenotypic changes encompass changes to activation status, homing receptor expression and 
apoptotic sensitivity. To test the hypothesis, expression of unspecified phenotypic markers 
(CCR5, IL-10, CD116 & VPAC-2), homing markers (CCR1, CCR2, CX3CR1, CCR7, CCR9 
& CD62-L) and activation markers (CD69 & HLA-DR), as well as markers related to 
apoptosis (TRAIL-R1, TNFR1, CD95, TNF-α, Bcl-2 & 7AAD/AnnexinV) were assessed, 
and the findings compared to the those of uninfected healthy controls. The implications of the 
changes observed and how they relate to current literature are discussed in the sections 
below. Strengths and limitations of the study follow afterwards. 
The current study met the objectives and answered the research questions put forth at the 
beginning. Through this the study was able to achieve its aim and prove the hypothesis of the 
study. 
HIV+ individuals have a higher immune activation status despite CD4 
counts > 300cells/µl  
In the current study infection with HIV-1 is associated a significant decrease in CD4 count 
and a higher immune activation status (measured by CD38/8 expression), phenomena well-
described in numerous other studies. This was observed despite individuals having CD4 
counts > 300cells/µl. HIV infection was also associated with changes to the total monocyte 
population (as a percentage of total blood events) and of the monocyte subsets. There appears 
to be disagreement in the literature with regard to the exact role of each monocyte subset. In 
Chapter 2, it was put forward that CD14+CD16+ monocytes are involved in promoting 
inflammation, whereas the CD14+CD16- subset are repair oriented (Kedzierska & Crowe, 
2002). This model seems restrictive as others have said CD14+CD16+ monocytes are 
involved in repair and CD14+CD16- in priming acquired immunity through their APC 
function (Gautier et al., 2009). Data from the current study shows that the CD14+CD16+ 
monocytes are expanded, activated, producing higher levels of IL-10 compared to 
CD14+CD16- monocytes and primed for migration during HIV-1 infection. This may be due 
to the HIV+ group in the current study having CD4 counts greater 300cells/µl and being 
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treatment naive. If CD14+CD16+ monocytes are also involved in repair, this could indicate 
the initiation of the fibrosis pathway at this stage as well.  
CD14+CD16+ monocyte subset is increased during HIV-1 infection 
During HIV-1 infection an overall increase in the circulating total monocyte population was 
observed, however this may reflect decreases in other blood cell types, especially CD4
+
 T-
cells. There also may be an element of production from the bone marrow but precise 
indicators of bone marrow emigration were not examined and therefore it is difficult make a 
comment with certainty. This, however, does not detract from the subsets changes, which are 
real as they are a component of the total monocyte population and as such subset shifts 
indicate real population changes.  
There was an increase in the CD14+CD16+ monocyte subset and a corresponding decrease in 
the CD14+CD16- monocyte subset in the HIV+ group. Various studies have also observed 
this preferential expansion of the CD14+CD16+ monocyte subset during HIV-1 infection 
(Ziegler-Heitbrock et al., 1993; Tacke & Randolph, 2006; Ancuta et al., 2008; Tallone et al., 
2011; Hijdra et al., 2012). Increases in the CD14+CD16+ monocyte subset are known to be 
accompanied by an increase in pro-inflammatory cytokines and a general shift towards M1-
activated macrophages that generate a pro-inflammatory milieu in the surrounding tissues. 
However, in this study it was observed that the CD14+CD16+ produced higher levels of IL-
10, compared to the CD14+CD16- subset. Ancuta et al. (2006) demonstrated that the 
CD14+CD16+ monocyte subset actively promotes HIV-1 replication during differentiation 
into macrophages and dendritic cells. CD14+CD16+ monocytes have also been suggested as 
a potential reservoir for HIV-1 even though a very low percentage of monocytes are thought 
to be infected with HIV-1 (Ancuta et al., 2006). However, since monocytes are known to be 
resistant to the cytopathic effects of HIV-1 infection, it‟s possible that this characteristic 
allows monocytes to serve as reservoir cells if they do become infected with HIV-1 
(Kedzierska & Crowe, 2002). 
Correlations of viral load and CD38/8 (immune activation) with CD14+CD16+ monocyte 
subset changes indicate that during HIV-infection an increase of the CD14+CD16+ monocyte 
subset is related to increases in viral replication and immune activation. Similarly related is 
the decrease in the CD14+CD16- monocyte subset. Furthermore, if monocytes were 
additionally stimulated with LPS (in this case ex vivo) then these relationships become more 
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evident. Since the CD14+CD16- monocyte subset and the CD14+CD16+ monocyte subset 
together constitute the total monocyte population, any increase in one subset should be 
mirrored by a decrease in the other. The increased CD14+CD16+ monocyte subset observed 
in HIV+ individuals as well as the significant relationships this subset has with well-known 
clinical markers highlight the importance of the CD14+CD16+ monocyte subset in HIV 
disease. The various functions CD14+CD16+ monocytes are suggested to perform, such as 
production of TNF-α and possible role as viral reservoir, furthermore emphasize the 
importance of this monocyte subset during HIV-1 infection. 
Dramatic increase in CCR5 expression observed in HIV-infection that may 
be related to, or facilitated by, increased IL-10 production. 
Possible increased susceptibility of monocytes to HIV-1 infection was evidenced by elevated 
expression of HIV co-receptor, CCR5, in HIV+ individuals. CCR5 expression was 
consistently elevated in the HIV+ group compared to the HIV- group. Within the HIV+ 
group, the CD14+CD16+ monocyte subset also expressed much higher levels of CCR5 than 
the CD14+CD16- monocyte subset. It has been suggested that increased CCR5 expression on 
monocytes/macrophages could stem from being exposed to a chronically inflammatory 
environment as a result of increased plasma LPS levels, known to occur during HIV-1 
infection as a result of gut leakage (Chang & Altfeld, 2009; Munsaka et al., 2009; Sandler & 
Douek, 2012). In contrast to this, Sozzani et al. (1997) suggests that IL-10 production by 
monocytes may maintain CCR5 expression in mucosal tissues and that this could enhance the 
dominant role of this co-receptor in R5-tropic HIV infection. Despite the multitude of 
possible reasons behind increased CCR5 expression, it is known that increased expression 
may eventually result, and has been suggested to facilitate, infection of these cells with R5-
tropic virus (Naif et al., 1998; Munsaka et al., 2009; Herbein & Varin, 2010). After ex vivo 
stimulation with LPS, CCR5 expression in the total monocyte population decreased 
dramatically compared to the HIV uninfected group. This decrease could be attributed to an 
interaction between HIV-1 infection and LPS stimulation. A minimal decrease of CCR5 
expression was also observed in the CD14+CD16+ monocyte subset after stimulation. 
However, in the CD14+CD16- monocyte subset CCR5 expression increased, albeit 
minimally, after stimulation. Franchin et al. (2000) also reported a down-regulation of CCR5 
after LPS stimulation, which the authors indicate to be a sign of resistance to infection. This 
Stellenbosch University  http://scholar.sun.ac.za
104 
 
is in contrast to a previously mentioned study, which suggests increased plasma LPS levels 
result in increased CCR5 expression (Munsaka et al., 2009). 
It is very interesting to note that together with high levels of CCR5 expression, IL-10 
production was also increased in the total monocyte population and monocyte subsets in the 
HIV+ group compared to the HIV- group. Again, the CD14+CD16+ monocyte subset was 
seen to express higher levels of IL-10 than the CD14+CD16- monocyte subset. Live virus 
and viral glycoproteins such as HIV-1 Tat, have been shown to induce IL-10 production in 
monocytes, which together with macrophages have been shown to be the main producers of 
IL-10 (Redpath et al., 2001; Coleman & Wu, 2009). LPS, however, has also been implicated 
as an inducer of IL-10 production (Mocellin et al., 2004). After ex vivo LPS stimulation, IL-
10 expression increased in the total monocyte population and CD14+CD16+ monocyte subset 
whilst expression decreased minimally in the CD14+CD16- monocyte subset of the HIV+ 
group. The decrease in expression observed in the CD14+CD16- subset could be due to a loss 
of cells (resulting from adherence to tubes and/or apoptosis) or active down-regulation of 
production in this subset, which may suggest that the CD14+CD16+ subset is the primary 
producer of IL-10. IL-10 production has also been suggested to increase levels of soluble 
sCD14 and high levels of sCD14 have been associated with reduced responses of monocytes 
to LPS (Redpath et al., 2001; Coleman & Wu, 2009).  
Herbein & Varin (2010) proposed a model for the HIV-1 viral life cycle where they expanded 
the classification of macrophages to include not only macrophage activation type, M1 
(Classical/Inflammatory tissue), and M2 (Alternative/repair), but also a new macrophage 
activation type, which they termed, “deactivated macrophage”. The authors suggest that when 
in the deactivated macrophage state viral entry is increased in the presence of high CCR5 and 
IL-10 expression. It is interesting to note, that Sozzani et al. (1997) have shown that 
monocytes are most readily infected with HIV BaL, a R5 viral strain, following stimulation 
with IL-10 and CCR5 expression was also seen to be increased. The authors associated this 
susceptibility to infection with the increase in CCR5 expression and suggest that infection by 
HIV BaL was facilitated by the increased CCR5 expression and resulted in increased viral 
entry. These authors also proposed that increased CCR5 expression results from an elevated 
IL-10 expression. Coleman & Wu (2009) proposed that secretion of IL-10 by monocytes and 
IL-10‟s immuno-regulatory properties may result in inadequate responses of monocytes to 
HIV-1 infection and LPS stimulation and could facilitate progression to AIDS. The proposed 
ability of opportunistic infections, like CMV, to utilize induced IL-10 production to delay 
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immune responses while it establishes an infection supports the hypothesis suggested by 
Coleman & Wu (Redpath et al., 2001). Although Herbein & Varin (2010) discuss activation 
states of macrophages, evidence from Sozzani (1997) and Coleman & Wu (2009) suggest that 
a similar “deactivated” state, which facilitates viral entry, could be a present in monocytes as 
well. IL-10 however has many effects and may inhibit HIV replication depending on the pro-
inflammatory cytokines it interacts with, such as TNF-α and IL-6 (Sozzani et al., 1997; 
Verani et al., 1997). 
From correlation tests performed, no relationship between the increased CCR5 expression 
and IL-10 production in monocytes during HIV-infection was seen. 
Monocytes are primed to exit circulation and migrate towards sites of 
infection 
An increased migration profile was observed in monocytes in HIV+ individuals as evidenced 
by up-regulation of several migration-associated markers. These include CCR2, CCR1 and 
CD62-L; and also the gut- and lymph node-homing markers, CCR7 and CCR9. This suggests 
monocytes are primed to exit circulation and travel towards sites of inflammation and 
infection. Monocytes may migrate to the GALT, where due gut leakage, microbial 
translocation occurs, contributing to immune activation through the release of cytokines and 
recruitment of various immune cells. Alternatively, monocytes could migrate towards lymph 
nodes where they may prime naïve T-cells (as monocyte-derived DCs) or memory or effector 
(as macrophages) through antigen presentation activity, thereby promoting the adaptive 
immune response. 
Migration out of systemic circulation to lymph nodes, the GIT and sites of infection/inflamed 
tissues can be facilitated through the chemokine receptors CCR2 and CX3CR1 which 
respond to their respective ligands, CCL2(MCP-1) and fractalkine, to assist in endothelial 
migration (Iijima et al., 2011). CX3CR1 and CCR2 are thought to have an inverse expression 
relationship, meaning that when CCR2 expression is high, CX3CR1 expression is low and 
vice versa. The CD14+CD16- monocyte subset is thought to express high levels of CCR2 and 
low levels of CX3CR1, whilst in the CD14+CD16+ monocyte subset it‟s thought that the 
opposite is observed (Ancuta et al., 2003). Our results show that in the CD14+CD16- 
monocyte subset of both study groups, the CCR2
high
/CX3CR1
low
 expression trend was 
observed in vivo but the expected CCR2
low
/CX3CR1
high
 pattern in the CD14+CD16+ 
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monocyte subset was not. Instead a CCR2
high
/CX3CR1
low 
expression trend was seen the 
CD14+CD16+ monocyte subset in vivo and CCR2 expression was higher in the 
CD14+CD16+ subset compared to the CD14+CD16- subset of both study groups. But despite 
CX3CR1 expression being lower than CCR2 expression, CX3CR1 was still elevated in the 
CD14+CD16+ monocyte subset compared to the CD14+CD16- monocyte subset in both 
study groups. These results challenge the notion that only the CD14+CD16- monocyte subset 
displays a CCR2
high
/CX3CR1
low
 expression trend, suggesting that expression of both these 
markers need to be investigated further. Correlation tests suggest that during HIV-infection a 
high CD38/8 expression results in an increase in CCR2 expression in the CD14+CD16+ 
monocyte subset and a decrease in CCR9 expression in the total monocyte population. This 
could explain why an unusually increased expression of CCR2 was seen in the CD14+CD16+ 
subset. Statistical correlations also showed that a higher viral load may lead the decreased 
CX3CR1 expression seen in the CD14+CD16- monocyte subset of HIV-1 infected 
individuals, which could supports the expression trend suggested by Ancuta et al. (2003). 
A review by Kedzierska & Crowe (2002), stated that monocytes of HIV-infected individuals 
experience decreased chemotactic ability as a result of a down-regulation of CCR2 and that 
they display defective migratory responses to chemotactic stimuli. This down-regulation of 
CCR2 was not observed during the current study; rather an increased expression of CCR2 in 
the total monocyte and both monocyte subsets was observed. It should be noted that the 
down-regulation of CCR2 was reported in AIDS patients, this is a stark comparison with this 
study‟s participants who had CD4 counts >300cells/µl. The increased CCR2 expression 
reported in this study could indicate a heightened sensitivity of monocytes in HIV-1 infection 
to CCL2 and therefore a potentially enhanced chemotactic ability compared to monocytes in 
uninfected individuals. Furthermore, the increased CCR2 expression in the CD14+CD16+ 
monocyte subset could indicate a preferential priming of CD14+CD16+ monocytes over the 
CD14+CD16- monocyte subset to exit circulation in response to elevated CCL2 levels (rather 
than increased fractalkine levels). However, comment cannot be made whether migratory 
responses were affected as only phenotypic characterization was studied. A study by 
Williams et al. (2013) also showed an up-regulation of CCR2 but in HIV-infected persons 
with neurocognitive impairment. The authors state that increased transmigration of HIV-
infected monocytes across the blood-brain-barrier was seen in the presence of high levels of 
CCL2 and speculate that this was in part due to the elevated levels of CCR2 and enhanced 
sensitivity to CCL2 compared to uninfected individuals. Furthermore, Ancuta et al. (2003) 
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suggests the expansion of the CD14+CD16+ monocyte subset during HIV-infection and its 
migration to tissues facilitates the dissemination of HIV-1, if these cells are infected, into the 
lymph nodes, brain and intestine and may therefore promote infection of CD4
+
 T-cells. It is 
also known that CCR2 is required for the migration of monocytes from the bone marrow 
(Iijima et al., 2011). This suggests that the increase in the monocyte population seen during 
HIV, mentioned earlier, could result from a higher migration of monocytes from the bone 
marrow.  
The generalized pattern of an increased migration profile is further supported by the 
increased CD62-L expression, a marker whose role in the recruitment of leukocytes has been 
well-documented. A study by Hayes et al. (1999) that investigated leukocyte adhesion 
molecule profiles in HIV-1 infection showed also showed a decreased CD62-L expression in 
HIV-1 infected individuals with CD4 counts ≥ 200cells/µl compared uninfected controls. 
However, this study measured mean fluorescence intensity (MFI), whilst the current study 
measured mean percentage expression. Furthermore, eventhough participants were also 
treatment naive blood was collected in potassium Heparin tubes for the Hayes et al. (1999) 
study, which could account for differences seen. This is in contrast to the current study‟s 
findings of an elevated CD62-L expression in HIV-1 individuals in the total monocyte 
population and both monocyte subsets. Furthermore, Ancuta et al. (2003) suggested that 
CD62-L expression in the CD14+CD16+ monocyte subset is lower than in the CD14+CD16- 
monocyte subset. However in the current study an increased expression of CD62-L in the 
CD14+CD16+ monocyte subset compared to the CD14+CD16- monocyte subset in both 
study groups was seen.  
The chemokine receptor CCR1 is known to also be involved in the recruitment of monocytes 
to and movement within inflamed tissues and mediates the arrest of monocytes in shear flow. 
In addition to this, CCR1 has been shown together with CCR5 to facilitate the movement of 
monocytes towards CCL5 via trans-endothelial migration in mice models (Shi & Pamer, 
2011). Furthermore, these receptors are known to respond to MCP-1α (Kaufmann et al., 
2001). Sozzani et al. (1997), showed enhanced chemotactic ability of monocytes stimulated 
with IL-10 compared to control cells. The authors also showed that this increased 
chemotactic ability was possibly due to the ability of IL-10 to up-regulate CCR1 and CCR2 
receptors. In the current study an increased expression of CCR1 in the total monocyte 
population and in both monocyte subsets was observed compared to the HIV- group. Within 
the HIV+ group, the CD14+CD16+ monocyte subset was observed to express higher CCR1 
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levels compared to the CD14+CD16- monocyte subset. These results, in addition to the 
increased CCR5 expression seen and the increased IL-10 expression, and increased CCR2 
expression indicate that monocytes and specifically the CD14+CD16+ monocyte subset, are 
strongly primed to exit the circulation. 
Increased expression of CCR7 and CCR9 was seen in the total monocyte population and both 
monocyte subsets in the HIV+ group compared to the HIV- group. In the HIV+ group the 
CD14+CD16+ monocyte subset showed higher expression of both CCR7 and CCR9 than the 
CD14+CD16- monocyte subset. CCR7 and CCR9 are homing markers which facilitate the 
movement of monocytes to secondary lymphoid tissues, including GALT and lymph nodes 
(Scandella et al., 2002; Linton et al. 2012). Damås et al. (2009) showed that CCR7 ligands, 
CCL19 & CCL21, have been linked to viral persistence and inflammation. The authors 
concluded that the CCL19/CCL21/CCR7 system may be in a pathogenic loop with HIV and 
may play a role during infection by contributing to abnormal inflammation. These results 
were observed in both treated and untreated HIV-infected individuals. So although CCR7 
works with its homeostatic ligands to regulate lymphocyte migration to lymph nodes it may 
also play a role in persistent HIV infection by promoting viral persistence through inducing 
replication in activated T-cells and facilitating infection of resting CD4
+
 T-cells as well as 
establishing latency (Saleh et al., 2007). This together with the current study‟s results could 
signify that monocytes and in particular, CD14+CD16+ monocytes are primed to migrate 
towards secondary lymph nodes, such as the GALT, using CCR7 ligands as opposed to 
CCR9 ligands. However, this can be explained by the negative correlation found between 
CCR9 expression in the total monocyte population and CD38/8 expression ex vivo, which 
suggests a decrease in expression CCR9 as immune activation increases,  making monocytes 
less sensitive/responsive to CCR9 ligands. 
Ex vivo LPS stimulation, as stated in the begging of this chapter, suggests that HIV-1 
infection does not alter the expression of migration-associated markers of monocytes with 
respect to CCR1 and CD62-L. Expression of CX3CR1, CCR2 and CCR9 in the 
CD14+CD16+ monocyte subset appeared to be conserved and even enhanced during HIV-
infection, since CX3CR1, CCR2 and CCR9 expression decreased in the total monocyte 
population and CD14+CD16- monocyte subset after LPS stimulation. The same expression 
patterns were seen in the HIV- group, with the exception of CCR2 expression, where the 
CD14+CD16+ monocyte subset CCR2 expression also decreased after LPS stimulation. It is 
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interesting to note that CCR7 expression was the only migration marker to have increased 
after LPS stimulation in both study groups.  
These results, together with the aforementioned functions of the respective migration and gut-
homing markers suggest that during HIV-1 infection (and with continual LPS stimulation), 
monocytes and specifically CD14+CD16+ monocytes could be primed to exit circulation and 
migrate towards the gut. As stated in Chapter 2 a study done in mice by Gautier et al. (2009) 
showed the behaviour of the CD14+CD16+ monocyte subset is context dependent, therefore 
more studies are needed to fully elucidate the role that the CD14+CD16+ monocytes subset 
plays during HIV-1 infection in particular. 
Monocytes have a higher activation status during HIV-1 infection 
CD69 expression was increased in the total monocyte population and in both monocyte 
subsets compared to HIV uninfected individuals in vivo. A statistically significant difference 
in CD69 expression in the CD14+CD16+ monocyte subset of HIV-infected individuals was 
observed. It has previously been shown that CD69 expression is increased in monocytes 
during HIV-1 infection (Funderburg & Sieg, 2012). This trend towards an increased CD69 
expression indicates that monocytes of HIV-infected individuals are at a higher activation 
state than monocytes in HIV- individuals. This higher state of activation may be facilitated 
through increased plasma LPS levels. A role for elevated LPS levels in driving monocyte 
activation in disease progression has been suggested by Ancuta et al. (2003), and is now 
generally accepted.  
The suggestion that monocytes have a higher activation status during HIV-1 infection is 
further supported but the high HLA-DR expression seen at baseline. HLA-DR was, however, 
constitutively expressed in both study groups (> 80% expression), although in the total 
monocyte population and CD14+CD16+ monocyte subset expression was marginally lower. 
There are however conflicting reports with regards to its expression on monocytes in HIV-1 
infection (Lochner et al., 1994). The expression of HLA-DR is thought to be important for 
the recognition of foreign antigen. T-helper cells are dependent on surface expression of both 
HLA-DR and foreign antigen for induction of a response and proliferation (Cheadle et al., 
1991). This, together with the HLA-DR expression observed in this study, would indicate that 
the ability of monocytes in HIV-infected individuals to stimulate an adaptive immune 
response and recognize foreign antigen is as good as in monocytes from healthy individuals. 
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Ideally, MFI values should have been compared; this however, depends on meticulous cross-
experimental standardization that was not implemented during the current study. This could 
be investigated in future studies. 
Expression of HLA-DR was similar in the HIV+ group and HIV- group after stimulation in 
vitro. CD69 expression on the other hand increased in the HIV+ group‟s total monocyte 
population and CD14+CD16- monocyte subset after stimulation. Expression appeared to 
decrease in the CD14+CD16+ monocyte subset of the HIV+ group and in both the monocyte 
subsets and the total monocyte population of the HIV- group. This loss in CD69 expression 
could be explained by adherence of monocytes to test tubes during stimulation and or 
apoptosis, as most activated cells may be primed to mature in macrophages or to die. The 
increased HLA-DR expression, together with increased CD69 expression in the total 
monocyte and CD14+CD16- monocyte subset suggests that stimulation with LPS could result 
in an activated cellular status during HIV-1 infection. This would support the hypothesis that 
microbial translocation and microbial products are major contributors to immune activation 
as stated by Brenchley et al. (2006).  
Based on statistical correlations, HLA-DR expression increases in both the total monocyte 
population and CD14+CD16- monocyte subset as CD4 count decreases, after LPS 
stimulation and at baseline respectively. After stimulation the negative relationship in the 
CD14+CD16- subset switched to a positive relationship. The negative relationship between 
the total monocyte population and CD4 count after LPS, suggests a stimulation of antigen 
presenting function during HIV-1 infection The switch to a positive relationship with CD4 
count in the CD14+CD16- monocyte subset could indicate a desensitization of this monocyte 
to stimuli as HIV-1 infection progresses and CD4 T-cell numbers become more depleted 
without the intervention of ART. 
Changes in apoptosis-associated markers in HIV-infection 
Both activated monocytes and other cells, such as T-cells, express and secrete TRAIL, the 
ligand for TRAIL-R1, under pro-CD14+CD16+ conditions. The amount of soluble TRAIL 
has been seen to increase during HIV-1 infection (Yang et al., 2003; Cerutti, 2009). Whilst 
TRAIL secretion was not measured in this current study per se, a high level of activation in 
monocytes (increased CD69 and HLA-DR), and also generalized activation (as evidenced by 
CD38 on CD8
+
 T-cells) was observed. Together with this, increased TRAIL -R1 expression 
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in the HIV+ group‟s total monocyte population and the CD14+CD16+ monocyte subset was 
also observed. TRAIL-R1, however, was decreased in the CD14+CD16- monocyte subset.  
Wei et al. (2010) have shown that despite high levels of TRAIL-R1 expression, monocytes 
displayed negligible sensitivity to TRAIL cytotoxity and that TRAIL does not induce death 
(through caspase activation) but rather monocyte migration. The authors also suggested that 
TRAIL exerts this non-apoptotic function using an alternative pathway, namely the “PI3K-
RhoGTPase” pathway, see Figure 5-1. These findings were supported by Cummins & 
Badley (2009). However, a study by Huang et al. (2006), using recombinant human TRAIL 
(rhTRAIL), showed that rhTRAIL induced apoptosis in monocyte-derived-macrophages 
(MDM) and inhibited viral replication of HIV-1 infection, whilst rhTRAIL has little to no 
effect on uninfected MDM. They also suggested that the viral inhibition seen was mediated 
through inhibition of the AKT-1 pathway. Whilst, Secchiero et al. (2002), on the other hand, 
showed that TRAIL-R1 mediates monocyte maturation. 
 
 
 
 
 
 
 
 
LPS has been shown to increase TRAIL secretion by monocytes (Halaas et al., 2000). A 
possible preservation, or in the CD14+CD16+ monocytes case an enhancement, of TRAIL-
R1 expression was observed. This suggests an increased migratory potential of monocytes, 
facilitated through TRAIL-R1, to sites of infection where monocytes may recruit more 
immune cells which HIV-1 could infect. Another role could be to not inhibit the 
Figure 5- 1: Hypothesis of the positive feedback loop for monocytes to eliminate foreign invaders 
suggested by Wei et al., 2010. After infection by foreign invaders such as bacteria or virus, the F peptide 
and N36 peptide (from HIV) and LPS (from bacteria) could stimulate monocytes to secrete TRAIL. 
TRAIL would induce monocyte migration toward the infection site, resulting in increased TRAIL 
secretion by the recruited monocytes that would in turn increase the accumulation of monocytes at the 
infection site, where monocytes can eliminate foreign invaders (Wei et al., 2010). 
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differentiation, possibly mediated by TRAIL-R1, of monocytes into macrophages which are 
more susceptible to HIV-1 infection.  
HIV Tat has been shown to increase Bcl-2 expression which has been shown to inhibit 
apoptosis by TRAIL (Coleman & Wu, 2009; Cummins & Badley, 2009). Through an in vitro 
model, Coleman & Wu (2009) showed HIV-1 Tat has been shown to use TRAIL to promote 
monocyte survival in situations where apoptosis would normally occur. In the current study, 
Bcl-2 expression in HIV-1 infected individuals showed a trend towards up-regulation in both 
monocyte subsets and the total monocyte population compared to uninfected individuals 
(although not attaining statistical significance). It is interesting to note that Bcl-2 expression 
was also higher in the CD14+CD16+ subset compared to the CD14+CD16- monocyte subset 
in HIV+ individuals (but again not statistically significant, possibly due to sample size). 
These results are however noteworthy as they suggest a possible priming of monocytes 
towards survival in HIV-1 infection. This, in addition the increased CCR5 and IL-10 
expression, could mean that HIV-1 infection could be inducing a prolonged life-span of 
monocytes during infection, which could enhance viral replication, and could suggest a 
possible role as a viral reservoir cell. Prolonged survival would also implicate these cells in 
promoting ongoing inflammation in this disease. 
HIV-1 Tat protein also been shown to target the TNFR signaling pathway by modifying gene 
expression, which leads to immune suppression and the formation of viral reservoirs. 
Furthermore, HIV viral proteins have also been shown to mimic TNFR signals and in this 
way circumvent the induction of apoptosis (Herbein & Khan, 2008). In addition, TNFR1 has 
also been implicated in HIV viral replication which is facilitated by TNF-α (Herbein & Varin, 
2010). TNFR1 expression was lower in the total monocyte population and in both monocyte 
subsets in HIV+ individuals. From the suggested role TNFR signal may play in resistance to 
apoptosis, the decreased expression could indicate an increased sensitivity to apoptosis and 
inhibition of viral replication mediated by the TNF-α mediated pathway. Further evidence for 
this suggested susceptibility to apoptosis during HIV-infection is the in vivo increase, albeit 
minimal, in expression of late apoptosis marker, 7AAD/AnnexinV, in both monocyte subsets 
and the total population in the HIV+ group compared to the HIV- group. After LPS 
stimulation expression TNFR1 increased moderately in both study groups. This indicated 
monocytes in HIV- individuals do not undergo apoptosis more readily than monocytes in 
HIV+ individuals would. Therefore, LPS stimulation in vivo may only be responsible for 
monocytes undergoing early apoptosis during HIV-infection. However, apoptosis was not 
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induced in the current which prevented investigation of apoptosis susceptibility in this way. 
This would clarify the mechanisms in play that affect apoptotic susceptibility in monocytes 
during HIV-infection. 
CD116 was expressed at a high level on all monocytes. CD116 is used as a monocyte marker, 
and differences in the high level expression would have better been assessed using mean 
fluorescence intensity data (see above discussion on HLA-DR). CD116 has multiple effects 
on monocytes including differentiation into macrophages, maturation and is prolonging 
monocyte survival. CD116 is also known to increase monocyte response to anti-inflammatory 
mediators (Bagasra et al., 1992; Jung et al., 1995; Allavena et al., 1998; Kedzierska et al., 
1998). It has been suggested that CD116‟s effect on monocyte differentiation may increase 
susceptibility of monocytes to HIV infection (Kedzierska et al., 1998). A review by 
Kedzierska et al. (1998) shows that there have been conflicting reports on the effect CD116 
has during HIV-1 infection with some studies showing that it plays a role in increasing HIV 
replication, whilst others show it inhibits replication and some showing that it has no effect at 
all on replication. Although an increased CD116 expression in HIV+ individuals in this 
study, comment cannot be made on whether the increased CD116 expression observed has 
any effect on HIV-1 viral replication as only phenotypic characterization was performed. 
However, it is interesting that most published data suggests that CD116 does indeed increase 
HIV replication and it only has beneficial effects in vivo when patients were on anti-retroviral 
therapy (Pomerantz et al., 1990; Kedzierska et al., 1998). The increased CD116 expression 
observed in the HIV+ group, and specifically the CD14+CD16+ monocyte subset, could infer 
an increased resistance to apoptosis or maturation of the monocyte population, as a result of 
the multiple effects CD116 has on monocytes. Furthermore, stimulation with LPS could 
increase survival and maturation of monocyte subsets during HIV infection and this may 
result in the enhancement of HIV replication. Expression of CD116 increased in both the 
total monocyte population and the monocyte subsets in the HIV+ after LPS stimulation. 
Interestingly in the HIV- group, expression decreased after LPS stimulation. This is in 
contrast to the TNFR1 findings from the current study and thus more studies have to be 
conducted to elucidate the exact role of CD116 expression in monocytes. 
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VPAC-2 expression in monocytes and its potential as a therapeutic target. 
Vaso-active intestinal peptide (VIP), the ligand of VPAC-2, is known to inhibit LPS-induced 
inflammatory pathways. VPAC-2 has been noted for its immune-regulatory role (neutralizing 
pro-inflammatory stimuli, inhibiting apoptosis) and is known to inhibit viral replication 
(Smalley et al., 2009). Temerozo et al. (2013) also showed that VIP promotes inhibition of 
HIV-1 viral replication through VPAC-2 rather than VPAC-1 and that VPAC-2 can be 
classified as an inhibition mediator, whilst VPAC-1 is an HIV production inducer. Bokaei et 
al. (2007) also reported that stimulation of VPAC-2 inhibits HIV-integration into host DNA 
and confers a strong resistance to infection. In this study VPAC-2 expression was 
investigated, as a first stage in investigating its usefulness as a putative target for therapeutic 
intervention – to down-regulate the pro-inflammatory functions of monocytes. An increased 
VPAC-2 expression in the total monocyte population and in both monocyte subsets of the 
HIV+ group compared to the HIV- group. Furthermore, the CD14+CD16- monocyte subset 
expressed lower levels than the CD14+CD16+ monocyte subset in the HIV+ group. The high 
expression of VPAC-2 in the HIV+ group and specifically by the CD14+CD16+ monocyte 
subset suggests an increased sensitivity to the effects of VIP and therefore its immune-
regulatory effects. Moreover, increased expression of VPAC-2 was observed in the HIV+ 
group after stimulation. The increased expression observed both in vivo and ex vivo after 
stimulation, indicates that thesis receptor may be exploitable in a VIP-based 
immunotherapeutic setting. In particular, the CD14+CD16+ monocyte subset may represent a 
useful therapeutic target cell for investigation of the impact of the immune modulating effect 
of VIP during HIV-1 infection and its associated chronic immune activation. The positive 
correlation that VPAC-2 expression exhibits with CD4 count in the total monocyte 
population and both monocyte subsets after LPS stimulation suggests that immune-
modulation via VPAC-2 with  VIP may need to be administered with ART to ensure CD4 
count is normalized and therefore VPAC-2 expression higher.  Further work need to be 
performed on this marker, and a detailed assessment of its relationship to other monocyte 
markers of activation and to monocyte function needs investigation. 
Strengths and limitations of the study 
The current study had a number of limiting factors such as sample size, which largely 
affected statistical significance of results. This would have been potentially eliminated with a 
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larger number of study participants. The size of the study cohort was primarily restricted due 
to the fact that the majority of patients only present at clinics during advanced stages of HIV-
infection, when their CD4 counts have dropped below the requirements of the study. Also, 
study participants were also lost due to failure to report for blood draw visits. The study 
design was cross-sectional due the difficulties in study participant recruitment mentioned 
would have meant that patient follow-up and adherence to the study would have been 
difficult, in addition to this time was also a constraint for the purposes of a Master‟s degree 
study. The current study was not able to investigate the changes of markers of interest over 
time to see fully clarify how they correlate to clinical markers. Standardization procedures for 
flow cytometry had to be repeated several times to major instrument modifications during the 
study. Whilst integrity of most markers was possible, inclusion of data on two markers 
originally included in the study design (TNF-α and CD95) was not possible. Post-acquisition 
analysis revealed that these two markers had generated spurious data to the extremely bright 
signal generated by positive-staining cells. Future studies should include both cell 
compensation procedures and direct post-acquisition analysis for all markers and panels. 
Finally, whole blood was also stored overnight for monocyte isolation in the morning which 
could have impacted responsiveness of monocytes to LPS in the purified monocyte 
experiments. 
Despite these short-comings, the current study is the first to investigate the expression of 
migration markers, gut-homing markers, phenotypic markers and activation markers 
simultaneously in monocytes in South Africa. A multi-colour (8 Colour) flow cytometry was 
used, which allowed a large range of markers to be investigated. Expression of these markers 
was correlated to well-known clinical markers in an effort to highlight the importance of 
specific markers of interest. In addition to this, functioning of monocytes during HIV-
infection using LPS stimulation was also assessed. Overall this study‟s findings highlight the 
important role that monocytes and specifically, CD14+CD16+ monocytes, play during HIV-
infection, furthermore the potential therapeutic use of the CD14+CD16+ subset emphasizes 
the need to perform more research on these cells in future. 
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Chapter 6: Conclusion 
Monocytes are integral members of the innate immune system and their functioning has 
direct effects on several other immune cell role players, including those within other branches 
of the immune system. Monocytes are one of the first cell types recruited to sites of 
inflammation, where they become major contributors to the inflammatory process and 
initiation of innate immunity. Monocytes are also important antigen presenting cells. Their 
ability to migrate from the blood to sites where they are needed is essential to their function. 
The recruitment of monocytes to sites of inflammation and infection is crucial for pathogen 
clearance, but it may also add to the damage associated with inflammation. Monocytes and 
macrophages are prime role players in several inflammation-associated degenerative diseases. 
HIV-1 infection, a chronic non-resolving viral infection, is thought to have a significant 
impact on the functioning of monocytes. The conflicting nature of many reports on monocyte 
function in HIV-1 may be due to the type of patients used (disease stage, sex etc.), the 
presence/absence of co-infection, whether they were on ART or not and also how monocytes 
were assessed (experimental methodology). In addition to the confusing nature of the 
literature, it is also important to remember that changes in monocytes in HIV infection may 
be due to direct infection, indirect viral-mediated effects (e.g. Tat) or bystander cell effects. 
The current study has demonstrated that monocytes and in particular CD14+CD16+ 
monocytes appear to maintain functional integrity (in chronic stable HIV infection), display 
phenotypic and other marker changes indicative of priming for lymphoid tissue migration and 
are the main producers of IL-10. The positive relationships between the percentage of 
CD14+CD16+ monocytes and CD38/8 expression, the subset‟s CCR2 expression with 
CD38/8 expression, and its IL-10 expression and viral load emphasize the role these cells 
play in contributing to immune activation, and suggest immune activation and viral 
replication are linked. Furthermore, if monocytes continue to be stimulated with LPS (in this 
case ex vivo) then these relationships become more established. This is further supported by 
the negative relationships between the percentage of CD14+CD16- monocytes and CD38/8 
and viral load.  
Future work should address the findings of this study, particularly how the expanded, 
activated and migration primed CD14+CD16+ subset function. Is the CD14+CD16+ subset 
primarily phagocytic, pro-inflammatory and damage inducing, or is it involved in repair 
and/or fibrosis? It is imperative that further studies are conducted that will help to shed light 
Stellenbosch University  http://scholar.sun.ac.za
117 
 
on monocyte function at different stages of disease, the impact of co-infections and ARV 
therapy and also how potential immune-modulatory approaches impact on these cells. 
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Appendix 1 
 
 
 
 
 
 
 
 
 
 
 
 
p-value = 0.0419 
 Figure 1: Box-and-whisker plot of total gated monocyte population across the two study groups, HIV+ (median 
2.65%, range [0.50-6.60]) and HIV-(2.00, [0.40-6.50]) at baseline. HIV-: Uninfected donors; HIV+: HIV-
infected donors. Statistically significant differences are indicated by bars with p-values. 
Figure 2: Representative flow cytometry dot plots showing CD116-FITC and Bcl-2-PE expression in the 
CD14+CD16+ monocyte subset. In the first dot plot on the left (Panel 3 Bcl-2 S), Bcl-2’s FMO sample (negative 
unstained control) is illustrated. The second dot plot (Panel 2 CD116 S) shows CD116’s FMO sample. The 
third dot plot from the left (RP25 Panel 3 US) shows the expression of both CD116-FITC (12.5%) and Bcl-2-
PE (2.4%)in a HIV- study sample and the dot plot on the far right (RP32 Panel 3 US) shows the expression of 
both CD116-FITC (84.5%) and Bcl-2-PE (16.8%) in HIV+ study sample. 
Figure 3: Representative flow cytometry dot plots showing CCR2-APC and CCR7-BV421 (shown here as BD 
HV450*) expression in the total monocyte population. In the first dot plot on the left (Panel 1 CCR2 US), 
CCR2’s FMO sample (negative unstained control) is illustrated. The second dot plot (Panel 1 CCR7 US) shows 
CCR7’s FMO sample. The third dot plot from the left (RP24 Panel 1 US) shows the expression of both CCR2-
APC (18.5%) and CCR7-BV421 (57.7%) in a HIV- study sample and the dot plot on the far right (RP28 Panel 
1US) shows the expression of both CCR2-APC (31.8%) and CCR7-BV421 (65.6%) in HIV+ study sample. 
CCR7-BV421 is shown as BD HV450 due to the settings of the FACS DIVA software that was used during 
analysis, see section 3.10. in Chapter 3 for study sample flow acquisition. 
1.5% 
0.9% 
11.0% 
86.6% 
70.8% 13.7% 
3.1% 13.4% 
7.6% 10.7% 
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Figure 6: Representative flow cytometry dot plots showing CCR9-PerCP and CX3CR1-PE-Cy7 in the total 
monocyte population. In the first dot plot on the left (Panel 1 CCR9 US), CCR9’s FMO sample (negative 
unstained control) is illustrated. The second dot plot (Panel 1 CX3CR1 US) shows CX3CR1’s FMO sample. 
The third dot plot from the left (RP24 Panel 1 US) shows the expression of both CCR9-PerCP (12.4%) and 
CX3CR1-PE-Cy7 (19.4%) in a HIV- study sample and the dot plot on the far right (RP28 Panel 1 US) shows 
the expression of CCR9-PerCP (3.2%) and CX3CR1-PE-Cy7 (13.7%) in HIV+ study sample. 
Figure 5: Representative flow cytometry dot plots showing VPAC-2-PerCP in the total monocyte population. In 
the first dot plot on the left (Panel 3 VPAC-2 S), VPAC-2’s FMO sample (negative unstained control) is 
illustrated. The middle dot plot (RP25 Panel 3 US) shows the expression of VPAC-2-PerCP (7.4%) in a HIV- 
study sample and the dot plot on the far right (RP28 Panel 3 US) shows the expression of VPAC-2-PerCP (9.2%) 
in HIV+ study sample. 
Figure 4: Representative flow cytometry dot plots showing IL-10-APC expression in the total monocyte 
population. In the first dot plot on the left (Panel 3 IL-10 US), IL-10’s FMO sample (negative unstained 
control) is illustrated. The second dot plot (RP25-Panel 3 US) shows the expression of IL-10-APC (3.7%) in 
a HIV- study sample and the dot plot on the far right (P204 Panel 3 US) shows the expression of IL-10-APC 
(13.7%) in HIV+ study sample 
4.7% 2.7% 
92.5% 
7.9% 1.3% 
90.6% 
6.6% 5.8% 
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Table-1: Correlation between viral load and CD4 count and CD38/8 expression at baseline 
Viral load vs. r-value P-value 
CD4 count -0.3530 0.0297 
CD38/8 0.6391 <0.005 
 
  
Figure 7: Representative flow cytometry dot plots showing TNFR1-APC expression in the CD14+CD16+ 
monocyte subset. In the first dot plot on the left (Panel 2 TNFR1 US), TNFR1’s FMO sample (negative 
unstained control) is illustrated. The second dot plot (RP25-Panel 2 US) shows the expression of TNFR1-
APC (4.2%) in a HIV- study sample and the dot plot on the far right (RP32 Panel 2 US) shows the 
expression of TNFR1-APC (0.9%) in HIV+ study sample.  
4.2% 0% 
0.9% 0% 
Figure 8: Representative flow cytometry dot plots showing CD16-APC-H7 and IL-10-APC expression in the 
CD14+CD16+ monocyte subset. The dot plot on the left (RP25-Panel 3 US) shows the expression of both CD16-
APC-H7 (14.5%) and IL-10-APC (5.89%) in a HIV- study sample and the dot plot on the far right (P204 Panel 
2 US) shows the expression of both APC-H7 (15.5%) and IL-10-APC (16.5%) in HIV+ study sample. It can be 
seen that the HIV+ sample displays a higher dual expression of CD16 and IL-10 (5.9%) compared to the HIV- 
sample (2.8%). 
2.8% 11.7% 
3.1% 82.4% 
5.9% 9.6% 
10.6% 73.9% 
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Table-2: Correlation between total monocyte population and CD4 count, viral load and CD38/8 
expression in response to stimuli 
Total monocyte 
population vs. 
Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.06790 0.6772 
LPS -0.05224 0.7350 
 
CD38/8 
Unstimulated 0.1119 0.5491 
LPS 0.1175 0.5289 
 
Viral load 
Unstimulated 0.1270 0.4473 
LPS 0.2855 0.0823 
 
Table-3: Correlation between CD14+CD16- monocyte subset and CD4 count, viral load and CD38/8 
expression in response to stimuli 
CD14+CD16- 
monocyte subset vs. 
Stimulus r-value P-value 
 
CD4 count 
Unstimulated -0.02947 0.8567 
LPS 0.1960 0.2256 
 
CD38/8 
Unstimulated -0.3884 0.0308 
LPS -0.5486 0.0014 
 
Viral load 
Unstimulated -0.2417 0.1437 
LPS -0.3356 0.0394 
 
Table-4: Correlation between CD14+CD16+ monocyte subset and CD4 count, viral load and CD38/8 
expression in response to stimuli 
CD14+CD16+ 
monocyte subset vs. 
Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.02894 0.8593 
LPS -0.1958 0.2260 
 
CD38/8 
Unstimulated 0.3862 0.0319 
LPS 0.5462 0.0015 
 Unstimulated 0.2422 0.1429 
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Viral load LPS 0.3362 0.0390 
 
Table-5: Correlation between total monocyte population’s CCR5 expression and CD4 count, viral load 
and CD38/8 expression in response to stimuli 
CCR5 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.3511 0.0263 
LPS -0.1248 0.4491 
 
CD38/8 
Unstimulated 0.09356 0.6166 
LPS 0.05206 0.7809 
 
Viral load 
Unstimulated -0.02152 0.8979 
LPS -0.0007604 0.9964 
Table-6: Correlation between CD14+CD16- monocyte subset’s CCR5 expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
CCR5 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.1948 0.2347 
LPS 0.1289 0.4309 
 
CD38/8 
Unstimulated -0.09805 0.5997 
LPS 0.08825 0.6369 
 
Viral load 
Unstimulated 0.1091 0.5203 
LPS 0.1501 0.3752 
 
Table-7: Correlation between CD14+CD16+ monocyte subset’s CCR5 expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
CCR5 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated -0.03489 0.8308 
LPS -0.1792 0.2684 
 
CD38/8 
Unstimulated -0.1349 0.4692 
LPS -0.04156 0.8243 
 
Viral load 
Unstimulated -0.1578 0.3441 
LPS -0.06914 0.6800 
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Table-8: Correlation between total monocyte population’s CD116 expression and CD4 count, viral load 
and CD38/8 expression in response to stimuli 
CD116 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.1940 0.2433 
LPS -0.0005419 0.9975 
 
CD38/8 
Unstimulated 0.1703 0.3596 
LPS 0.09953 0.5942 
 
Viral load 
Unstimulated -0.03323 0.8474 
LPS 0.09841 0.5733 
 
Table-9: Correlation between CD14+CD16- monocyte subset’s CD116 expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
CD116 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.1579 0.3370 
LPS 0.02388 0.8853 
 
CD38/8 
Unstimulated 0.1440 0.4395 
LPS 0.3395 0.0617 
 
Viral load 
Unstimulated -0.02803 0.8692 
LPS 0.07919 0.6413 
 
Table-10: Correlation between CD14+CD16+ monocyte subset’s CD116 expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
CD116 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.3075 0.0604 
LPS 0.2243 0.1757 
 
CD38/8 
Unstimulated 0.1334 0.4745 
LPS 0.3537 0.0509 
 
Viral load 
Unstimulated -0.1004 0.5602 
LPS 0.06668 0.6992 
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Table-11: Correlation between total monocyte population VPAC-2 expression and CD4 count, viral load 
and CD38/8 expression in response to stimuli 
VPAC-2 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.2573 0.1138 
LPS 0.4493 0.0041 
 
CD38/8 
Unstimulated -0.3677 0.8445 
LPS -0.1113 0.5570 
 
Viral load 
Unstimulated -0.02788 0.8708 
LPS -0.06189 0.7159 
 
Table-12: Correlation between CD14+CD16- subset’s VPAC-2 expression and CD4 count, viral load and 
CD38/8 expression in response to stimuli 
VPAC-2 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated -0.08714 0.6021 
LPS 0.3935 0.0132 
 
CD38/8 
Unstimulated -0.2512 0.1728 
LPS -0.1276 0.4941 
 
Viral load 
Unstimulated -0.1750 0.3073 
LPS 0.05762 0.7605 
 
Table-13: Correlation between CD14+CD16+ subset’s VPAC-2 expression and CD4 count, viral load and 
CD38/8 expression in response to stimuli 
VPAC-2 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.1519 0.3628 
LPS 0.4063 0.0114 
 
CD38/8 
Unstimulated -0.1166 0.5322 
LPS -0.1870 0.3137 
 
Viral load 
Unstimulated 0.009277 0.9572 
LPS -0.08357 0.6267 
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Table-14: Correlation between total monocyte population’s IL-10 expression and CD4 count, viral load 
and CD38/8 expression in response to stimuli 
IL-10 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.1793 0.2814 
LPS 0.04269 0.7991 
 
CD38/8 
Unstimulated -0.06867 0.7136 
LPS -0.05010 0.7890 
 
Viral load 
Unstimulated 0.1384 0.4209 
LPS -0.03353 0.8461 
 
Table-15: Correlation between CD14+CD16- monocyte subset’s IL-10 expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
IL-10 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated -0.1498 0.3965 
LPS 0.09004 0.5909 
 
CD38/8 
Unstimulated -0.03185 0.8694 
LPS -0.2671 0.1464 
 
Viral load 
Unstimulated 0.2200 0.1972 
LPS 0.01303 0.9399 
 
Table-16: Correlation between CD14+CD16+ monocyte subset’s IL-10 expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
IL-10 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated -0.2462 0.1418 
LPS -0.2947 0.0725 
 
CD38/8 
Unstimulated 0.1433 0.4419 
LPS 0.1011 0.5884 
 
Viral load 
Unstimulated 0.1347 0.4404 
LPS 0.2868 0.0898 
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Table-17: Correlation between total monocyte population’s CCR1 expression and CD4 count, viral load 
and CD38/8 expression in response to stimuli 
CCR1 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated -0.2213 0.1700 
LPS 0.1811 0.2633 
 
CD38/8 
Unstimulated 0.2469 0.1806 
LPS 0.1581 0.3956 
 
Viral load 
Unstimulated 0.1284 0.4423 
LPS -0.1345 0.1811 
 
Table-18: Correlation between CD14+CD16- monocyte subset’s CCR1 expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
CCR1 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated -0.04670 0.7771 
LPS 0.03854 0.8158 
 
CD38/8 
Unstimulated 0.06890 0.7127 
LPS -0.08296 0.6573 
 
Viral load 
Unstimulated -0.009020 0.9577 
LPS -0.08935 0.5990 
 
Table-19: Correlation between CD14+CD16+ monocyte subset’s CCR1 expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
CCR1 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated -0.1306 0.4218 
LPS 0.01873 0.9087 
 
CD38/8 
Unstimulated -0.02675 0.8821 
LPS -0.1983 0.2327 
 
Viral load 
Unstimulated -0.1967 0.2365 
LPS -0.09762 0.6014 
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Table-20: Correlation between total monocyte population’s CX3CR1 expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
CX3CR1 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.07702 0.6367 
LPS 0.02441 0.8811 
 
CD38/8 
Unstimulated 0.3255 0.0739 
LPS 0.03627 0.8464 
 
Viral load 
Unstimulated 0.6298 0.05882 
LPS 0.05078 0.7621 
 
Table-21: Correlation between CD14+CD16- monocyte subset’s CX3CR1 expression and CD4 count, 
viral load and CD38/8 expression in response to stimuli 
CX3CR1 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.03367 0.8366 
LPS 0.001146 0.9559 
 
CD38/8 
Unstimulated 0.1530 0.4114 
LPS -0.4916 0.0050 
 
Viral load 
Unstimulated 0.7751 0.0388 
LPS -0.005454 0.7485 
 
Table-22: Correlation between CD14+CD16+ monocyte subset’s CX3CR1 expression and CD4 count, 
viral load and CD38/8 expression in response to stimuli 
CX3CR1 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated -0.3573 0.8267 
LPS -0.06509 0.6099 
 
CD38/8 
Unstimulated -0.2450 0.1841 
LPS -0.1382 0.4586 
 
Viral load 
Unstimulated -0.1947 0.2367 
LPS -0.1160 0.4887 
Stellenbosch University  http://scholar.sun.ac.za
136 
 
Table-23: Correlation between CD14+CD16- monocyte subset’s CX3CR1 and CCR2 before and after 
stimulation 
CX3CR1 vs. Stimulus r-value P-value 
 
CCR2 
Unstimulated -0.9408 0.5689 
LPS -0.6416 0.6980 
 
Table-24: Correlation between CD14+CD16+ monocyte subset’s CX3CR1 and CCR2 before and after 
stimulation 
CX3CR1 vs. Stimulus r-value P-value 
 
CCR2 
Unstimulated -0.4401 0.0045 
LPS -0.1046 0.5205 
Table-25: Correlation between total monocyte population CCR2 expression and CD4 count, viral load 
and CD38/8 expression in response to stimuli 
CCR2 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.07702 0.06367 
LPS 0.02441 0.8811 
 
CD38/8 
Unstimulated 0.09019 0.6294 
LPS 0.2088 0.2597 
 
Viral load 
Unstimulated 0.05882 0.7257 
LPS 0.05078 0.7621 
 
Table-26: Correlation between CD14+CD16- monocyte subset’s CCR2 expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
CCR2 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.3309 0.0396 
LPS 0.2069 0.2063 
 
CD38/8 
Unstimulated -0.02215 0.9059 
LPS 0.09593 0.6077 
 
Viral load 
Unstimulated -0.1099 0.5171 
LPS -0.1809 0.2840 
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Table-27: Correlation between CD14+CD16+ monocyte subset’s CCR2 expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
CCR2 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated -0.003075 0.9850 
LPS -0.2315 0.2103 
 
CD38/8 
Unstimulated 0.5946 0.0004 
LPS 0.4801 0.0063 
 
Viral load 
Unstimulated 0.2366 0.1526 
LPS 0.2527 0.1186 
 
Table-28: Correlation between total monocyte population CCR7 expression and CD4 count, viral load 
and CD38/8 expression in response to stimuli 
CCR7 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.03602 0.8277 
LPS 0.04310 0.7917 
 
CD38/8 
Unstimulated 0.1151 0.5448 
LPS 0.06645 0.7225 
 
Viral load 
Unstimulated 0.1779 0.2922 
LPS -0.04947 0.7745 
 
Table-29: Correlation between CD14+CD16- monocyte subset’s CCR7 expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
CCR7 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.1528 0.3530 
LPS 0.2460 0.1311 
 
CD38/8 
Unstimulated -0.1502 0.4198 
LPS -0.03848 0.8791 
 
Viral load 
Unstimulated 0.2542 0.1289 
LPS 0.1792 0.2886 
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Table-30: Correlation between CD14+CD16+ monocyte subset’s CCR7 expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
CCR7 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.03237 0.8428 
LPS 0.02290 0.8885 
 
CD38/8 
Unstimulated -0.1747 0.3473 
LPS -0.2315 0.2103 
 
Viral load 
Unstimulated -0.06196 0.7117 
LPS -0.2627 0.1111 
 
Table-31: Correlation between total monocyte population CCR9 expression and CD4 count, viral load 
and CD38/8 expression in response to stimuli 
CCR9 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.02014 0.9018 
LPS 0.02441 0.8811 
 
CD38/8 
Unstimulated -0.4015 0.0252 
LPS 0.03829 0.8379 
 
Viral load 
Unstimulated -0.01985 0.9058 
LPS -0.04941 0.7745 
 
Table-32: Correlation between CD14+CD16- monocyte subset’s CCR9 expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
CCR9 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.07416 0.6537 
LPS 0.2460 0.1311 
 
CD38/8 
Unstimulated 0.06246 0.7385 
LPS -01041 0.5773 
 
Viral load 
Unstimulated -0.1579 0.3507 
LPS -0.1688 0.3417 
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Table-33: Correlation between CD14+CD16+ monocyte subset’s CCR9 expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
CCR9 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated -0.1609 0.3213 
LPS -0.1377 0.3969 
 
CD38/8 
Unstimulated 0.07247 0.6894 
LPS 0.1678 0.3668 
 
Viral load 
Unstimulated -0.1020 0.5424 
LPS -0.001311 0.9938 
 
Table-34: Correlation between total monocyte population’s CD62-L expression and CD4 count, viral load 
and CD38/8 expression in response to stimuli 
CD62-L vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.1008 1.5526 
LPS 0.03496 0.8373 
 
CD38/8 
Unstimulated 0.03885 0.8370 
LPS -0.4428 0.8130 
 
Viral load 
Unstimulated -0.1172 0.5027 
LPS 0.2401 0.1647 
 
Table-35: Correlation between CD14+CD16- subset’s CD62-L expression and CD4 count, viral load and 
CD38/8 expression in response to stimuli 
CD62-L vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.07812 0.6364 
LPS 0.01950 0.9662 
 
CD38/8 
Unstimulated -0.1508 0.5912 
LPS -0.07437 0.6909 
 
Viral load 
Unstimulated -0.1880 0.2657 
LPS -0.1304 0.4416 
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Table-36: Correlation between CD14+CD16+ monocyte subset’s CD62-L expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
CD62-L vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.05474 0.7476 
Stimulated -0.2023 0.2299 
 
CD38/8 
Unstimulated 0.1547 0.4060 
Stimulated 0.1845 0.3204 
 
Viral load 
Unstimulated -0.2502 0.1417 
Stimulated 0.1362 0.4355 
 
Table-37: Correlation between total monocyte population’s CD69 expression and CD4 count, viral load 
and CD38/8 expression in response to stimuli 
CD69 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.1920 0.2401 
LPS 0.2032 0.2148 
 
CD38/8 
Unstimulated 0.08045 0.6671 
LPS 0.1255 0.5011 
 
Viral load 
Unstimulated -0.01523 0.9287 
LPS 0.2380 0.1561 
 
Table-38: Correlation between CD14+CD16- subset’s CD69 expression and CD4 count, viral load and 
CD38/8 expression in response to stimuli 
CD69 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.1314 0.4251 
LPS 0.03841 0.8164 
 
CD38/8 
Unstimulated 0.1295 0.4574 
LPS 0.1306 0.4839 
 
Viral load 
Unstimulated 0.009857 0.9537 
LPS 0.3232 0.0510 
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Table-39: Correlation between CD14+CD16+ monocyte subset’s CD69 expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
CD69 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated -0.0774 0.6489 
LPS -0.07557 0.6566 
 
CD38/8 
Unstimulated 0.1354 0.4777 
LPS 0.2010 0.2783 
 
Viral load 
Unstimulated 0.1811 0.4994 
LPS 0.2986 0.1052 
 
Table-40: Correlation between total monocyte population’s HLA-DR expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
HLA-DR vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated -0.1823 0.2666 
LPS -0.3506 0.0168 
 
CD38/8 
Unstimulated -0.1780 0.3381 
LPS 0.2471 0.1802 
 
Viral load 
Unstimulated 0.1242 0.4640 
LPS 0.2284 0.1739 
 
Table-41: Correlation between CD14+CD16- subset’s HLA-DR expression and CD4 count, viral load and 
CD38/8 expression in response to stimuli 
HLA-DR vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated -0.3629 0.0232 
LPS 0.3325 0.0452 
 
CD38/8 
Unstimulated 0.1686 0.6347 
LPS 0.2027 0.2742 
 
Viral load 
Unstimulated 0.1771 0.2944 
LPS 0.1811 0.02385 
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Table-42: Correlation between CD14+CD16+ monocyte subset’s HLA-DR expression and CD4 count, 
viral load and CD38/8 expression in response to stimuli 
HLA-DR vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.008016 0.9624 
LPS -0.05853 0.7308 
 
CD38/8 
Unstimulated -0.1179 0.5277 
LPS -0.09387 0.6155 
 
Viral load 
Unstimulated 0.113 0.5171 
LPS 0.09967 0.5689 
 
Table -43: Correlation between total monocyte population’s TRAIL-R1 expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
TRAIL-R1 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated -0.04925 0.7659 
LPS -0.09843 0.5511 
 
CD38/8 
Unstimulated -0.05200 0.7811 
LPS -0.02210 0.9061 
 
Viral load 
Unstimulated 0.1124 0.9474 
LPS 0.1981 0.2400 
 
Table -44: Correlation between CD14+CD16- subset’s TRAIL-R1 expression and CD4 count, viral load 
and CD38/8 expression in response to stimuli 
TRAIL-R1 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated -0.1923 0.2409 
LPS 0.038880 0.8142 
 
CD38/8 
Unstimulated -0.105 0.5647 
LPS 0.1530 0.4110 
 
Viral load 
Unstimulated 0.07786 0.6469 
Stimulated 0.04862 0.7751 
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Table-45: Correlation between CD14+CD16+ monocyte subset’s TRAIL-R1 expression and CD4 count, 
viral load and CD38/8 expression in response to stimuli 
TRAIL-R1 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.1523 0.3681 
LPS 0.1171 0.4901 
 
CD38/8 
Unstimulated 0.07172 0.7014 
LPS -0.04786 0.7982 
 
Viral load 
Unstimulated 0.1153 0.5097 
LPS 0.05716 0.7443 
 
Table-46: Correlation between total monocyte population’s TNFR1 expression and CD4 count, viral load 
and CD38/8 expression in response to stimuli 
TNFR1 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated -0.03417 0.8409 
LPS -0.07471 0.6603 
 
CD38/8 
Unstimulated 0.2427 0.1884 
LPS 0.06042 0.7468 
 
Viral load 
Unstimulated -0.08329 0.6364 
LPS -0.2432 0.1591 
 
Table-47: Correlation between CD14+CD16- subset’s TNFR1 expression and CD4 count, viral load and 
CD38/8 expression in response to stimuli 
TNFR1 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.3789 0.0174 
LPS 0.4230 0.0073 
 
CD38/8 
Unstimulated -0.03758 0.9540 
LPS -0.1199 0.5206 
 
Viral load 
Unstimulated -0.2672 0.1099 
LPS -0.1751 0.2999 
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Table-48: Correlation between CD14+CD16+ monocyte subset’s TNFR1 expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
TNFR1 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated -0.1345 0.0604 
LPS 0.2243 0.1757 
 
CD38/8 
Unstimulated 0.1348 0.4697 
LPS 0.06599 0.7243 
 
Viral load 
Unstimulated -0.09545 0.5855 
LPS -0.1763 0.3111 
 
Table-49: Correlation between total monocyte population’s Bcl-2 expression and CD4 count, viral load 
and CD38/8 expression in response to stimuli 
Bcl-2 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.2729 0.0928 
LPS 0.3573 0.0256 
 
CD38/8 
Unstimulated 0.1510 0.4176 
LPS -0.2079 0.2617 
 
Viral load 
Unstimulated -0.007106 0.9667 
LPS -0.1873 0.2671 
 
Table-50: Correlation between CD14+CD16- subset’s Bcl-2 expression and CD4 count, viral load and 
CD38/8 expression in response to stimuli 
Bcl-2 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.3551 0.0265 
LPS 0.3935 0.0132 
 
CD38/8 
Unstimulated 0.1659 0.3724 
LPS 0.2049 0.2688 
 
Viral load 
Unstimulated -0.02949 0.8624 
LPS -0.03580 0.8334 
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Table-51: Correlation between CD14+CD16+ subset’s Bcl-2 expression and CD4 count, viral load and 
CD38/8 expression in response to stimuli 
Bcl-2 vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.4138 0.0098 
LPS 0.4788 0.0024 
 
CD38/8 
Unstimulated 0.1289 0.4895 
LPS -0.04320 0.8175 
 
Viral load 
Unstimulated -0.06007 0.7278 
LPS -0.1278 0.4578 
 
Table-52: Correlation between total monocyte population’s 7AAD/AnnexinV expression and CD4 count, 
viral load and CD38/8 expression in response to stimuli 
7AAD/AnnexinV vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated -0.1485 0.8515 
LPS -0.2679 0.7321 
 
CD38/8 
Unstimulated -0.1590 0.6820 
LPS 0.5215 0.1500 
 
Viral load 
Unstimulated -0.3153 0.4085 
LPS -0.3032 0.4277 
 
Table-53: Correlation between CD14+CD16- subset’s 7AAD/AnnexinV expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
7AAD/AnnexinV vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.2590 0.7410 
LPS -0.8336 0.1614 
 
CD38/8 
Unstimulated -0.7373 0.0234 
LPS -0.09978 0.7984 
 
Viral load 
Unstimulated 0.6967 0.0370 
LPS -0.3265 0.3912 
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Table-54: Correlation between CD14+CD16+ subset’s 7AAD/AnnexinV expression and CD4 count, viral 
load and CD38/8 expression in response to stimuli 
7AAD/AnnexinV vs. Stimulus r-value P-value 
 
CD4 count 
Unstimulated 0.7742 0.2258 
LPS 0.5481 0.4519 
 
CD38/8 
Unstimulated -0.2073 0.5926 
LPS 0.04952 0.8993 
 
Viral load 
Unstimulated 0.3831 0.3089 
LPS 0.3530 0.3514 
 
Table-55: Correlation between viral load and IL10 and CCR5 expression at baseline in total monocyte 
population and monocyte subsets 
IL-10 vs. CCR5 Stimulus r-value P-value 
Total monocyte population Unstimulated 0.02507 0.8813 
CD14+CD16- monocyte subset Unstimulated -0.1906 0.2517 
CD14+CD16+ monocyte subset Unstimulated -0.1249 0.4551 
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